Clinical studies in obstructive airways disease by Holme, Jayne
   
 
 
CLINICAL STUDIES IN ALPHA-1 
ANTITRYPSIN DEFICIENCY  
 
by 
 
JAYNE HOLME 
 
 
 
 
A thesis submitted to The University of Birmingham for the 
degree of DOCTOR OF MEDICINE 
 
 
 
 
 
 
 
 
 
Department of Medical Sciences 
       The Medical School 
       The University of Birmingham 
   June 2011
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
 ABSTRACT 
 
Four clinical studies in subjects with alpha-1 antitrypsin deficiency were 
undertaken. 
The first examined CT densitometry and health status in 4 groups with 
discordant pulmonary physiology.  It demonstrated that subjects with an isolated gas 
transfer abnormality had more emphysema, the least basal predominant emphysema 
and a worse health status than those with normal physiology.  Subjects with an 
isolated spirometry abnormality had the most basal emphysema. 
The second study examined the age at which radiological, physiological and 
health status measures started to deviate from values expected for a normal 
population, and concluded that CT densitometry and gas transfers measures were 
the first to deviate from normal, while spirometry was the last. 
The third study examined the relationship of γ-glutamyl transferase to 
physiology, symptoms, mortality and liver disease in alpha-1 antitrypsin deficiency, 
and demonstrated associations between γ-glutamyl transferase and spirometry, 
mortality and cirrhosis after correction for associated factors. 
The final study described subjects with the PiSZ phenotype compared to 
matched PiZ subjects.  CT revealed emphysema (mainly panacinar) in 46% of PiSZ 
index and 15% of non-index subjects.  Health status was impaired in PiSZ subjects, 
who had less lower zone emphysema, better health status, pulmonary physiology 
and symptom profile compared with PiZ subjects.  
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1. INTRODUCTION 
  
This thesis explores four separate clinical studies based on subjects with the 
genetic condition alpha-1 antitrypsin deficiency which predisposes to chronic 
obstructive airways disease1 and liver disease2-4.   
 
1.1 Alpha-1 Antitrypsin 
 
Alpha-1 antitrypsin (AAT) is a 394 amino acid glycoprotein coded for on 
chromosome 14q3-32.15.  It is the principal inhibitor of serine proteases, such as 
neutrophil elastase6.  Alpha-1 antitrypsin consists of 3 β-sheets and an exposed 
mobile reactive loop, onto which the target protease docks.  After docking, the 
protease cleaves a peptide bond on the loop, releasing it to move from the upper to 
the lower pole of the protein, inserting into β-sheet A, thereby „trapping‟ and 
inactivating the protease7.  This process is depicted in figure 1.1 below.  
Proteases are an important host defence mechanism in the lung.  The 
protease, neutrophil elastase, plays a particularly important role by catalysing the 
breakdown of micro-organisms that can lead to infection in the lung, and in the 
clearance of necrotic lung tissue8.  However, if left unopposed, studies have shown 
that neutrophil elastase can also cause damage to the host lung similar to that seen 
in chronic obstructive pulmonary disease (COPD) [see section 1.2.2.2.2.3.].  These 
changes include alveolar destruction leading to emphysema9, loss of ciliated 
epithelium10, squamous cell metaplasia11, reduced ciliary beat frequency12 and 
mucous gland hyperplasia13.  In health, alpha-1 antitrypsin blocks these harmful 
effects of proteases. 
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FIGURE 1.1: The mechanism of protease deactivation by alpha-1 antitrypsin.  
(Reprinted with permission from Macmillan Publishers Ltd: Lomas et al. Nature 
Reviews Genetics 2002;3:759–68, copyright 2002).   
 
 
 
Neutrophil elastase (dark grey) docks onto the mobile reactive loop of alpha-1 
antitrypsin (red) and cleaves a peptide bond on the loop (picture on left).  The loop 
moves and inserts into β-sheet A (green), thereby ‘trapping’ and inactivating the 
protease (picture on right).  
 
 
AAT is produced mainly by hepatocytes14, but small amounts can also be 
synthesised by macrophages15, intestinal16 and respiratory epithelial cells17.  In 
subjects who have the usual protease inhibitor M (PiM) type of AAT, newly 
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synthesised monomeric AAT enters the circulation and is transported to the lung 
where it diffuses into the tissues and inhibits neutrophil elastase released by 
migratory neutrophils, thereby minimising the associated tissue damage and  hence 
subsequent development of features of COPD (Figure 1.2).   
 
FIGURE 1.2: The production and dissemination of alpha-1 antitrypsin in a 
healthy subject with the normal ‘M’ type of alpha-1 antitrypsin protein. 
  
 
 
 
  
 
 
 
 
 
The normal ‘PiM’ type of alpha-1 antitrypsin protein is synthesised mainly by 
hepatocytes (1).  The ‘PiM’ type of alpha-1 antitrypsin protein exists mainly as a 
monomer and is able to pass out of the hepatocyte and into the circulation through 
the normal secretory pathway (2). The ‘PiM’ type of alpha- antitrypsin monomers 
enter the lung tissue from the circulation by simple diffusion (3) where they inhibit 
serine proteases. 
 
 
AAT 
AAT 
AAT AAT AAT 
Hepatocyte 
1 
2 
3 
Lungs 
AAT 
Circulation 
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1.2 Alpha-1 Antitrypsin Deficiency 
 
Alpha-1 antitrypsin deficiency (AATD) was first described in 1963 by Laurell 
and Eriksson18.  It is a genetic condition resulting in a major reduction of serum and 
hence lung concentrations of the protein alpha-1 antitrypsin.  AATD is associated 
with a markedly increased risk of developing chronic obstructive pulmonary disease1 
and liver disease, including neonatal jaundice2, cirrhosis 3 and primary hepatocellular 
carcinoma4. 
 
 
1.2.1 Genetics of alpha-1 antitrypsin deficiency 
 
More than 100 genetic mutations of AAT have been identified and around 30 
of these lead to AATD19.  Each of these 30 mutations code for an AAT protein that is 
either abnormal in structure or function, or genes that are not transcribed or 
translated.   
Subjects inherit one AAT allele from each of their parents in a co-dominant 
manner.  The most common allele is M (95% of alleles), and this produces normal 
levels of circulating AAT19.  The most common AAT alleles associated with a 
circulating deficiency of AAT in Caucasians are Z (1-3% of alleles), S (2-3% of 
alleles) and null (<0.1% of alleles)20.  Table 1.1 summarises the circulating levels of 
AAT associated with these genotypes19. 
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TABLE 1.1: Typical plasma concentrations of AAT (μM) associated with various 
genotypes19. 
AAT Genotype AAT level (μM) 
MM 20-48 
MZ 17-33 
SS 15-33 
SZ 8-16 
ZZ 2.5-7 
Null 1.3-3.5 
NullNull 0 
 
 
 
1.2.2 PiZ Alpha-1 Antitrypsin Deficiency 
 
1.2.2.1 PiZ Alpha-1 Antitrypsin Protein 
 
The most common significant genetic variant of AAT in the Caucasian 
population is the PiZ (protease inhibitor Z) variant.  The Z allele is more prevalent in 
northern Europe, and it becomes less common towards the south west of Europe, as 
demonstrated in figure 1.3, in relationship to the heterozygous PiMZ phenotype. 
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FIGURE 1.3: European distribution by country of the PiMZ phenotype of alpha-
1 antitrypsin deficiency. The figure illustrates the percentage of the population 
estimated to have the PiMZ phenotype of alpha-1 antitrypsin in each European 
country. (Figure by Olve Utne and reproduced from 
http://upload.wikimedia.org/wikipedia/commons/0/0d/PiMZ_Europe.png. Creative 
Commons Attribution ShareAlike 2.5 Licence). 
 
 
 
 
The PiZ allele occurs as the result of a point mutation causing the substitution 
of glutamine for lysine in position 342 of the protein7.  The abnormal PiZ AAT protein 
is prone to polymerisation after being produced in the liver21, and as a result it 
becomes blocked in the terminal secretory pathway of the hepatocytes22, with only a 
small percentage reaching the circulation (Figure 1.4).   
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FIGURE 1.4:  Mechanisms by which the PiZ type of alpha-1 antitrypsin causes a 
deficiency state in the circulation and the lungs. 
 
 
 
 
 
 
 
 
The abnormal PiZ type of alpha-1 antitrypsin protein is produced in hepatocytes (1). 
The PiZ alpha-1 antitrypsin protein is prone to polymerisation within the hepatocytes 
(2).  The PiZ alpha- antitrypsin polymers are unable to enter the circulation, and are 
retained within the endoplasmic reticulum of the hepatocytes (3).  This significantly 
reduces the plasma level and hence the delivery of alpha-1 antitrypsin to the lung (4). 
 
This leads to a subsequent deficiency in the lungs, and consequently 
neutrophil elastase released by migratory neutrophils becomes relatively unopposed 
at this site, leading to the pathological changes seen in COPD.  Furthermore, the 
small amount of PiZ AAT that does reach the circulation and subsequently the lung is 
approximately five times less potent as an inhibitor of neutrophil elastase compared 
with the normal PiM type of AAT protein23-26 decreasing the protective role even 
further.   
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1.2.2.2. The Respiratory System in PiZ Alpha-1 Antitrypsin 
Deficiency 
 
1.2.2.2.1. Respiratory System Anatomy 
 
The respiratory system is the site of gas exchange between the circulation and 
the air.  The delivery of oxygen from the circulation to respiring tissues and the 
removal of carbon dioxide (CO2) from tissues back to the circulation, and 
subsequently the lung, is critical to support the metabolic needs of cells.   
The respiratory system includes airways through which air is transported to 
and from the lung parenchyma.  The airways start at the nasal or oral cavities and 
include the pharynx, larynx and trachea which splits into the left and right main 
bronchi.  The main bronchi give rise to the segmental and sub-segmental bronchi, 
and, after some 15 to 25 generations, become bronchioles.  Each bronchiole 
branches into several alveolar ducts, which each lead to an alveolar sac and such a 
unit is termed the primary pulmonary lobule.   Alveolar sacs, alveolar ducts and 
respiratory bronchioles are surrounded by capillaries which provide the interface 
through which gas exchange occurs.  These capillaries are supplied with 
deoxygenated blood from the right side of the heart via the pulmonary arteries27.  The 
ratio of ventilation of the alveoli to perfusion of capillaries tends to be greater at the 
apices of the lungs compared with the bases due to a higher basal pulmonary artery 
pressure as a result of the interaction of gravity with the physiological effects of the 
cardio-respiratory system28.    
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1.2.2.2.2. COPD 
 
AATD is known to be a risk factor for the development of COPD18, and 
approximately 1- 4% of subjects with COPD have severe AATD29-31, whereas 5-10% 
have at least moderate AATD29-31.  The definition of COPD differs slightly depending 
on which national or international guidelines are used.  However, all state that COPD 
is a chronic inflammatory condition characterised by airflow obstruction that is not 
fully reversible and usually progressive32-34.  
 
 
1.2.2.2.2.1. Protease / anti-protease balance in COPD 
 
The protease / anti-protease hypothesis of COPD pathogenesis arose from 
the observation by Laurell and Eriksson in 1963 that deficiency of alpha-1 antitrypsin 
was associated with a susceptibility to the development of early onset emphysema18.  
Since this time, many studies in animal models have shown that serine proteases 
such as neutrophil elastase, proteinase 3 and the cysteine protease, cathepsin B, 
can reproduce the pathological features of emphysema13,35-37.  The serine proteases 
are contained in the azurophilic granules within the neutrophil and are made early in 
differentiation.  Neutrophils are recruited from the vascular compartment into lung 
tissues in response to chemoattractants such as leukotriene B4 (LTB4) and 
interleukin-8 (IL8), which are released by alveolar macrophages or respiratory 
epithelial cells in response to stimuli including cigarette smoke, pollutants or 
microorganisms38,39 (Figure 1.5).   
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FIGURE 1.5: The pathogenesis of COPD – Protease / Antiprotease balance. 
(See next page for legend). 
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FIGURE 1.5 (Legend): The pathogenesis of COPD – Protease / Antiprotease 
balance. 
Stimuli such as cigarette smoke, microorganisms and air pollution in the airways 
activate alveolar macrophages (1) and respiratory epithelial cells (2).  These cells 
produce chemoattractants and cytokines such as IL8, LTB4 and tumour necrosis 
factor alpha [TNFα] (3), which are instrumental in the movement of neutrophils from 
the pulmonary circulation into the lung parenchyma and airways(4).  IL8 and LTB4 
activate the neutrophil (5) and lead to the release of proteases such as neutrophil 
elastase (6) and matrix metalloproteinases [also released by macrophages](7), which 
cause lung damage such as that seen in COPD (8).  Serine proteases further 
activate MMPs (9), and in turn, MMP (10) and TNF (11) increase and activate 
proinflammatory cytokines like IL6 and IL8, amplifying the inflammatory process.  The 
effects of serine proteases are blocked by antiproteases such as AAT (12).  MMP is 
also capable of inactivating these antiproteases causing further amplification of the 
inflammatory process by an alternative pathway(13).  The net effect is excessive 
protease activity leading to the pathological changes of COPD. 
 
 
TNFα is released from leucocytes, airway epithelial cells and endothelial cells, 
and is capable of increasing the expression of adhesion molecules on leukocytes and 
the pulmonary endothelium, thereby aiding migration of the leucocytes into the 
lung40.  TNFα also increases levels of many other inflammatory cytokines, thereby 
potentiating the inflammatory process further40. 
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Activated neutrophils release proteases such as neutrophil elastase and 
matrix metalloproteinase (MMP) from the relevant granules, and these proteases are 
thought to break down connective tissue (including elastin) in the lung to create a 
passage through which they can pass until they reach their destination within the 
lung tissue or airways41,42.  As proteases dissipate, their concentration decreases as 
the distance from the neutrophil increases.  Protease inhibitors in the tissues form 
complexes with proteases with a 1:1 ratio, and inhibit their activity.  As the distance of 
the protease from the activated neutrophil increases, the concentration of the 
protease is reduced to a level that equals that of protease inhibitors such as alpha-1 
antitrypsin, and at this point, protease activity is stopped43.  However, in alpha-1 
antitrypsin deficiency, the concentration of the protease inhibitor is much reduced, 
and therefore the distance over which the concentration of protease exceeds that of 
its protease inhibitor is greatly increased, leading to a marked increase in the area of 
tissue destruction which may result in the accelerated development of emphysema43.   
Serine proteases also activate MMPs, which in turn activate proinflammatory 
cytokines and inactivate protease inhibitors like AAT, further potentiating the 
inflammatory and hence destructive process41.   
Hence, the balance between protease and anti-protease plays a central role in 
determining which subjects will develop emphysema42.   
Alpha-1 antitrypsin deficiency is an example of a specific protease anti-
protease imbalance.  Usual COPD is caused mainly by smoking and it is known that 
lung tissue in smokers contains a high number of neutrophils which in turn release 
proteases44.  In addition the neutrophils of smokers who develop COPD have a 
greater response to chemoattractants, and a greater ability to destroy lung tissue 
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than those without COPD.  Therefore, in usual COPD there is also an imbalance 
between proteases and anti-proteases caused largely by the excessive protease load 
rather than inhibitor deficiency, but the net effect is similar leading to the 
development of destructive lung disease45. 
 
 
1.2.2.2.2.2. Oxidant /antioxidant balance in COPD 
 
 
The protease / anti-protease hypothesis described in section 1.2.2.2.2.1. is 
thought to be a key pathogenic process in COPD.  In addition, there is increasing 
evidence that the balance of oxidants and antioxidants is also important and 
interrelated, involving leucocytes such as neutrophils and alveolar macrophages 
(Figure 1.6).   
Reactive oxygen species are released from these cells when activated46, and 
are directly inhaled in cigarette smoke47 and as air pollutants48.  These oxygen 
species have several effects that can result in tissue damage similar to that seen in 
COPD.  They have been associated with direct tissue damage involving elastin and 
collagen breakdown49, cell membrane damage via lipid peroxidation, epithelial cell 
detachment, and lysis50.  In addition, they play a role in potentiating inflammation as 
described below.   
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FIGURE 1.6: The pathogenesis of COPD – Oxidant / Antioxidant balance. 
 
 
 
 
 
 
 
 
 
 
 
 
Cigarette smoke and air pollution deliver oxidants to the lung which in turn 
stimulate alveolar macrophages (1) and neutrophils in the lung (2), both directly and 
indirectly via LTB4 and IL8 released by alveolar macrophages (3).  Reactive oxygen 
species are released by activated alveolar macrophages (4) and neutrophils (5).  
Reactive oxygen species also facilitate further neutrophil migration from the vascular 
compartment into the lung, which perpetuates the process (6).  Reactive oxygen 
species in the lung cause lung damage directly (7) which, in health, is blocked by 
antioxidants such as glutathione (8).  Again, an imbalance of the oxidants and 
antioxidants can result in an excess of oxidant activity and hence influence the 
pathogenesis of COPD. 
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Neutrophils are relatively large cells, and must be able to change shape in 
order to pass through the pulmonary microcirculation.  Reactive oxygen species are 
thought to affect the cell exoskeleton and make it more rigid51.  The neutrophil is not 
able to „deform‟ adequately and therefore passes more slowly through the pulmonary 
microcirculation52.  This increases the likelihood that the neutrophil will adhere to the 
vessel wall and migrate into the lung tissue where it may cause damage as described 
in section 1.2.2.2.2.1. 
Reactive oxygen species in cigarette smoke are also thought to upregulate 
adhesion molecules and perpetuate this effect further52-54.  Furthermore, cigarette 
smoke reduces elastin synthesis and repair, thereby compounding tissue damage55.  
It is also possible that reactive oxygen species are responsible for the reduced 
activity of antiproteases such as AAT56,57, although this concept remains 
controversial. 
Various antioxidants are present in the lung, which counteract the effects of 
the oxidants described above.  The most prevalent antioxidants are reduced 
glutathione (gamma-glutamyl-cysteinylglycine or GSH), mucin, uric acid, albumin and 
ascorbic acid58.  GSH is known to be elevated in the bronchoalveolar lining fluid 
(BALF) of smokers, but this protective response is not thought to be sufficient to 
counteract the quantity of oxidants present in cigarette smoke58.  Therefore, in 
smokers, an oxidant/antioxidant imbalance is thought to exist which will increase the 
inflammatory processes central to the development of COPD.  Levels of the other 
anti-oxidants are either greater or less than normal in cigarette smokers compared 
with non-smokers, although the nature of this has not been precisely determined.  
However, it is thought that some antioxidants may be consumed due to the increased 
17 
 
oxidant load, and others upregulated as a protective response.  The balance 
between oxidants and antioxidants is therefore believed to be important in the 
pathogenesis of COPD58, although what influences the „susceptibility‟ in this pathway 
remains unknown. 
 
 
1.2.2.2.2.3. Pathological changes in COPD 
 
COPD is associated with many pathological changes affecting the airways, 
parenchyma and vasculature. 
Changes in the airways include loss of ciliated epithelial cells59, reduced ciliary 
beat frequency, mucous gland hyperplasia13, increased intraluminal mucus60, 
squamous cell and goblet cell metaplasia11, airway wall thickening resulting from a 
combination of subepithelial fibrous tissue, airway smooth muscle hyperplasia & 
thickened fibrotic adventitia61, and loss of peribronchial alveolar attachments62.  
Emphysema is defined as an „abnormal permanent enlargement of the 
airspaces distal to the terminal bronchiole accompanied by destruction of their walls 
without obvious fibrosis‟63.  Several pathological types of emphysema are recognised 
including centrilobular emphysema (figure 1.7) which is located in the central part of 
the lobule of Miller, panlobular emphysema (figure 1.8) which is located throughout 
the lobule and paraseptal emphysema which is located at the periphery of the 
lobule62.   
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FIGURE 1.7: Histology slide showing centrilobular emphysema. (Reproduced 
with permission from J. L. Wright & A. Churg. Histopathology 2006;49:1-962) 
    
 
 
 
 
FIGURE 1.8: Histology slide showing panlobular emphysema. (Reproduced with 
permission from J. L. Wright & A. Churg. Histopathology 2006;49:1-962) 
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Panlobular emphysema is classically associated with alpha-1 antitrypsin 
deficiency64 and the centrilobular pattern with usual smoking-related emphysema65. 
It is often possible to differentiate centrilobular and panlobular (also called 
panacinar) emphysema in vivo, by the appearance of the CT scan66.   Emphysema is 
characterised by areas of abnormally reduced attenuation which lack a distinct wall 
on an HRCT scan.  Centrilobular emphysema is characterised by small focal, 
approximately circular areas of lung destruction, seen centrally in a secondary 
pulmonary lobule.  Panlobular emphysema is characterised by areas of uniform 
hypoattenuated lung involving the whole of the secondary pulmonary lobule67.  
Figures 1.9 and 1.10 show CT scan slices from subjects with typical appearances of 
centrilobular and panacinar emphysema respectively.  
 
FIGURE 1.9: CT scan slice showing centrilobular emphysema.  
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In addition to these pathological changes, the pulmonary vasculature exhibits 
intimal and muscular thickening62 in COPD. 
 
 
 
1.2.2.2.2.4. Clinical features of COPD 
 
Subjects with COPD may complain of exertional dyspnoea, exercise limitation, 
cough and chronic sputum production (which fulfils the criteria for „chronic bronchitis‟ 
if it occurs on most days for 3 months in 2  consecutive years, as defined by the 
Medical Research Council [MRC]68).   
COPD is associated with periodic exacerbations, which are defined as, “a 
sustained worsening of the subject‟s condition, from the stable state and beyond 
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FIGURE 1.10: CT scan slice showing panlobular emphysema. 
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normal day-to-day variations, necessitating a change in regular medication”69.  The 
classical features of these episodes were described by Anthonisen and colleagues70.  
In general the three major features are an increase in dyspnoea, sputum volume and 
sputum purulence supported by a series of minor symptoms such as fever, cough 
and upper respiratory symptoms.  These episodes are classed as type I (all three 
major criteria present), type II (two major criteria present) and type III (one major 
criterion present together with at least one minor criterion).   
On clinical examination, subjects with COPD may be centrally cyanosed, 
exhibit physical signs of hyperinflated lungs, have an expiratory wheeze and reduced 
air entry.  Early in the disease there may be none or few clinical signs, but as COPD 
becomes more advanced, it may be associated with respiratory failure, evidence of 
cor pulmonale and episodes of right heart failure.     
Anxiety and depression are often associated with COPD and there is an 
increased incidence of co-morbidities including cardiovascular disease, osteoporosis, 
peptic ulcer disease, diabetes, cachexia and muscle wasting which may be 
associated with systemic inflammation71. 
The most informative data concerning  the natural history of lung disease in 
AATD is a Swedish cohort study72, in which 200, 000 infants born over a two year 
period from 1972 to 1974 in Malmo, Sweden were phenotyped.  127 PiZ and 48 
protease inhibitor SZ (PiSZ) subjects were identified, and have been followed up 
periodically.  The PiZ subjects were 30 years of age at the last full assessment73, at 
which time 42% reported dyspnoea, 31% wheeze and 17% sputum production.  
These proportions were greater in those who had smoked (65%, 48% and 30% 
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respectively).  Despite this, subjects generally had spirometry in the normal range.  
However, gas transfer was lower in PiZ smokers compared with PiM smokers74. 
 
 
1.2.2.2.2.5. Pulmonary physiology in COPD 
 
Spirometry is the basis of all assessment of COPD as, by definition, the ratio 
of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) defines 
airflow obstruction.  These measurements change with age, gender, size and ethnic 
group and hence are usually expressed in both absolute terms and corrected for 
these factors as a percentage of the predicted normal value (% predicted)75.  
Airflow obstruction that is not fully reversible is currently a defining feature of 
COPD, and is characterised as a post-bronchodilator FEV1:FVC ratio of less than 
70%.  Spirometry is also used to characterise COPD severity32-34.  A lower FEV1 has 
been associated with worse symptoms76,77, worse quality of life78,79, a greater 
frequency of exacerbations80, a more rapid decline in exercise capacity81 and 
increased mortality82 in subjects with usual COPD.  Similarly, in subjects with AATD, 
a lower FEV1 has been associated with more severe symptoms83, more frequent 
acute exacerbations84, and greater mortality85,86.  However, the relationship of FEV1 
to health status in AATD remains controversial87.   
Previous observational cross-sectional studies suggest that spirometry in 
AATD becomes abnormal from age 50-65 in never-smokers88,89 and from 25 years in 
smokers90, although definitive data from the prospective Swedish cohort study  
described in section 1.2.2.2.4.72 are unlikely to be available for several decades.  The 
most recent complete report from this cohort suggest that spirometry is generally 
normal in PiZ subjects at 30 years of age74. 
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The diffusing capacity (DLCO) or transfer factor (TLCO) for carbon monoxide 
(CO) measures the gas exchange in the lung and are often used as interchangeable 
terms.  These measures reflect both the distribution of gas to the alveoli as well as 
the efficiency of uptake in the alveoli.  KCO is a measure of DLCO corrected for 
alveolar volume and as such is more informative of the alveolar efficiency and hence 
more specific to the emphysema component of COPD91. 
In general there is a broad relationship between FEV1 and gas transfer for 
COPD subjects.  However many subjects do not have emphysema and hence 
disparity may occur between the results of spirometry and gas transfer. 
KCO has been less well characterised compared with FEV1 in COPD.  
Nevertheless,  gas transfer is related to symptoms92and exercise capacity93in usual 
COPD.  A small study94 has also shown that subjects with a KCO of less than 75% of 
predicted have a more rapid decline in FEV1 over time than those with a KCO of 
greater than 75% of predicted.  Few studies have examined the implications and 
associations of reduced gas transfer in subjects with AATD.  However, impairment in 
gas transfer is associated with an increase in mortality in AATD85, and is generally 
lower in AATD subjects who have more frequent acute exacerbations although this 
relationship is lost  when gas transfer is corrected for alveolar volume84.   
There are little previous data available regarding the age at which gas transfer 
starts to deviate from normal in AATD.  However, it was measured in a small cohort 
of PiZ subjects (4 current smokers and 52 subjects who had never smoked) from the 
Swedish cohort at the age of 3074.  The mean KCO was 81% of predicted in smokers 
and 99% in those who had never smoked, suggesting that it had already started to 
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deviate from expected normal values in the smoking subset by the age of 30, when it 
was first measured in this group.   
The measurement of lung volumes such as total lung capacity (TLC), 
functional residual capacity (FRC) and residual volume (RV) can be measured by 
either inert gas dilution or body plethysmography.  The former method compares a 
known concentration of inert gas present in a closed system prior to the test, to the 
concentration present after a steady state has been achieved after several minutes of 
tidal breathing to allow concentration equilibrium.  However, due to inefficient gas 
distribution in COPD the achievement of steady state may take a long time, and 
measurements are often made near rather than at plateau.  Plethysmography 
compares the pressure in a closed box when the subject is at FRC with an open 
airway and when the subject is making respiratory effort with a closed airway91.  As 
such it is more rapid and more likely to reflect the true volume of gas in the lung. 
In COPD, these investigations often reveal evidence of gas trapping, with 
increased RV:TLC ratio, and reduced inspiratory capacity (IC).  This can be 
associated with marked breathlessness95, reduced exercise capacity96 and 
mortality97.  In AATD, gas trapping has been associated with more frequent 
exacerbations84, although it has yet to be assessed against the parameters above. 
Arterial blood gas measurements give the partial pressures of oxygen (PaO2) 
and carbon dioxide (PaCO2), pH, and bicarbonate level in oxygenated blood.  
Subjects with usual COPD are often hypoxic and eventually develop respiratory 
failure.  A reduction in PaO2 is associated with dyspnoea92, reduced exercise 
capacity98 and mortality99 in subjects with usual COPD.  Indeed, survival can be 
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increased by administering long-term oxygen therapy to subjects with severe chronic 
hypoxia who meet specified criteria100.  Similar data have not been reported in AATD.  
 
 
1.2.2.2.2.6. CT scans in COPD 
 
Computed tomography (CT) scans were shown to detect emphysema in 1978 
by Rosenblum et al101.  The extent of emphysema can be characterised using CT 
scans subjectively with visual scoring systems102 or objectively by assessing the 
density of the scanned images103. In 1988, Muller et al.103 described the method of 
densitometric analysis using CT scans.  The technique uses information derived from 
the cumulative frequency distribution histogram of lung voxel densities measured 
using specialised software either integrated into the CT scanner, or available 
externally.  For example, figure 1.11 shows a CT scan slice through the lungs.  
Specialised software (in this case Pulmo-CMS software (MEDIS Medical Imaging 
Systems BV, Leiden, The Netherlands)) has been used to identify and outline the 
margins of the lungs. 
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FIGURE 1.11: CT scan slice through the lungs. 
 
Pulmo-CMS software has been used to identify the right (blue surround) and left (red 
surround) lung fields. 
 
 
The software can then be used to assess the density of each CT voxel in 
Hounsfield Units (HU), and a cumulative frequency distribution histogram of the 
densities is constructed similar to that shown in figure 1.12.  Density mask analysis 
describes the proportion of voxels that are less dense than a given threshold of 
Hounsfield Units (-910 in the example shown in figures 1.12 and 1.13 below), while 
the percentile point method describes the density in HU below which a defined 
percentage of voxels are distributed (in this case 15% or Perc 15).  These points are 
labelled on the cumulative frequency distribution histogram in figure 1.12.   
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FIGURE 1.12: Example of a cumulative frequency distribution histogram of CT 
scan slice voxel densities.  
 
 
 
The cumulative proportion of voxels (y-axis) of increasing densities (x-axis) is plotted 
for a CT scan slice. The 15th percentile point (Perc15) and the voxel index (VI) using 
the -910HU threshold (VI -910) are shown. 
 
 
Figure 1.13 highlights the process of density mask analysis where specialised 
software (in this case Pulmo-CMS) has highlighted any voxel that is less dense than  
-910 HU.  In this case, the Voxel Index (VI) describes the percentage of voxels that 
are less dense than -910 Hounsfield Units (VI-910). 
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FIGURE 1.13: CT scan slice showing density mask analysis of the lung using a 
threshold of -910HU.   
 
Each CT voxel with a density of less than -910 HU has been highlighted in purple 
using Pulmo-CMS software. 
 
 
Muller103 demonstrated that densitometric measurements correlated well with 
the pathological grade of emphysema in resected lungs, and Gevenois et al.104 
subsequently proved this relationship existed when both macroscopic and 
microscopic pathological features of emphysema were examined using computer 
assisted techniques. 
Kinsella et al.105 also demonstrated that CT densitometry correlated well with 
spirometry, lung volumes and gas transfer measurements derived from physiological 
29 
 
testing105.  Soejima et al.106 added to this work by reporting that KCO related better to 
upper zone than lower zone densitometry, and conversely, FEV1 related better to 
lower zone compared with upper zone densitometry, at least in normal subjects.  A 
similar relationship was also seen by Dowson et al.107 in subjects with AATD, and 
persisted even after correction for mean lung density, gender, method of 
ascertainment, smoking and the presence of chronic bronchitis108.  However, most of 
the subjects in the latter studies had both airflow obstruction and reduced gas 
transfer factor. 
Very recently, Bernspang et al.109 described CT densitometry findings in a 
small group of non-index (identified to have AATD as a result of screening tests, 
rather than diagnostic tests) PiZZ AATD subjects from the Swedish cohort described 
in section 1.2.2.2.2.4.72 compared with PiM subjects (mean age 32), and concluded 
there was no difference between the two groups.  However, less than one fifth of the 
study population consented to the examination, introducing a large selection bias.  
Furthermore, only a small proportion of these subjects had ever smoked, making the 
results difficult to interpret and apply to the general AATD population (albeit index 
[identified to have AATD as a result of diagnostic tests following the development of 
symptoms] or non-index).  Furthermore, the PiZ smoking subjects with reduced gas 
transfer who had been previously described by the Swedish investigators74 were not 
included in this study.  Nevertheless, the subject with the most abnormal CT 
densitometry results was a PiZ smoker. 
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1.2.2.2.2.7. Heterogeneity of COPD 
 
COPD is a heterogenous condition in terms of clinical, pathological, 
radiological and physiological features, and it is possible that different inflammatory 
mediators and processes are involved in the pathophysiology of the different 
phenotypes, as in animal models with COPD110.  If so, it is increasingly important to 
identify these different COPD phenotypes reliably, in order to understand the 
pathophysiology and design clinical trials of treatments targeting the relevant 
inflammatory process and site111. 
Clinically, only 17 to 40% of subjects with COPD have chronic bronchitis112, 
and approximately 40 to 60% do not develop regular acute exacerbations113.  In 
addition, pathologically, different morphological types of emphysema exist.  
Centrilobular emphysema affects the central parts of the primary pulmonary lobule 
and is common in usual COPD65, whereas panlobular emphysema affects the whole 
lobule and is the most common type of emphysema seen in AATD64.  After 
examining pathological specimens, Thurlbeck et al.65 described that centrilobular 
emphysema occurred more frequently in the upper lobes of the lungs, and that 
panlobular emphysema was more common in the lower lobes, consistent with this 
observation, emphysema in usual COPD, is classically described as apical, whereas 
AATD related panlobular emphysema is more frequently basal.  However, despite 
these classical descriptions, subjects with usual COPD can develop emphysema in 
the lower lobes65 and those with AATD can develop upper lobe emphysema in up to 
one third of cases114. 
Although part of the definition of COPD includes airflow obstruction 
(postbronchodilator FEV1:FVC ratio of less than 70%32-34), subjects are recognised 
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who have no evidence of airflow obstruction but have visible emphysema on CT 
scanning, with or without an isolated abnormality of gas transfer115.  Recognising this 
phenomenon is becoming more common as CT scanners become more widely used.  
In addition it is becoming appreciated that significant bronchiectasis can be identified 
in 29% of scans from subjects with usual COPD116 and up to 40% from subjects with 
AATD117.  A further defining characteristic of COPD is that the airflow obstruction is 
largely irreversible.  However, around one third of subjects with usual COPD116 and 
up to half of those with AATD118 have evidence of significant bronchodilator 
reversibility suggesting a further COPD phenotype. 
Some relationships between these clinical, pathological, radiological and 
physiological phenotypes have already been established, in order to define 
phenotypes of COPD more specifically.  One example, described above, is the 
association of centrilobular emphysema with the upper lobes of the lungs and with 
smoking, and conversely the association of panlobular emphysema with the lower 
zones of the lungs and with AATD. 
In order to understand the mechanisms behind these various phenotypes and 
develop effective therapy that is specifically targeted, it is becoming increasingly 
important to define the different aspects of COPD effectively.   
 
 
32 
 
1.2.2.3 The Liver in PiZ Alpha-1 Antitrypsin Deficiency 
 
1.2.2.3.1. Pathological changes of Liver Disease in alpha-1 
antitrypsin deficiency 
 
Liver disease in AATD is thought to be related to the presence of AAT 
polymers in the hepatocytes, although the exact mechanism remains unclear119.  
Pathologically, the retained AAT polymers appear as periodic acid-Schiff diastase 
(PAS-D) resistant globules (figure 1.14)120, which are present in all subjects with PiZ 
AATD, irrespective of whether they have clinically significant liver disease or 
abnormal liver function tests.   
 
FIGURE 1.14: Liver biopsy specimen (x400) showing periodic acid-Schiff 
diastase (PAS-D) resistant globules (arrows) in peri-portal hepatocytes from a 
subject with PiZZ AATD. (Reproduced with permission121). 
 
 
The factors that influence the development of clinically relevant liver disease 
are largely unknown.  There may be genetic factors122, and environmental factors 
such as co-infection with hepatitis B or C viruses123.  Furthermore, it has been 
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hypothesised that breast feeding a child with AATD protects against the development 
of liver disease124.  However, no clear consensus regarding the influence of these 
environmental factors has yet been reached. 
 
 
1.2.2.3.2. Clinical features Of Liver Disease In PiZ Alpha-1 
Antitrypsin Deficiency 
 
The most informative study of the natural history of liver disease in AATD is 
the Swedish cohort described in section 1.2.2.2.2.4.72.  Of the 127 PiZ infants 
identified by population screening, 14 (11%) developed neonatal cholestasis (most 
often caused by extrahepatic biliary atresia), and a further 8 (6%) had other signs of 
liver disease. Of the 14 who developed cholestasis, 2 subsequently developed liver 
cirrhosis between the ages of 2 & 4 and eventually died.  A further child developed 
aplastic anaemia and died, but was found to have cirrhosis at post mortem, and a 
fourth child with liver disease in infancy died in an accident. The other infants with 
neonatal cholestasis or hepatomegally improved and by the age of 26, none had 
clinical evidence of liver disease2,72,125-128.   
In young adults, cohort studies have suggested that the risk of developing 
chronic liver disease is around 2%129, but in older adults this figure increases to 15-
20%129-131.  However, due to the nature of these cohort studies it is likely that 
selection bias exists which may lead to overestimation of the presence of liver 
disease.  Despite this, in post-mortem studies, the pathological incidence of liver 
cirrhosis is often even greater, and largely asymptomatic hepatomas have been 
found in around 16% of PiZ subjects132.  Selection bias is likely to also lead to an 
overestimation of liver disease in these post-mortem studies, as they study only 
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subjects who have died (possibly in relation to their liver disease).  Subjects who 
have never smoked are at increased risk of developing liver cirrhosis as they 
generally survive long enough for it to become clinically overt, as opposed to 
smokers who are more likely to die at a younger age because of lung disease133. 
Despite the relatively low levels of clinical liver disease in the Swedish cohort 
described above72, abnormal liver function tests (either gamma-glutamyl transferase 
[GGT], aspartate transaminase [AST] or alanine transaminase [ALT]) were observed 
in all of the PiZ infants72, reducing to 40%in 4-year olds127, 3-15% in 12 - 18 year 
olds134,135 and 5-8% in 26 year old subjects126. 
 
 
1.2.2.3.3. Gamma-glutamyl transferase in PiZ alpha-1 antitrypsin 
deficiency 
 
Most current knowledge about GGT in subjects with AATD comes from the 
Swedish cohort identified via population screening72.  These subjects have been 
followed up periodically from birth and are currently in their thirties.  At 2–4 months of 
age, all infants had an abnormally high serum GGT activity, but only 17% had clinical 
evidence of liver disease72.  By the age of 4, serum GGT activity was only abnormal 
in 4%, and by the age of 26, the proportion with an abnormal GGT remained between 
1 and 8%, and abnormalities were usually transient in any one individual.  From the 
ages of 8 to 26 years, none of the subjects had clinical  evidence of liver 
disease2,125,126.  Serum GGT activity has not been described in older adult subjects 
with AATD. 
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1.2.2.3.3.1. The structure of gamma-glutamyl transferase 
 
Gamma-glutamyl transferase is a glycoprotein consisting of a heavy chain 
comprising of 351 amino acids, which is covalently bound to a light chain comprising 
189 amino acids.  The two chains are derived from the cleavage of a single precursor 
peptide136.  The active site of GGT is situated on the hydrophilic light chain, while the 
heavy chain is hydrophobic and anchors GGT to the cell membrane. The 
deoxyribonucleic acid (DNA) that codes for GGT is located on chromosome 22q11 in 
humans, and several transcript variants are seen in different tissues, with variation 
usually occurring in untranslated sequences in the 5‟ region.  Two mRNA populations 
exist in human lung. The first is similar to the transcripts seen in the liver, but the 
second appears unique to the lung, and is half the size of the first transcript137.  
Although, these transcripts both encode for the same protein138,139, GGT is known to 
undergo various post-translational changes, including glycosylation, and sialylation 
and it may exist complexed to various substances including lipoproteins and 
immunoglobulins.  Such post-translational changes are likely to result in a hydrophilic 
form of GGT as found in the circulation and various bodily secretions140-143.  GGT 
activity is present in the kidney, pancreas, intestine, liver and lung144. 
 
1.2.2.3.3.2. The function of gamma-glutamyl transferase  
 
GGT plays an important role in the synthesis of intracellular glutathione, which 
is the main antioxidant in the lung (see section 1.2.2.2.2.2.)145.  This process is 
shown in figure 1.15.   
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FIGURE 1.15: The role of GGT in the metabolism of gluthathione.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1: Membrane bound GGT catalyses the breakdown of glutathione to cysteinylglycine 
plus a γ–glutamyl moiety. 
2: Cysteinylglycine dissociates into its constituents cysteine and glycine. 
3: Cysteine and glycine can pass easily into the cell, whereas glutathione cannot. 
4. Cysteine, glycine and a γ–glutamyl moiety combine to form the antioxidant, 
intracellular glutathione. 
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Intracellular glutathione (GSH) is utilised rapidly after exposure to oxidative 
stress, and GGT subsequently catalyses the breakdown of extracellular GSH, 
thereby releasing the amino acids cysteine and glycine.  Unlike extracellular GSH, 
these amino acids can then pass easily into the cell, where they are reconstituted 
with a gamma glutamyl moiety to reform intracellular GSH, and hence provide 
antioxidant activity146. 
 
1.2.2.3.3.3. Known associations of gamma-glutamyl transferase 
 
GGT, measured as an activity assay, has been recognised as a sensitive but 
non-specific biomarker of all types of liver disease since the 1960s147, and has 
become a „routine‟ serum liver function test since the 1970s148.  The mechanism 
behind this relationship is poorly understood, although it is known that serum GGT 
activity increases disproportionately compared to hepatic GGT activity in subjects 
with liver disease149,150, which suggests it is unlikely that GGT is simply released from 
damaged liver cells.  Hypotheses promoted to explain this disparity include the 
increased release of the enzyme from surface cell membranes, the induction of GGT 
transcription, and the reduced clearance of GGT from the circulation, but none of 
these have incontrovertible supporting data. 
During the many studies exploring the relationship between GGT and liver 
disease, it was noted that serum GGT activity was particularly elevated in subjects 
with alcoholic liver disease compared with other liver pathologies150, and an 
independent relationship between alcohol consumption and serum GGT activity was 
also reported in both alcohol abusers151 and healthy subjects152,153. 
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However, serum GGT activity has subsequently been related to many other 
factors, including age154 (it increases with age), race155 (it is greater in Afro-caribbean 
subjects compared with white subjects), gender155 (greater in males) and smoking155 
(greater in current smokers than in ex-smokers and those who have never smoked).  
GGT in the circulation may have several other tissue sources (kidney, pancreas, 
brain, spinal cord, reproductive system156) and may be a marker of systemic 
inflammation with increased oxidative stress.  Inflammation is being increasingly 
implicated in the pathophysiology of many systemic diseases71, and this is supported 
by the relationship of these diseases to circulating GGT.  In 1988, Perry et al.157 
reported the results of a prospective study of 7458 British men (age 40-59), and 
demonstrated that higher GGT activity levels at baseline were associated with an 
increased future risk of developing diabetes over the mean follow-up period of 12.8 
years.  Lee et al.158-160 performed 3 further studies using large cohorts of healthy 
subjects, and demonstrated a similar relationship between GGT (with values that 
were mainly within the normal reference range), and diabetes together with impaired 
glucose tolerance, even after correction for confounding factors such as age, gender, 
race, alcohol consumption and smoking. 
Serum GGT activity has also been shown to be associated with myocardial 
infarction since as early as the 1970s161,162.  However, confounding factors were 
often present causing difficulties in interpreting the results of studies.  In 2001, Emdin 
et al.163 prospectively studied the relationship between serum GGT activity and 
myocardial disease over 6 years, and found that subjects with an elevated GGT 
activity at baseline had a greater risk of future myocardial infarction or cardiac death 
even after correcting for confounders.  The relationships were particularly strong for 
39 
 
subjects who had a history of previous myocardial infarction and those who had 
multi-vessel disease.  Subsequently, GGT was implicated in the pathological 
processes of atherosclerotic plaque formation164, and has been shown to be 
associated with hypertension, independently of other confounding factors159.    
Other studies have also established relationships between serum GGT activity 
and the metabolic syndrome along with its individual components (insulin resistance, 
hyperinsulinaemia, dyslipideamia, central obesity and hypertension)165-167.  
Furthermore, serum GGT activity has been shown to relate to all-cause mortality, 
even after correction for confounding factors167-169. 
COPD is becoming increasingly recognised to be related to several co-morbid 
conditions, including ischaemic heart disease170, osteoporosis171 and diabetes172.  
The development of these co-morbidities is thought to be mediated by a common 
systemic inflammatory process involving the cytokine tumour necrosis factor alpha 
(TNFα), oxidative stress, and associated with high serum measurements of high 
sensitivity C-reactive protein (CRP)71.  Serum GGT activity has been shown to relate 
to serum CRP in healthy subjects173, as well as the co-morbidities described above.   
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1.2.2.3.3.4. Gamma-glutamyl transferase and the lung 
 
Previous studies have been performed using rat alveolar epithelial cells to 
examine the characteristics of GGT and its relationship to the antioxidant, 
glutathione, in the lung.  In 1994, Kugelman et al.174 exposed such cells to oxidative 
stress using menadione.  Intracellular glutathione levels initially decreased, but 
subsequently increased to a greater level than at baseline, in conjunction with an 
increase in GGT mRNA and GGT activity.  These changes were prevented by the 
specific GGT inhibitor acivicin.  This study suggested that GSH was initially 
consumed in the pro-oxidant conditions, but the expression of GGT was 
subsequently increased and the enzyme was involved in the breakdown of 
extracellular GGT and re-synthesis of intracellular GGT, as a protective response to 
oxidative stress.  Other similar studies have since been performed using different 
substances to induce oxidative stress, and yielded similar results175,176. 
Moreover, a GGT deficient mouse model was studied by Jean et al. in 
2002177, and demonstrated a six-fold reduction in glutathione levels within alveolar 
macrophages in conjunction with an intense signal for 3-nitrotyrosine (a marker of 
oxidative stress).  When mice were exposed to pro-oxidant conditions, their survival 
was reduced by 25%, due to severe bronchiolar cellular injury and pulmonary 
oedema, associated with glutathione depletion and diffuse oxidant stress measured 
by nitrotyrosine staining. 
In 2004, Payne et al.178 exposed alveolar macrophages and type II epithelial 
cells from human lung to airborne particulate matter collected in the aftermath of the 
World Trade Centre collapse, (which contained pro-inflammatory, pro-oxidant 
inducing substances), and examined the release of GGT, IL-8 and interleukin 6 (IL6).  
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The release of GGT was related to the concentration of particulate matter in a dose 
dependant manner.   
In 1974, Barton et al.179 showed that GGT activity was greater in human 
subjects with chronic bronchitis compared to healthy subjects, and that sputum GGT 
activity correlated with the DNA content of the sputum, which was used as a marker 
of inflammation.  Furthermore, children with an inflammatory phenotype of cystic 
fibrosis had greater GGT activity in bronchoalveolar lavage fluid compared with those 
with a non-inflammatory phenotype of cystic fibrosis180.  
Despite these associations between lung disease and GGT in lung secretions, 
and the relationships of serum GGT activity to co-morbidities associated with COPD, 
which are associated with oxidative stress, no studies have explored serum GGT 
activity in human subjects with COPD, and no attempt has been made to examine 
the relationship between lung secretions and serum GGT levels.  
 
 
1.2.2.3.3.5. Biomarkers 
 
A biomarker is a molecule or substance that can be measured and reflects 
disease process181.  Biomarkers should be involved in the pathophysiological 
process of the disease, they should be stable, (only vary with events known to relate 
to the disease), predict disease progression and be sensitive to effective therapeutic 
interventions182.  Biomarkers should not only be sensitive, specific, but ideally, non-
invasive, acceptable to the subject, inexpensive and easy to obtain and analyse.  
There is currently much research into biomarkers in COPD, including markers in the 
serum, sputum, exhaled breath condensate, bronchoalveolar lavage fluid (BAL) and 
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tissue.  A recent meta-analysis revealed increasing trends with disease severity for 
sputum neutrophils, macrophages and IL8, serum CRP and TNFα and BAL IL8.  
Serum CRP also relates to the MRC dyspnoea score, exercise tolerance183, acute 
exacerbations184, hospitalisation185, disease progression and all cause mortality186 in 
subjects with COPD. 
AATD is generally associated with evidence of increased airway inflammation.  
Elastin breakdown (as part of the inflammation) is a by-process thought to be central 
to the development of emphysema.  However, inflammation is also detectable in the 
airways in subjects with AATD.  It is present to a greater extent in subjects with AATD 
compared with those with usual COPD187, (especially in the presence of chronic 
bronchitis188), and is reduced in subjects receiving augmentation therapy189. 
Biomarkers of inflammation may be important in order to identify subjects at 
risk of developing COPD, or at risk of clinical deterioration such as progression of 
disease severity or to predict or characterise exacerbations.  GGT is an oxidative 
stress component of inflammation and hence has the potential to be an important 
biomarker in lung disease.   
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1.2.3. The PiSZ Phenotype of Alpha-1 Antitrypsin 
Deficiency  
 
1.2.3.1 Epidemiology of the PiSZ Phenotype of AATD 
 
The S allele of AAT exists throughout the world but is most common in 
Europe, where the prevalence increases towards the most South-western parts, 
especially around the Iberian Peninsula190.  This is thought to result from population 
movements eastwards from the presumed origin of the mutation in the North of the 
Iberian peninsula191.  The geographical distribution of the S allele as part of the PiMS 
phenotype in European countries is demonstrated in figure 1.16.  This figure can be 
contrasted to the distribution of the Z allele represented by the PiMZ phenotype in 
figure 1.3, which tends to be more common in northern Europe and less so towards 
the south west. 
It is estimated that over 70,000 people in the U.K. have the PiSZ phenotype of 
AATD and around 130,000 have the PiSS phenotype, and these phenotypes are 
more common than the PiZ phenotype, which is estimated to be present in over 
10,000 subjects190. 
The PiS type of AAT results from a substitution of glutamate for valine at 
position 264192 which leads to increased intracellular degradation of the protein within 
hepatocytes and subsequently a reduction in secretion into the circulation193 (Figure 
1.17).  The PiS AAT also has the capability of forming polymers in a similar way to 
PiZ AAT albeit less readily194.  And has also been shown to form heteropolymers with 
PiZ AAT195. 
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FIGURE 1.16: European distribution by country of the PiMS phenotype of 
alpha-1 antitrypsin deficiency. The figure illustrates the percentage of the 
population estimated to have the PiMS phenotype of alpha-1 antitrypsin in each 
European country. (Figure by Olve Utne and reproduced from 
http://commons.wikimedia.org/wiki/File:PiMS_Europe.png.  Creative Commons 
Attribution ShareAlike 2.5 Lisence). 
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FIGURE 1.17:  Mechanisms by which the PiS type of alpha-1 antitrypsin causes 
a deficiency state in the circulation and the lungs. 
 
 
 
 
 
 
 
 
 
The abnormal PiS type of alpha-1 antitrypsin protein is produced in hepatocytes (1). 
The PiS alpha-1 antitrypsin is more likely to undergo intracellular degradation 
compared with the normal PiM protein (2).  The PiS alpha-1 antitrypsin protein also 
has a mild tendency to polymerise within the hepatocytes (3).  Despite points 2 and 
3, which inevitably cause a reduction in the levels of circulating protein, some active 
PiS alpha-1 antitrypsin is able to enter the circulation and subsequently the lung to 
provide a slightly reduced level of antiprotease activity (4).  
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1.2.3.2. Risk of developing lung disease with PiSZ phenotype of 
AATD 
 
The circulating level of AAT is thought to be an important determinant for the 
risk of developing lung disease.  Previous epidemiological studies suggested that 
serum AAT levels above a threshold of 11microMolar (μM) were not associated with 
a significant risk of developing emphysema196,197.  In 1987, Wewers et al. 
demonstrated that AAT could be infused at a dose of 60mg/kg weekly, and trough 
serum levels were consistently maintained above this 11μM threshold in recipients198.  
If subjects with severe AATD received AAT replacement at this dose, the decline in 
FEV1 over time tended to be lower199,200 and sputum inflammatory mediators fell in 
conjunction with an increase in sputum AAT189, suggesting that serum AAT at 
intermediate levels reduces inflammation and hence protects against the 
development of lung disease.   
In addition, in 1999, Campbell et al.43 demonstrated a non-linear relationship 
in vitro between serum AAT level and the extent of proteolytic damage produced in 
vitro, suggesting this may mimic events critical in the development of emphysema.  It 
was shown that at AAT levels of less than 10μΜ, there was a dramatic increase in 
the area of proteolytic damage produced by polymorphonuclear degranulation both 
theoretically and in vitro compared to levels of greater than 10μM, where relatively 
large increases in AAT concentration result in only a small decrease in the area of 
damage. 
Subjects with the PiSZ phenotype of AATD have circulating AAT levels of 8 to 
16μM19, and therefore some fall above the „protective threshold‟ of 10-11μM, 
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whereas others fall below.  Hence, it is possible that some PiSZ subjects may be at 
increased risk of developing COPD as a result of low levels alone. 
However, some AAT phenotypes also have impaired inhibitory function 
irrespective of their serum level20.  This is possibly relevant for the PiSZ phenotype, 
as the Z variant has a reduced association rate constant for neutrophil elastase.  
Whether this is critical for the borderline SZ level remains unknown.  As such the 
AAT level per se cannot be related directly to the risk of lung disease in AATD, 
although an association with the AATD level is clearly important.     
The neutrophil elastase inhibitory capacity is also slightly lower in both plasma 
and lung epithelial lining fluid with PiS AAT compared with PiM AAT201, and this may 
in turn influence the susceptibility to develop emphysema in subjects with S alleles.  
The interstitial concentration of AAT are predicted to be about 80% of the plasma 
level202 so the critical concentration of 10-11µM would be expected in subjects with a 
plasma level of 13µM, which would include at least the majority of the PiSZ subjects. 
A further factor that should be considered when relating AAT level to the risk 
of lung disease is the fact that alpha-1 antitrypsin is an acute phase protein203.  
Therefore, its‟ level may be elevated in the presence of inflammation such as that 
seen in COPD42, especially during acute exacerbations204.   
Previous case control and cohort studies have tried to assess the risk of 
developing COPD for subjects with the PiSZ phenotype.  In 1969, Fagerhol et al. 
conducted the first case control study and reported a greater frequency of the PiSS, 
PiSZ and PiZZ phenotypes of AATD in Norwegian subjects with lung disease in 
general, when compared with Norwegian blood donors and pregnant women29.  Two 
subjects with the PiSZ phenotype were identified from 503 with pulmonary disease. 
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One had chronic bronchitis and the other had a primary lung cancer.  Three subjects 
with the PiSS phenotype were also identified - one had asthma, the second had 
sarcoidosis and the third a primary malignant tumour.  However this study examined 
subjects with lung diseases of different types, and not exclusively COPD.  
Furthermore, no objective measures, such as pulmonary function were obtained.  
However, some ten years later, the same group attempted to identify the risk of 
developing obstructive lung disease for various phenotypes205.  Three subjects with 
the PiSZ phenotype and 2 with the PiS phenotype were identified from 1258 people 
from the population of Oslo.  Of these, 1 PiSZ subject had COPD, and the numbers 
were too small to draw firm conclusions regarding any increase in risk of COPD in 
subjects with these phenotypes.   
In 1985, Bartmann et al.206 provided the first case control study to show that 
the proportion of PiSZ individuals was greater in German subjects with COPD 
(18/526) compared with blood donors and a group of healthy employees (1/642).  In 
addition, vital capacity was lower and airways resistance higher in PiSZ subjects 
compared with PiMM controls matched for age, gender, disease duration, smoking, 
environmental exposure and serum immunoglobulin E.  However, the S allele 
frequency was not significantly different between the 2 groups.  Nevertheless, this 
was the first study that provided reasonable support that the PiSZ phenotype was 
associated with an increased risk of COPD.  The following year, Lieberman et al.30 in 
a larger study, reported no difference in the proportion of American subjects with 
severe COPD and the PiSZ (2/965) or the PiSS (3/965) phenotypes compared with 
controls (5/1380 and 1/1380 respectively).  Alvarez-Grandez et al.207 produced 
similar results to Lieberman when studying a Spanish population in 1997.  
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Subsequently, Dahl et al. performed a cohort study in a general Danish population 
using data from the Copenhagen City Heart Study.  From 9187 subjects, 10 were 
found to have the PiSZ phenotype.  When compared to subjects with the normal 
PiMM phenotype, the odds ratio for airflow obstruction was 5.4 (CI: 1.6-40), even 
when corrected for age, gender, smoking, occupational exposure and childhood 
infections at 5.3 (CI:1.0-26).  However, the confidence interval for the corrected data 
included 1.0, thus failing to achieve statistical significance.  Nevertheless, a greater 
proportion of PiSZ cases had airflow obstruction (40%) compared with PiM controls 
(15%)208, and PiSZ subjects had a lower mean FEV1 and a more rapid decline in 
FEV1 (56ml per year) if they had previously smoked, compared with PiMM subjects 
(21 ml/year)209.  Twelve PiSS subjects were identified from this study, but no 
differences were observed between these subjects and those with the PiMM 
phenotype.  These data suggested that the PiSZ but not the PiSS phenotype 
conferred an increased risk of developing lung disease although the risk is low. 
As these studies had produced conflicting results, Dahl et al. performed a 
meta-analysis in 2005 to attempt to answer the question, “Is there an increased risk 
of COPD in individuals with the PiSZ genotype?”210.  Six studies were included, 
yielding 42 subjects with the PiSZ phenotype, of whom, 27 had COPD.  They 
reported an odds ratio of 3.26 (95% CI: 1.24-8.57) of PiSZ subjects having COPD 
compared with PiMM subjects.  However, sensitivity analysis revealed that the 
removal of one unusually positive study206 from the analysis meant that this result 
was no longer significant.  In addition, not all studies adjusted for confounding factors 
such as smoking, patient acquisition or ethnicity.  Therefore, despite this further 
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analysis, uncertainty still remains regarding the risk of developing COPD for the PiSZ 
phenotype. 
Although several studies have reported a greater than expected frequency of 
asthma with the PiMS phenotype compared with healthy subjects in Hispanic 211,212 
and white American213 populations, little data are available regarding the risk of 
asthma in the PiSZ, PiSS and PiSVar phenotypes of AATD.  In 1990, Lindmark et 
al.214 described that the frequency of the PiSZ phenotype in 172 Swedish children 
with asthma was similar to that expected in the general population, inferring that the 
PiSZ phenotype was not associated with an increased risk of asthma in minors.  
Similar conclusions were reached by Miravittles et al.215 while studying Spanish adult 
asthmatics.  Contrary to this, Prados et al.216 showed that the PiSZ phenotype was 
more prevalent (p<0.001) in 31 Spanish subjects with intrinsic asthma compared with 
200 subjects representative of the general Spanish population.  In 2000, Sigsgaard et 
al.217 grouped farming students according to their phenotype - PiMM, PiMZ, PiMS, or 
rare (PiSS, PiSZ, PiZZ). Male farming students with rare phenotypes had a higher 
prevalence of doctor diagnosed asthma than subjects with the PiMM phenotype, and 
the odds ratio of having bronchial hyperresponsiveness was increased with the rare 
phenotypes  (4.34; 95%CI:1.19-15.8) in farming students but not in non-farming rural 
based control subjects.  The authors concluded that the S and Z alleles were 
associated with asthma but only in a specific group of subjects, suggesting that the 
relationship between phenotype and asthma was not simple, but a more complex 
gene/environment interaction.  
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The incidence of bronchiectasis in subjects with the PiSZ phenotype is 
unknown, as CT scan appearance has only been reported in 4 such subjects in total, 
as described in more detail in the next section.   
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1.2.3.3. Characterisation of lung disease in PiSZ AATD 
 
Few PiSZ subjects have been characterised in detail involving more complete 
physiology, symptoms and quality of life.  Radiological features and specifically CT 
scans have never been described in a cohort of such subjects. 
The first study to provide a more detailed description of pulmonary physiology 
in subjects with the PiSZ phenotype was by Larsson et al.218 in1976. Seven PiSZ and 
6 PiZ subjects who were diagnosed with AATD due to abnormal serum 
electrophoresis after investigation for conditions other than lung disease were 
described, along with 4 symptomatic PiZ subjects.  These asymptomatic PiSZ 
subjects all had a normal FEV1:FVC ratio, but 2 showed evidence of gas trapping 
with an elevated RV/TLC ratio expressed as a % predicted, and 1 had an abnormal 
gas transfer measurement.  Tests of elastic recoil were abnormal in most PiSZ 
subjects, but pulmonary artery pressures were normal in all subjects. 
In 1982114 and 1983219, Hutchinson et al. described details of 25 PiSZ subjects 
from the UK (14 index and 11 non-index cases).  Of the 8 non-index cases who had 
smoked, one (age 67) had an abnormal FEV1(% predicted) and 2 (age 45 and 63) 
had abnormal gas transfer values, the oldest of whom also had radiological evidence 
of emphysema.  Spirometry or gas transfer was impaired in all 12 index subjects who 
had smoked, and in one of the 2 subjects who had never smoked.  There were signs 
of emphysema on the chest X-ray (CXR) in 9/25 (36%) PiSZ subjects of whom 5 had 
generalised changes, 3 lower zone changes and 1 upper zone changes, compared 
with 85% of PiZ subjects from the same registry.  No radiological signs of 
emphysema were visible in PiSZ subjects who had never smoked. 
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In 1996, Turino et al.220 described the clinical characteristics of 50 PiSZ 
subjects compared with 1090 PiZ subjects from the National Institute for Health 
combined registries.  10 PiSZ subjects had a serum AAT level less than the 
protective11μΜ threshold, and 36% were non-index cases.  A smaller proportion of 
the total 50 PiSZ subjects reported respiratory symptoms (productive cough - 44%; 
wheeze – 42%; dyspnoea – 64%) compared with PiZ subjects (50%, 66%, 85% 
respectively).  However, PiSZ index subjects had a similar incidence of the two latter 
symptoms compared with the PiZ group.  Only 4/14 (29%) PiSZ subjects who had 
never smoked had abnormal spirometry, compared with 51% of PiZ subjects who 
had never smoked.  A similar proportion of PiSZ and PiZ ex or current smokers had 
evidence of airflow obstruction (approximately 70% & 80% respectively).  Pack years 
of cigarettes smoked correlated with FEV1% predicted (r = -0.68) and FEV1:FVC % 
predicted (r = -0.7) more closely in PiSZ subjects compared with PiZ subjects (r = -
0.42 & r = -0.41 respectively).  Evidence of hyperinflation (42%) or bullae (12%) were 
seen less frequently on chest X-rays (CXR) in PiSZ subjects compared with PiZ 
subjects (73% & 29% respectively), and a greater proportion of PiSZ ex or current 
smokers (76%) had an abnormal CXR compared with PiSZ subjects who had never 
smoked (17%).  No differences were found between PiSZ subjects with an AAT level 
<11μM or >11μM when analysed categorically, although multivariate logistical 
analysis revealed an increased prevalence of cough and wheeze with increasing 
serum AAT levels when modelled as a continuous predictor.  The authors suggested 
that cigarette smoking may be a more important risk factor than the AAT level or 
phenotype per se for the development of airflow obstruction in PiSZ subjects 
compared with PiZ subjects.   
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However, there were difficulties regarding the interpretation of this work, as 
fewer PiSZ subjects had smoked compared with PiZ subjects, and an obvious 
selection bias existed, as most data were derived from index subjects who were 
initially diagnosed with AATD due to the presence of lung disease. 
This latter issue was addressed (at least partly) by Seersholm et al. in 1998221, 
who compared 66 index PiSZ cases to 28 non-index PiSZ cases from the Danish 
registry.  It was shown that index subjects had an elevated standardised mortality 
ratio (SMR) of 18 (95% CI: 1.9-171), but non-index subjects did not.  Mean FEV1 
was also higher in non-index subjects (94 %predicted) compared with index subjects 
(59 %predicted) and in never-smokers (94 %predicted) compared with ex or current 
smokers (73 %predicted). However, spirometry data were only available for 62% of 
non-index and 86% of index cases, again introducing a potential selection bias.  It is 
also unclear how subjects diagnosed with AATD due to liver disease or after 
investigation of other diseases were categorised (index / non-index). 
The most informative study regarding the natural history of PiSZ subjects with 
AATD is likely to be the Swedish cohort study described in section 1.2.2.2.2.4.72, 
where 200,000 neonates underwent population screening for AATD in 1972 to 1974, 
resulting in the identification of 127 PiZ and  53 PiSZ subjects.  These subjects have 
been followed up since, and data published at the age of 30 showed that PiSZ 
subjects who had never smoked were more likely to produce sputum (29%) than PiM 
controls (11%), but spirometry values remained normal, even in subjects who had 
smoked73.  Data from a very small subset (n=11) of these PiSZ subjects has very 
recently been made available109 in regards to gas transfer and CT densitometry, 
which was generally comparable with PiM subjects of the same age (mean 32 years).  
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However, significant selection bias exists in this very small subset, making 
generalisation to the PiSZ population as a whole difficult.  Complete spirometric and 
symptomatology follow-up data throughout life will not be available for some 
decades.   
The gross appearance of the thoracic CT scan has only been described in 4 
subjects with the PiSZ phenotype.  The first as part of a case control study by 
Cuvelier et al.222 to determine whether the incidence of AAT phenotypes was 
different in 204 subjects with bronchiectasis compared with healthy controls.  One of 
the 204 subjects was identified as having the PiSZ phenotype and 3 had the SS 
phenotype.  These proportions were no different to control subjects, suggesting these 
phenotypes did not confer an increased risk of bronchiectasis.  The second PiSZ 
subject was presented as a case report and had bronchiectasis in the absence of 
emphysema223.  Finally, McMahon et al. described CT scan findings in 21 subjects 
with the PiZ, 3 with the PiMZ and 2 with the PiSZ phenotypes. One of the PiSZ 
subjects had widespread emphysema, but neither had bronchiectasis224.   
Overall the studies do not support an increased risk of PiSZ subjects 
developing emphysema or asthma.  
 
 
1.2.3.4. Risk of developing liver disease in PiSZ AATD 
 
The risk of developing neonatal, childhood and adolescent liver disease with 
the PiSZ phenotype has been addressed by Sveger et al. and Pittscheiler et al. using 
2 separate cohorts identified by neonatal screening72,225.  Neither have reported 
cases of PiSZ infants developing clinical evidence of liver disease.  However, serum 
biochemistry tests such as alanine transaminase (ALT) and GGT were abnormal in 
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approximately one quarter of PiSZ infants at the age of 3 months The proportion with 
such abnormal tests decreased to 5% at the age of 22 and 2% at the age of 4127, and 
remained at this level until the age of 162,128,226.  However, from 18 years of age226, 
around 10% of PiSZ adolescents had abnormalities of either ALT or GGT, although 
these abnormalities appeared transient, as rarely had the same subjects had 
abnormal results at the ages of 18, 22 and 26126.   
The risk of developing liver disease in older adult subjects with the PiSZ 
phenotype of AATD has not been studied. However, Rakela et al.227 reviewed 19 
subjects with AATD and liver disease, 3 of whom had the PiSZ deficiency, from a 
clinic in the United States of America (USA).  It was noted that PiSZ subjects were 
older than PiZ subjects (mean age 66 in PiSZ compared with 58 in PiZ), and that 2 
PiSZ subjects had liver cirrhosis and 1 had steatohepatitis.  As there are likely to be a 
greater number of PiSZ than PiZ subjects in the USA228, yet fewer subjects with liver 
cirrhosis and AATD have the PiSZ compared with the PiZ phenotype, it seems likely 
that although PiSZ subjects can develop liver disease, it is a far less frequent 
occurrence than in PiZ subjects.  However, as the numbers are small comparisons 
with the incidence of the phenotype in the general population is unlikely to be 
informative. 
 
1.2.4. Testing For Alpha-1 Antitrypsin Deficiency 
 
The World Health Organisation (WHO) recommended that all subjects with 
adult onset asthma or COPD should be tested for AATD64.  However, this approach 
would delay the diagnosis until disease and symptomatology are established.  The 
alternative is neonatal screening although this raises some ethical issues.  
57 
 
Nevertheless when such an approach was initiated in the Swedish cohort described 
previously, subjects responded positively to advice about the hazards of smoking229, 
with little psychological impact.  In practice, it is unlikely that the WHO advice is 
adhered to, possibly due to cost implications and general unawareness of its 
existence.  
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1.3 Background to the current research projects 
 
 
ADAPT (Antitrypsin Deficiency Assessment and Programme for Treatment) is 
the U.K. registry for alpha-1-antitrypsin deficient subjects, and was established in 
1996.  Subjects with alpha-1-antitrypsin deficiency are referred to ADAPT by their 
general practitioner or hospital consultant (predominantly because of the presence of 
lung disease), or are identified by family screening of an index subject, organised 
through the ADAPT programme.   
  Subjects attend annually and clinical, social, physiological, radiological, 
biochemical and microbiological data are collected as detailed in section 2.  Subjects 
undergo a full medical review and examination, following which, advice is given to the 
subject and their general practitioner (GP) regarding current and future management 
of their condition. 
Data are stored in medical records and protected electronic databases, and 
analysed as required. The ADAPT programme is approved by the South Birmingham 
Research and Ethics Committee (LREC Number 3359), and all subjects provide 
written informed consent. 
Four separate studies have been performed using the data acquired from 
ADAPT as summarised below.  Some of the data included in this thesis has 
previously been published230-232. 
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1.4 Purpose of the Research 
   
It is clear that various clinical, radiological and physiological phenotypes of 
COPD exist, in both the smoking population and the alpha-1 antitrypsin deficient 
population.  In order to understand the mechanisms behind these various 
phenotypes and develop effective therapy that is specifically targeted, it is becoming 
increasingly important to define the different aspects of COPD effectively.  The 
current thesis contains projects to further our understanding of the condition.   
 
1. Of the subjects who attend ADAPT, approximately 27% have a normal 
FEV1 and a normal KCO (greater than or equal to 80% of predicted), 14% 
have an abnormal FEV1, but a normal KCO, 7% have a normal FEV1 and 
an abnormal KCO and 52% have abnormalities of both FEV1 and KCO.  
The aim of the first study presented here was to assess the influence of 
different physiological impairments on radiological and clinical factors in 
subjects with each of these physiological patterns, in order to understand 
the implications of different physiological phenotypes. It was hypothesised 
that subjects with an abnormality of KCO would have more upper zone 
emphysema and those with an abnormality of FEV1 would have more 
lower zone emphysema. 
 
 
2. The clinical data from the Swedish cohort of AATD subjects described in 
section 1.2.2.2.2.4.72 suggests that subjects become symptomatic prior to 
spirometry becoming abnormal73, suggesting that spirometry may be 
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insensitive to early change.  Furthermore, we have identified subjects with 
established emphysema and reduced gas transfer but normal 
spirometry230, suggesting that other tests may be more informative. 
The UK database of AATD subjects (ADAPT) includes smokers, non-
smokers, index and non-index subjects who have undergone extensive 
assessment including spirometry, gas transfer, HRCT scanning and health 
status.   In the second study, these parameters were related to age to 
determine, by retrograde analysis, when they deviated from normal values 
in order to provide a more informed approach to monitoring for early lung 
disease.  It was hypothesised that measures of gas transfer and CT 
densitometry would start to deviate from normal prior to spirometry. 
 
  
 
 
3. Biomarkers of inflammation may be important in order to identify subjects 
at risk of developing COPD, or at risk of clinical deterioration such as 
progression of disease severity or before / during exacerbations.  GGT as 
a member of the oxidative stress component of inflammation has the 
potential to be an important biomarker in lung disease.  The third study 
investigated the association of GGT with the inflammation of lung disease 
in order to establish if it had the potential to be a biomarker of lung disease 
as well as liver disease in AATD. It was hypothesised that serum GGT 
would be related to the severity of lung disease in subjects with AATD, and 
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that this would be independent of an anticipated, primary association with 
liver disease. 
 
4. Neither CT scan appearance nor health status have been characterised in 
subjects with the PiSZ phenotype of COPD.  Although physiology and 
clinical features have been described in a small number of subjects and 
compared to subjects with the PiZ phenotypes, confounding factors such 
as differences in smoking history have been present.  Hence the final study 
describes CT scan appearance, CT densitometric analysis and health 
status in PiSZ subjects for the first time.  Physiology and clinical features 
are also described, and those are compared to subjects with the PiZ 
phenotype matched for age, gender, smoking status, pack years and finally 
ascertainment method to determine any differences in disease phenotype 
and its impact.   
 
 
 
 
 
62 
 
2. GENERAL METHODS 
 
This chapter describes the general methodologies used in ADAPT to perform 
the biochemical, social, physiological and radiological assessments on the subjects 
studied.  The manner in which the data were collated and analysed to perform each 
individual study is described in sections 3, 4, 5 and 6, which detail the individual 
research projects. 
 
2.1 AAT Level and phenotype 
 
 The AAT level (μM) is measured at the baseline visit, and the phenotype is 
determined by isoelectric focusing at a central USA laboratory (Salt Lake City, Utah). 
 
2.2 Questionnaires 
 
 Each subject completes an annual questionnaire including demographics and 
current symptoms such as the Medical Research Council (MRC) dyspnoea score233, 
the presence of chronic bronchitis as defined by the MRC criteria 68, sputum colour in 
the stable state using the Bronko Test chart (BronkoTest, Middlesex, U.K.)234, and 
the number and features of exacerbations of COPD using the Anthonisen criteria70.  
Subjects are asked to recall the reason they were initially tested for AATD.  Those 
who were tested because of the presence of respiratory or liver disease are termed 
„index‟ subjects, and those who underwent testing primarily due to family screening 
or population screening are termed „non-index‟ subjects.  All „index‟ subjects 
described in the current studies refer to those index subjects who were initially tested 
for alpha-1 antitrypsin deficiency due to lung disease unless stated otherwise in the 
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relevant section.  The database also captures information about medication use, past 
medical history, smoking, alcohol consumption, occupational history and family 
history. 
 At the baseline visit, subjects complete a St Georges Respiratory 
Questionnaire (SGRQ)235 and the Short Form-36 (SF-36)236.  The SGRQ is a 
reproducible 76 item questionnaire to assess quality of life, and is validated for use in 
COPD subjects235. The questionnaire provides 3 separate domain scores (symptoms, 
activity and impacts) along with a total score.  The greater the score, the worse the 
health status, and an increase of 4 points in the total score is suggestive of a 
clinically significant difference235. 
 The SF-36 is a 36 item questionnaire used to assess general health.  It 
produces 8 health profile scales, which can be used to calculate a physical health 
summary score and a mental health summary score. The lower the score, the worse 
the health status, and normal values are available for the general population237.  
 
 
2.3 Pulmonary physiology 
 
All pulmonary physiology tests are performed in accordance with the 
ARTP/BTS Guidelines238.  Spirometry is measured at the initial visit, using 
Vitalograph Wedge Bellows (Vitalograph, Bucks, U.K.), before and after the 
administration of 5mg of nebulised salbutamol and again following the addition of 500 
μg of nebulised ipratropium bromide 30 minutes later.  For subsequent visits, 
spirometry is only undertaken after these medications have been administered.  A 
significant bronchodilator response is defined as an increase in FEV1 of greater than 
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200ml from baseline and more than 12 % of the predicted value as per the American 
Thoracic Society (ATS) guidelines239.   Carbon monoxide transfer is determined 
using the single breath method described by Ogilvie240 using Benchmark TT501 
(Morgan Medical, Kent, U.K.), and corrected for alveolar volume (KCO).  Lung 
volumes are measured by the helium dilution technique described by Meneely241 
using Benchmark TT501 (Morgan Medical, Kent, U.K.). 
Values are expressed as a percentage of the average value for normal 
subjects (% predicted) as defined by the European Community for Steel and Coal75.  
The partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2) are determined 
in arterialised capillary blood from the earlobe, using a Radiometer ABL5 
(Radiometer Ltd, Copenhagen, Denmark). 
 
 2.4 Computed tomography scans 
 
 High resolution computed tomography (HRCT) scans of the thorax are 
performed at the initial visit in most subjects unless a recent scan had been 
performed at the referring centre.  A GE Prospeed Scanner (General Electrical 
Medical Systems, Milwaukee, USA) was utilised until March 2002, and a GE 
Lightspeed Scanner (General Electrical Medical Systems, Milwaukee, USA) was 
used subsequently.  Slices of 1mm are taken at 10mm intervals through the thorax at 
full inspiration.  A thoracic radiologist provides a radiological report for each CT scan, 
commenting on the presence of emphysema, bronchiectasis and any other 
abnormality visualised.  All CT scans performed from 1996 to 2001, and CT scans for 
selected subjects relevant to a particular study hypothesis in subsequent years, were 
analysed using density mask analysis.  This technique assesses the percentage of 
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voxels with a density of less than a fixed level, which for these studies was -910 
Hounsfield units.  This percentage is known as the voxel index (VI) and was 
calculated for the upper zone (using one slice at the level of the aortic arch) and the 
lower zone (using one slice at the level of the inferior pulmonary veins).  These 
calculations were performed using a GE proprietary density mask programme 
integral to the CT scanner, or Pulmo-CMS software (MEDIS Medical Imaging 
Systems BV, Leiden, The Netherlands).  These objective measures were unavailable 
for any scan performed at the original patient referring centres.    
 Emphysema distribution was assessed, with upper zone predominance 
defined as the upper zone voxel index (VI) being greater than the lower zone voxel 
index, and lower zone predominance defined as the lower zone VI being greater than 
the upper zone VI. 
 
2.5 Biochemical and haematological investigations 
 
Venous blood is taken at each visit to determine the full blood count and liver 
function tests, including gamma-glutamyl transferase (GGT) (Instrumentation 
Laboratory Ltd, Warrington, U.K.), aspartate transaminase (AST), alkaline 
phosphatase (ALP) and bilirubin.  Serum and plasma are also stored for use in any 
future analyses of relevant biomarkers. 
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3. RADIOLOGICAL AND CLINICAL FEATURES 
OF SUBJECTS WITH DISCORDANT LUNG 
FUNCTION 
 
 
3.1 Aims of the study 
 
Of the subjects who attend ADAPT, approximately 27% have a normal FEV1 
and a normal KCO (greater than or equal to 80% of predicted), 14% have an 
abnormal FEV1, but a normal KCO, 7% have a normal FEV1 and an abnormal KCO 
and 52% have abnormalities of both FEV1 and KCO.   
We aimed to assess the influence of these different patterns of physiological 
impairment on radiological and clinical factors, in order to define further the 
characteristics of these phenotypes of COPD associated with AATD.  It was 
hypothesised that subjects with an abnormality of KCO would have more upper zone 
emphysema and those with an abnormality of FEV1 would have more lower zone 
emphysema. 
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3.2 Method 
 
Patients are listed on the ADAPT database in chronological order depending 
on the date of their baseline visit.  The database was reviewed to identify the first 15 
PiZ subjects to undergo a baseline visit, who had complete CT densitometry data 
and a normal FEV1 (> 80% of predicted), a normal FEV1:FVC ratio (>70%) and a 
normal KCO (>80% of predicted) at baseline (group 1); In a similar fashion, the first 
10 PiZ subjects with an abnormal FEV1 and a normal KCO (group 2); the first 15 PiZ 
subjects with a normal FEV1, FEV1:FVC ratio and an abnormal KCO (group 3) and 
the first 10 PiZ subjects with an abnormal FEV1 and an abnormal KCO (group 4) 
were identified. 
A thoracic radiologist reported the presence or absence of emphysema and 
bronchiectasis without previous knowledge of the subject‟s physiological 
measurements.  The upper zone voxel index (UZVI) and lower zone voxel index 
(LZVI) were noted, and the relative distribution of emphysema was calculated as 
described in section 2.4.  These radiological data along with the presence of chronic 
bronchitis defined by the MRC criteria68, the number of exacerbations per year, the 
MRC dyspnoea score233, the PaO2 while breathing room air, and the SGRQ total 
scores235 were compared between the 4 physiological groups. 
Statistical analyses were performed using SPSS 12.0.1 for Windows. For 
parametric data, the t – test was used to compare 2 categories and one way ANOVA 
was used to compare more than 2 categories.  For non-parametric data, the Mann-
Whitney test was used to compare 2 categories and the Kruskall-Wallis test was 
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used to compare more than 2.  A p value of < 0.05 was taken as statistically 
significant. 
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3.3 Results 
 
3.3.1 Demographic data 
 
Data describing the demographic details and pulmonary function parameters 
are shown in table 3.1.  80% of subjects in groups 2 & 4 were female, but in view of 
the small numbers, this was not different (p = 0.1 and 0.1 respectively) to the 
proportion of females in group 1 (40%) or group 3 (53%; p = 0.18 and 0.23 
respectively).  Subjects in group 4 were older than those in group 1 (p = 0.043), but 
otherwise the groups were of a similar age.  The majority of subjects from groups 1 
(73%) and 3 (73%) had never smoked, whereas the majority of subjects from groups 
2 (90%) and 4 (100%) were current or ex-smokers (p<0.001). 
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TABLE 3.1: Demographic data for four groups of subjects with differing 
patterns of lung function. 
 GROUP 1 
Normal 
FEV1 & KCO 
GROUP 2 
Abnormal 
FEV1 
GROUP 3 
Abnormal 
KCO 
GROUP 4 
Abnormal 
FEV1 & KCO 
n = 15 10 15 10 
Male gender n = 9         (60%) 2       (20%) 7     (47%) 2 (20%) 
Age  Mean (S.D.) 44.4    (12.6) 48.4     (4.2) 48.0  (15.6) 53.7  (6.7) 
p=0.043* 
Smoking status       Never   n = 
 
        Ex       n =
  
        Current n = 
 
  
11     (73%) 
 
3       (20%) 
 
1       (7%) 
1         (10%) 
 
9         (90%) 
 
0 
 
* p=0.004 
11        (73%) 
 
3          (20%) 
 
1          (7%) 
 
●p=0.004 
0 (0%) 
 
9          (90%) 
 
1          (10%) 
 
* p<0.001 
¶ p=0.001 
Pack years mean (S.D.) 2.3       (5.2) 20.7    (11.7) 
*p<0.001 
4.3     (7.7) 
●p=0.001 
34.1    (17.0) 
*p<0.001 
¶p<0.001 
FEV1 % Predicted  mean (S.D.) 105.7  (13.2) 31.3    (5.6) 
*p<0.001 
111.7  (19.6) 
● p=0.001 
30.3     (8.6) 
*p<0.001 
¶p<0.001 
KCO % Predicted   mean (S.D.) 97.3    (16.7) 89.0    (7.4) 69.5   (10.2) 
*p<0.001 
●p<0.001 
56.8    (5.1) 
*p<0.001 
●p<0.001 
¶p=0.001 
FEV1:FVC mean (S.D.) 87.6    (10.2) 34.4    (7.4) 
*p<0.001 
75.4   (11.1)  
●p<0.001 
27.7     (9.3)  
*p<0.001 
¶p<0.001 
The table shows demographic data for the 4 groups of PiZ subjects with differing 
patterns of lung function.  Categorical variables are given as n= (% of group); 
continuous data are stated as mean (+/- S.D.). The data for pack years is derived 
from smokers alone.  
* = significantly different from group 1.         ● = significantly different from group 2.  
¶ = significantly different from group 3. 
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3.3.2 CT Appearance & Densitometry 
 
Emphysema was visible on the CT scan in 2/15 with „normal‟ physiology.  This 
proportion was greater in all groups with abnormal lung function (all of group 2, p < 
0.001; 12/15 from group 3, p = 0.05; and all of group 4, p < 0.001).   
Densitometry data are shown in table 3.2 for all groups and summarised in 
figures 3.1 & 3.2 for group 2 with an isolated abnormal FEV1 and group 3 with an 
isolated abnormal KCO.  
UZ VI was greater (indicating more severe upper zone emphysema) in all 
groups with abnormal lung function (2, 3 & 4) than in those with normal lung function 
(p = 0.003, 0.044 & < 0.001 respectively).  Subjects with an abnormality of both FEV1 
and KCO (group 4) had a greater UZ VI than subjects with either an isolated 
abnormality of FEV1 (p = 0.017) or those with an isolated abnormality of KCO (p = 
0.006). 
LZ VI was also greater (indicating greater lower zone emphysema) in groups 2 
and 4, compared to those with normal lung function (p < 0.001 & p < 0.001 
respectively) or subjects with an isolated abnormality of KCO (p < 0.001 & p < 0.001 
respectively).  Those with an isolated abnormality of KCO (group 3) had a similar LZ 
VI to those with normal lung function (p = 0.073).  The LZ VI in subjects with an 
abnormal KCO and an abnormal FEV1 was no different to those with an isolated 
abnormality in FEV1 (p = 0.147). 
Groups 2 and 4, with an abnormal FEV1, had relatively more basal 
emphysema than group 1 with normal lung function (p < 0.001 and p < 0.001 
respectively) or group 3 with an isolated abnormality of KCO (p < 0.001 and p < 
0.001 respectively).  Group 2 (isolated FEV1 abnormality) had the greatest relative 
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basal emphysema score, indicating basal dominant emphysema and group 3 had the 
lowest score indicating relatively more upper zone emphysema. 
 
TABLE 3.2: CT scan densitometry data for four groups of subjects with 
differing patterns of lung function. 
 
 GROUP 1 
Normal 
GROUP 2 
Abnormal 
FEV1 
GROUP 3 
Abnormal 
KCO 
GROUP 4 
Abnormal 
FEV1 & KCO 
Upper zone voxel index 
(UZVI)  mean (S.D.) 
 
13.2  (5.9) 
 
28.1     (11.8)  
*p=0.003 
 
23.0     (16.6)  
*p=0.044 
 
40.4   (8.8) 
*p<0.001 
●p=0.017 
¶p=0.006 
Lower zone voxel index 
(LZVI)  mean (S.D.) 
 
14.8  (9.6) 
 
54.9     (13.3)  
*p<0.001 
 
23.8     (16.1) 
●p<0.001 
 
62.8   (9.4)  
*p<0.001 
¶p<0.001 
Relative emphysema 
distribution (LZVI-UZVI) 
  mean (S.D.) 
 
 
+1.6  (9.1) 
 
 
+26.8   (11.2)  
*p<0.001 
 
 
+0.8  (8.4)  
●p<0.001 
 
 
+22.4 (10.8)  
*p<0.001 
¶p<0.001 
The table shows the mean (+/- S.D.) voxel index for the upper and lower zones and 
relative distribution of emphysema (LZ VI – UZ VI) for each group with differing 
patterns of lung function.  
* = significantly different from group 1.  
● = significantly different from group 2. 
¶ = significantly different from group 3. 
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FIGURE 3.1: Relative emphysema distribution related to FEV1in subjects with 
an abnormal FEV1 & normal KCO and those with a normal FEV1 & abnormal 
KCO.   
 
 
 
The figure shows the relative distribution of emphysema (LZ VI -UZ VI), and the 
relationship to FEV1 % predicted for each case in group 2 (■) and group 3 (●).   
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FIGURE 3.2: Relative emphysema distribution related to KCO in subjects with 
an abnormal FEV1 & a normal KCO and those with a normal FEV1 and an 
abnormal KCO.   
 
 
 
 
 
The diagram shows the relative distribution of emphysema (LZ VI -UZ VI), and the 
relationship to KCO % predicted for each case in group 2 (■) and group 3 (●).   
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3.3.3 Symptoms 
 
Chronic bronchitis was present in 4/15 (27%) subjects from groups 1 and 3 
and in 4/10 (40%) of subjects from groups 2 and 4, but these proportions were not 
different between the groups (p=0.815).   
The median number of annual exacerbations was 0.6 (I.Q.R. = 0 – 1.5) in 
group 2, compared with 0 (0 – 0) in group 1, 0 (0-1.0) in group 3 and 0 (0 – 1.1) in 
group 4, and again these differences between groups did not achieve statistical 
significance (p=0.345). 
All subjects in groups 2 and 4 had mild symptomatic impairment as 
determined by the MRC dyspnoea score as summarised in figure 3.3.  Interestingly 
only 40% of subjects in group 1 had a normal MRC dyspnoea score despite having 
normal lung function.  Two subjects in group 3 had moderate to severe 
breathlessness as assessed by the MRC score, whereas no subjects from group 2 or 
4 had this degree of dyspnoea.  However, there were no statistically significant 
differences in MRC dyspnoea score between the four groups (p=0.248). 
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FIGURE 3.3: MRC dyspnoea scores in subjects with differing patterns of lung 
function.   
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The graph shows the proportion of subjects with different MRC dyspnoea scores in 
each of the groups with differing patterns of lung function. A higher MRC dyspnoea 
score indicates more severe breathlessness. 
 
 
 
3.3.4 PaO2 
 
Figure 3.4 summarises the mean PaO2 for each of the groups.  Groups 2 and 
4 had lower PaO2 measurements than group 1 (p < 0.001 and p < 0.001 
respectively) and group 3 (p < 0.001 and p < 0.001 respectively). 
 
 
MRC Dyspnoea Score 
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FIGURE 3.4: PaO2 in KPa for each group with differing patterns of lung 
function.   
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The columns represent the mean PaO2 and the bars represent the standard 
deviation (S.D.).  The asterix marks a significant difference compared with groups 1 
and 3 (see text). 
 
 
3.3.5 Health status 
 
Total SGRQ scores were greater, (indicating a worse quality of life) in group 2 
(mean =56.8, S.D. = +/- 15.3; p < 0.001), group 3 (29.7 +/- 24.1; p = 0.048) and 
group 4 (59.2 +/- 16.7; p < 0.001) compared to those with normal lung function (17.7 
+/- 11.5).  There was no difference in total SGRQ scores between group 2 and group 
4 (p = 0.894), although both these groups had worse scores than those in group 3 (p 
= 0.01 and p = 0.01 respectively).  
* 
* 
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3.3.6 Summary of the results 
 
Differences existed between the different physiological groups with respect to 
age, smoking history, emphysema (prevalence, distribution and extent), PaO2 and 
health status, demonstrating that different physiological phenotypes are associated 
with different radiological and clinical features. 
Generally the 2 groups with abnormalities of FEV1 consisted of more smokers, 
subjects with greater severity of emphysema, lower PaO2 and worse health status 
than groups with normal lung function or those with an isolated abnormality of KCO.  
However, subjects with an abnormal KCO in addition to an abnormal FEV1 had more 
extensive upper zone emphysema, even though it was not associated with a worse 
health status or PaO2 compared with subjects who had an isolated abnormality of 
FEV1.   
Subjects with an isolated abnormality of KCO had more emphysema and a 
worse health status than those with normal lung function.  They also had a more 
apical distribution of emphysema compared with subjects with an isolated 
abnormality of FEV1 who had the most basal distribution. 
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3.4 Discussion     
 
The current findings exploring the relationship between lung function and 
emphysema demonstrate that FEV1 is associated with the most lower zone 
emphysema predominance whereas KCO is associated with the most upper zone 
emphysema predominance.  These data support the results obtained by Dowson et 
al.107 and Parr et al.108.   
Gurney et al.242 studied 59 non-deficient subjects who had been heavy 
smokers, 42% of whom had a normal FEV1 and DLCO, 25% of whom had 
abnormalities of FEV1 and DLCO and the remainder who had either an isolated 
abnormality of FEV1 or an isolated abnormality of DLCO.  Two thirds of the subjects 
had evidence of emphysema on CT scanning, presumed to be usual smoking-related 
emphysema, with the upper zones being affected in 59% of the subjects, and the 
lower zones in 39%.  Gurney compared pulmonary function tests to CT density mask 
analysis using the -910HU threshold.  Contrary to the current study results, Gurney 
suggested that DLCO correlated with lower zone densitometry to a greater extent 
than FEV1, and that lower zone densitometry generally correlated with lung function 
better than upper zone densitometry.  However it should be noted that DLCO is not 
corrected for alveolar volume.  It represents overall gas uptake and is influenced by 
both distribution (i.e. not getting to the gas exchanging areas) as well as reduced 
alveolar surface area.  Obstruction of small airways will thus also influence this 
measure and may explain why lower zone changes correlate best where airflow 
obstruction may have a more significant effect.   
 Gurney‟s explanation for this phenomenon was that the lower zone of the lung 
made a much greater contribution to total lung volume than the upper zone, and 
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therefore, a relatively large degree of emphysema in the upper zone would have 
relatively little impact on lung function parameters, as the greater intact bulk of tissue 
in the lower zone would act as good reserve, thereby relatively sparing pulmonary 
function abnormality and it‟s decline.  This would certainly be consistent with the 
observation that FEV1 is strongly associated with lower zone emphysema in the 
current study.  
However, the relationship between abnormalities in KCO and upper zone 
emphysema demonstrated in the current study cohort are consistent with this area 
being important in overall gas exchange.  This could be explained by changes in the 
ventilation perfusion ratio in the presence of basal emphysema.  Normally, the 
ventilation perfusion ratio in the upper zones is greater than in the lower regions 243.  
Therefore, deficiencies in gas transfer caused by reduced ventilation and perfusion in 
the presence of basal emphysema can be compensated for by the upper zones, by 
increasing perfusion of this region as a result of the increase in pulmonary perfusion 
pressure caused by basal lung disease.  The result would enable KCO to be 
relatively preserved in predominantly basal disease, which is far more prevalent in 
this AATD cohort, but not if the emphysema is predominantly apical, as in the Gurney 
cohort.   
A further explanation for the association between FEV1 and lower zone 
predominant emphysema demonstrated in the current study is that the lower lobe 
airways start to close earlier in expiration 244.  The presence of emphysema in the 
lower zones would exaggerate this due to dynamic collapse of the airways because 
of paucity of supporting tissue, and thereby also contribute to a reduction in 
FEV1which acts as a surrogate for emphysema in this region. 
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 In the current cohort, subjects with an abnormal FEV1 had greater relative 
distribution of emphysema at the bases, which is consistent with these concepts.  
Also, subjects with an isolated abnormality of KCO had the least basal emphysema 
relative to the apical region and the addition of an abnormal KCO to an abnormal 
FEV1 was associated with a further increase in upper zone but not lower zone 
emphysema.  These observations add further credence to the concept that the upper 
zones are more likely to reflect gas transfer abnormalities than the lower zones, at 
least in AATD. 
The optimal density threshold for performing density mask analysis is still a 
matter of controversy.  Although studies in usual COPD have shown that density 
mask analysis using a threshold of -950HU correlates best with macroscopic and 
microscopic emphysema measured from pathological specimens, no such 
pathological studies have been done in AATD.  However densitometry using the 
threshold of -910HU has been shown to relate to physiology, health status107, decline 
in lung function245 and mortality85 in subjects with AATD.  Furthermore, in a study of 
33 subjects with AATD, the correlations of voxel indices to FEV1, KCO and TLCO 
were better using a threshold of -910HU than -950HU 246.  Finally, the -950HU 
threshold sensitivity is influenced by disease severity247.  In early disease, -950HU is 
relatively insensitive to small changes in lung density, whereas unpublished data 
from our group suggest that using a threshold of -910HU is more sensitive.  For 
these reasons, density mask analysis was performed using a threshold of -910HU. 
The current study also raises issues concerning the accepted definitions of 
COPD, its severity and treatment, all of which are based on the presence of airflow 
obstruction33,248,249. Subjects have been identified who have no airflow obstruction yet 
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have evidence of emphysema on a CT scan, with or without an isolated abnormality 
of gas transfer and reduced health status. 
Two of the fifteen subjects in the current study with no evidence of airflow 
obstruction and a normal KCO had evidence of emphysema.  Gurney et al.242 also 
described, however, that in non-deficient heavy smokers, 40% of subjects with 
normal lung function had CT evidence of emphysema. 
On the other hand, 80% of subjects with an isolated abnormality of KCO in the 
current study cohort had radiological evidence of emphysema, associated with a 
reduced health status.  Emphysema in these subjects was generally mild in severity 
and evenly distributed throughout the lung.  Despite the poor health status in this 
group compared with subjects with normal pulmonary physiology, there was no 
difference in the mean MRC dyspnoea score, annual number of exacerbations or the 
proportion with chronic bronchitis.  However, there was a greater range of dyspnoea 
reported in this group compared to the other groups, with some subjects reporting no 
dyspnoea, and others reporting severe dyspnoea. 
The fact that subjects can be identified who have evidence of emphysema and 
/ or reduced gas transfer but no airflow obstruction suggests that gas transfer and CT 
scan should be used to assess all subjects suspected of having COPD, and 
investigations should not be confined to spirometry alone, particularly in the presence 
of symptoms.   
It remains to be seen if subjects from the 4 different physiological groups 
progress from one group to another (for example, do subjects in group 1, with or 
without CT scan evidence of emphysema subsequently develop either airflow 
obstruction alone, or an impaired gas transfer alone, and eventually progress so that 
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both FEV1 and KCO become abnormal), or do they represent a completely separate 
phenotype.  Long term prospective studies such as the Swedish study described 
earlier72 are required to address this issue in AATD.  However, unfortunately gas 
transfer and CT scans have not routinely been performed in the Swedish cohort to 
date. 
In usual COPD, evidence that an isolated abnormality of KCO is related to 
early emphysema was demonstrated previously by Klein et al.115, who found that 
62.5% of smokers who had recently complained of dyspnoea, had a normal chest X-
ray but had visible emphysema on the CT scan, and were shown to have an isolated 
abnormality of KCO.  In addition, Tylen et al.250 showed that 44% of asymptomatic 
smokers had evidence of emphysema on CT scanning compared to 3% of subjects 
who had never smoked, and those with emphysema had a significantly lower KCO 
but a similar FEV1 compared to the subjects without emphysema.  Both of these 
studies in usual COPD support the current findings.  
However, these studies also relate to subjects who were smokers, and the 
majority of subjects in the present study from groups 1 and 3 had never smoked.  It is 
possible that AATD influences the way different physiological phenotypes develop.  
For example, non-smoking subjects may develop upper zone emphysema first, with 
an associated reduction in the KCO, but the addition of smoking leads to more 
extensive basal emphysema in which airflow obstruction predominates.  This is 
contrary to the process in usual COPD, where smoking is the major risk factor, and 
the emphysema predominantly affects the upper zone.  It is possible that other 
genetic modifiers exist in AATD, in a similar way to the matrix metalloproteinase 
(MMP) 9 (C-1562T) polymorphism in usual COPD 251.  This polymorphism may 
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influence the distribution of non-smoking related emphysema in AATD but this 
concept clearly requires further study. 
Whether the different physiological groups represent subjects at different 
stages of lung disease or whether each physiological phenotype is a separate entity, 
influenced by environmental or other genetic factors requires further investigation.  
This may be crucial to the development of future treatment strategies for AATD in 
order to reduce decline in lung function at an earlier stage and / or to minimise the 
deterioration in health status observed in these individuals depending on their 
physiological phenotype. 
An interesting observation from the current study is that even AATD subjects 
with normal lung function have impaired health status (mean SGRQ score of 17.7 +/- 
11.5) compared with a general population of a similar age (mean SGRQ score 5.8).  
This may be related to symptoms of breathlessness, (60% described being 
breathless while walking on the level or up a slight hill), or chronic bronchitis, which 
was reported in 27%.  In addition, 2 subjects with normal lung function reported 
having exacerbations and a further 2 had emphysema visible on the CT scan.  These 
symptoms have previously been associated with a worse SGRQ score in subjects 
with COPD252.  Furthermore, in subjects with AATD, the presence of chronic 
bronchitis84, and CT measures of emphysema severity83 have also been associated 
independently with the SGRQ, and these factors may also explain (at least in part) 
impaired health status in subjects with AATD and normal lung function. 
Subjects with an isolated abnormality of KCO had a worse health status than 
those with normal lung function.  By definition, this group had a worse mean KCO 
than group 1, and KCO does reflect a worse SGRQ score in subjects with AATD107.  
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A much greater proportion of subjects from group 3 had emphysema on the CT scan 
(80%) compared to group 1 (13%), and this was reflected as a difference in the UZVI 
but not the LZVI between the groups.  Worse UZVI scores have also been shown to 
be associated with worse SGRQ scores in AATD 83, but no data are available 
regarding the influence the subjective description of visible emphysema on the CT 
scan on the SGRQ.  In addition, some subjects from group 3 described having 
moderate to severe breathlessness (MRC grade 3-4), whereas no subjects from 
group 1 were dyspnoeic to this level.  As SOB is associated with a worse health 
status in COPD252, it is possible that this factor also contributed to the difference in 
health status between groups 1 and 3.  
Groups 2 and 4 had worse mean SGRQ scores than groups 1 or group 3.  
Groups 2 and 4 had worse FEV1 and LZVI measurements than groups 1 and 3, and 
subjects from groups 2 and 4 had smoked more.  As all these factors have been 
independently associated with SGRQ scores in AATD, even after correction for other 
associated factors, the observed differences in health status remain predictable. 
No difference in health status was observed between groups 2 and 4 despite 
differences in KCO, UZVI and age, which have previously been shown to influence 
the SGRQ scores in AATD84,107.  However, compared to FEV1, LZVI and pack years 
smoked, the relationships of these variables to health status is relatively weak, and 
may not be adequate to result in a significant difference in health status.   
In summary different patterns of physiological abnormalities reflect differences 
in the radiological distribution of emphysema in AATD.  Subjects with an isolated 
abnormality of KCO clearly have pathological and clinical abnormalities.  Furthermore 
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even subjects with lung function in the normal range have some evidence of 
emphysema and symptoms consistent with impaired health status.  
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4. AGE AT WHICH RADIOLOGICAL, 
PHYSIOLOGICAL AND HEALTH STATUS 
MEASURES DEVIATE FROM NORMAL IN NON-
INDEX ALPHA-1 ANTITRYPSIN DEFICIENCY 
 
 
4.1 Aims of the study 
 
The aim of the current study was to determine the age at which spirometric, 
gas transfer, HRCT densitometric and health status measures in subjects with alpha-
1 antitrypsin deficiency start to deviate from values expected in the normal healthy 
population, in order to provide a more informed approach to monitoring for the early 
identification of lung disease.  It was hypothesised that measures of gas transfer and  
CT densitometry would start to deviate from normal prior to spirometry. 
 
  
88 
 
4.2 Methods 
 
All 591 PiZ subjects who were included on the ADAPT database at the time 
this study was performed were included and data from their baseline visit were 
analysed.  FEV1, the ratio of FEV1 to forced vital capacity (FEV1:FVC) and carbon 
monoxide transfer factor corrected for alveolar volume (KCO) were measured and 
expressed as a percentage of predicted75.  
 A high resolution CT scan (HRCT) had been performed for 563 subjects, and 
density mask analysis was available for 368, to determine the proportion of CT 
voxels with a density of less than -910 HU (Hounsfield Units) in the upper zone 
(UZVI) and lower zone (LZVI) as described earlier.  The presence or absence of 
visible emphysema on CT was determined independently by a thoracic radiologist.  
Subjects‟ St Georges Respiratory Questionnaire (SGRQ) and demographic data, 
including smoking history and the reason for initial diagnosis of AATD were obtained 
from the ADAPT database.   
 The proportions of subjects with abnormal results was taken as those with an 
FEV1, FEV1:FVC and KCO of less than 80% of the predicted values for age, gender 
and height75.  There are no defined reference ranges for SGRQ scores, UZVI or 
LZVI, so we calculated the proportion of subjects with a score greater than 1.96 
standard deviations above the mean obtained from a healthy population106,253, based 
on a theoretical reference range encompassing values obtained in 95% of healthy 
subjects.  These calculated normal values are shown in table 4.1 below.   
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TABLE 4.1: Mean and reference ranges calculated for St Georges Respiratory 
Questionnaire Total Scores, Upper Zone Voxel Index and Lower Zone Voxel 
Index. 
 CALCULATED 
MEAN VALUE 
CALCULATED REFERENCE 
RANGE 
SGRQ Total score 8.41 0 – 30.61 
Upper zone voxel index 5.0 0 – 16.76 
Lower zone voxel index 13.0 0 - 44.36 
The reference ranges are calculated as being between 1.96 standard deviations 
above and below the mean, based on a theoretical reference range encompassing 
values obtained in 95% of subjects.  Data are derived from previously published 
values in subjects from a general population in whom lung disease had been 
excluded106,253 . 
 
 
The age at which test parameters start to decline was determined by 2 
methods.   
Firstly, the cohort was split into 5-year age strata, and the proportion of 
subjects in each strata who had values „worse‟ than the healthy population mean was 
determined for each measure.  The earliest age group in which this proportion was 
consistently greater than 50% was determined. 
 Secondly, a mathematical model was constructed including all subjects, using 
forward logistic regression (SPSS 12.0.1 for Windows, SPSS, Chicago, IL), with 
FEV1 <100% predicted as the dichotomous dependant variable, and age, gender, 
smoking status and method of ascertainment as co-variates.  Using the model, an 
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equation was produced to determine the probability of the FEV1 being <100% 
predicted, expressed in terms of the covariates stated above.  Coefficients for these 
covariates were inserted into the equation to represent the patient ascertainment, 
smoking status and gender. By definition, in a healthy population, it is expected that 
half of subjects will have an FEV1 <100% predicted.  We therefore inserted different 
ages into the equation to determine the earliest age at which the probability of the 
FEV1 being <100 % predicted was consistently greater than 0.5 (i.e. started to 
deviate from normal).  
 Similar models were constructed for FEV1:FVC ratio, KCO, SGRQ total score, 
upper zone voxel index (UZVI) and lower zone voxel index (LZVI) being less than or 
greater than the respective mean for a healthy population as the dichotomous 
dependant variables.  The mean values used for the healthy population were 100% 
predicted for FEV1:FVC and KCO, and previously published normal values related to 
age for the SGRQ253.   No normal values for density mask analysis at a threshold of -
910HU have been published.  Therefore, previously published values determined 
using a GE Prospeed CT scanner with a density mask analysis threshold of -912HU, 
in subjects who had never smoked and had no evidence of lung disease on 
pulmonary physiology and HRCT were used106 .  
 Using SPSS 12.0.1 for Windows (SPSS, Chicago, IL), data were compared 
between index & non-index subjects (identified by family screening) and subjects 
who had smoked or not.  The Chi Squared and Fishers exact tests were used to 
compare categorical data, the one-way ANOVA test was used if continuous data 
were parametric and the Kruskal-Wallis test was used for non-parametric data.    
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 Subjects gave written informed consent, and the study was approved by South 
Birmingham Research and Ethics Committee. 
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4.3 Results 
 
4.3.1. Subject demographics 
 
Demographic data are shown below in table 4.2 for the 591 subjects divided 
into index and non-index cases and smoking status groups. 
TABLE 4.2: Demographic, physiological, radiological and health status data. 
Data are presented as mean (± SD) if parametric and median (IQR) if non-parametric 
unless otherwise stated. 
 NON-INDEX 
NEVER SMOKED 
 
(n = 54) 
NON-INDEX 
EX/CURRENT 
SMOKERS 
(n = 95) 
INDEX NEVER 
SMOKED 
 
(n = 90) 
INDEX 
EX/CURRENT 
SMOKERS 
(n = 352) 
Age 44.8 (13.8) 46.9 (11.4) 60.5 (11.4)*† 49.7 (9.1)*‡ 
Male gender         n (%) 18 (33.3%) 49 (51.6%)* 53 (58.9%)* 227 (64.5%)*† 
Pack years smoked N/A 12.0 (5.0-21.5) N/A 21.0 (12.8-28.0) 
FEV1 %Predicted 102.9 (26.7) 76.3 (29.3)* 65.2 (28.5)*† 43.2 (19.6)*†‡ 
FEV1:FVC %Predicted 95.0 (20.9) 71.9 (23.2)* 63.3 (23.7)*† 45.4 (16.9)*†‡ 
KCO %Predicted 91.0 (20.9) 77.4 (21.5)* 73.6 (24.2)* 62.3 (19.8)*†‡ 
SGRQ Total score 22.4 (20.2) 37.5 (24.3)* 42.2 (17.7)* 54.2 (18.0)*†‡ 
Upper zone voxel index 
(%) 
16.1 (13.9) 
(n = 35) 
20.7 (15.4) 
(n=58) 
28.9 (17.1)*† 
(n=47) 
35.9 (16.4)*†‡ 
(n=227) 
Lower zone voxel index 
(%) 
19.5 (16.6) 
(n = 35) 
31.7 (19.8)* 
(n=58) 
40.0 (22.1)* 
(n=47) 
51.9 (16.2)*†‡ 
(n=227) 
*= p<0.05 compared with non-index never smoked. 
† = p<0.05 compared with non-index ex/current smokers. 
‡ = p<0.05 compared with index never smoked. 
93 
 
4.3.2. Proportion of subjects with abnormal test 
parameters  
 
The proportion of subjects with abnormal physiological, radiological and health 
status parameters (see definitions in section 4.2) are shown below in table 4.3 for 
index and non-index subjects depending on the smoking status. 
TABLE 4.3: Percentage of subjects with abnormal physiological, radiological 
and health status parameters at baseline. 
 NON-INDEX 
NEVER 
SMOKED 
(n = 54) 
NON-INDEX 
EX/CURRENT 
SMOKERS 
(n = 95) 
INDEX NEVER 
SMOKED 
 
(n = 90) 
INDEX 
EX/CURRENT 
SMOKERS 
(n = 352) 
FEV1 < 80 % predicted 16 52* 72*† 95*†‡ 
FEV1:FVC < 80 % 
predicted 
16 61* 73* 96*†‡ 
KCO < 80 % predicted 19 54* 60* 84*†‡ 
SGRQ Total score >1.96 
S.D. above mean 
29 59* 73*† 89*†‡ 
UZVI >1.96 S.D. above 
mean 
40 48 67* 86*†‡ 
LZVI >1.96 S.D. above 
mean 
9 36* 52* 73*†‡ 
Emphysema on CT scan 20 
(n=49) 
54* 
(n=86) 
64* 
(n=88) 
69*† 
(n=340) 
*= p<0.05 compared with non-index never smoked. 
† = p<0.05 compared with non-index ex/current smokers. 
‡ = p<0.05 compared with index never smoked. 
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4.3.3. Age at which test parameters start to deviate from 
a healthy population  
 
4.3.3.1. 5-year age strata method 
  
The numbers of subjects in each 5 year age strata are shown below in table 
4.4.   
TABLE 4.4: Number of subjects in each age strata 
AGE STRATA NUMBER OF SUBJECTS IN AGE 
STRATA 
15-20 2 
20-25 7 
25-30 11 
30-35 27 
35-40 60 
40-45 75 
45-50 101 
50-55 107 
55-60 87 
60-65 56 
65-70 32 
70-75 18 
75-80 4 
80-85 2 
85-90 1 
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Using the 5-year age strata method and forward regression analysis (see 
later), all parameters had deviated from the mean normal value between the ages of 
20 and 32 (figure 4.1).  
However, index cases accounted for 75% of subjects and (by definition) were 
likely to have had abnormal test results at presentation to health care services.  The 
analysis of non-index cases alone gave different results, with the FEV1 deviating 
from normal in the age range 40-45 whereas other parameters deviated in the 20-25 
and 25-30 age cohorts.  Again similar results were obtained with the logistic 
regression analysis (see later) as shown in figure 4.2.   
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FIGURE 4.1: Age at which physiological, radiological and health status 
parameters had deviated from normal values (defined in section 4.2) for the 
whole population. 
The columns represent the age at which the various physiological, radiological and 
health status parameters started to deviate from those expected in a normal healthy 
population. The columns filled with diagonal lines represent the values obtained 
using the age strata method and the solid black columns represent values obtained 
using the logistic regression model. 
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FIGURE 4.2: Age at which physiological, radiological and health status 
parameters had deviated from normal values (defined in section 4.2) for non-
index subjects only. 
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The columns represent the age at which the various physiological, radiological and 
health status parameters started to deviate from those expected in a normal healthy 
population for non-index subjects. The columns filled with diagonal lines represent 
the values obtained using the age strata method and the solid black columns 
represent values obtained using the logistic regression model. 
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4.3.2.2. Logistic regression method 
  
Using the initial model, gender was not an important determinant of any 
variable so was not included in any predictive equations.  The equations generated 
for each variable are shown in table 4.5. 
 
TABLE 4.5: Equations derived from logistic regression using age and index 
case status as covariates. 
 
P (FEV1 % Predicted <100) = 1/(1+e –(-1.704+0.047(age)+2.742(I)) ) 
P (FEV1:FVC % Predicted <100) = 1/(1+e –(-1.708+0.059(age)+2.601(I)) ) 
P (KCO % Predicted <100) = 1/(1+e –(-0.113+0.03(age)+1.223(I)) ) 
P (SGRQ Total score > mean of healthy population) = 1/(1+e –(-0.0681+0.051(age)+3.157(I)) ) 
P (UZVI > mean of healthy population) = 1/(1+e –(-2.385+0.085(age)+1.846(I)) ) 
P (LZVI > mean of healthy population) = 1/(1+e –(-2.581+0.071(age)+2.245(I)) ) 
The probability of each test parameter being worse than the population mean was 
calculated as a function of age and index case status.  The age at which this 
probability consistently exceeded 0.5 (i.e. greater than expected in the healthy 
population) was determined. 
P (x) refers to the probability of event x occurring. e = the base of natural logarithms. 
I = 1 for index cases or 0 for non-index cases. 
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Most of the index cases had a least one physiological (99.5%), radiological 
(98.2%) or health status (99.3%) parameter worse than the healthy population mean 
at their first visit, which is reflected in the ages at which deviations from normal were 
predicted to occur.  These predicted ages were less than the age of the youngest 
subject at their baseline visit, because most of the data had to be derived by 
extrapolation.  Therefore, this model could not be used to determine, with confidence, 
the ages at which test parameters started to deviate from normal in these index 
subjects.  
 However, the results obtained for non-index cases did not involve data 
extrapolation but utilised primary information.  The ages at which each variable is 
predicted to deviate from normal are shown in figure 4.2 for all non-index cases.  
The SGRQ and KCO were predicted to deviate from normal before the age of 
16. Following this, the UZVI and FEV1:FVC were predicted to deviate from normal at 
age 29, followed by the LZVI and FEV1 (age 37). 
 To explore the model further in non-index subjects, the logistic regression 
analysis was repeated using smoking status as an additional covariate.  The 
equations generated for each variable are shown in table 4.6.  Smoking status was 
related to all variables except UZVI.   
For non-index never smokers, the earliest test predicted to deviate from 
normal was the SGRQ and UZVI (age 29), followed by KCO (age 32), FEV1:FVC and 
LZVI (age 50) and finally FEV1 (age 63). These results are depicted in figure 4.3 
below.  
 For non-index ex and current smokers, SGRQ and KCO were again among 
the earliest results predicted to deviate from normal (age < 16), followed by 
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FEV1:FVC (age 17), FEV1 (age 24) then UZVI and LZVI (age 29). These results are 
depicted in figure 4.4 below. 
 
TABLE 4.6: Equations derived from logistic regression using age, index case 
status and smoking status as covariates. 
 
P (FEV1 % Predicted <100) = 1/(1+e –(-3.752+0.06(age)+2.546(I)+2.319(S)) ) 
P (FEV1:FVC % Predicted <100) = 1/(1+e –(-3.356+0.068(age)+2.25(I)+2.257(S)) ) 
P (KCO % Predicted <100) = 1/(1+e –(-1.183+0.038(age)+0.91(I)+1.358(S)) ) 
P (SGRQ Total score > mean of healthy population) = 1/(1+e –(-1.383+0.049(age)+2.856(I)+1.434(S)) ) 
P (UZVI > mean of healthy population) = 1/(1+e –(-2.385+0.085(age)+1.846(I)) ) 
P (LZVI > mean of healthy population) = 1/(1+e –(-3.628+0.074(age)+1.932(I)+1.523(S)) ) 
The probability of each test parameter being worse than the population mean was 
calculated as a function of age, index case status and smoking status (where it was a 
significant predictor).  The age at which this probability consistently exceeded 0.5 
(i.e. greater than expected in the healthy population) was determined. 
P (x) refers to the probability of event x occurring. e = the base of natural logarithms. 
I = 1 for index cases or 0 for non-index cases. S = 1 for ex and current smokers or 0 
for subjects who have never smoked. 
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FIGURE 4.3: Age at which physiological, radiological and health status 
parameters had deviated from normal values (defined in section 6.2) for non-
index subjects who had never smoked. 
The columns represent the age at which the various physiological, radiological and 
health status parameters started to deviate from those expected in a normal healthy 
population for non-index subjects who had never smoked. The columns filled with 
diagonal lines represent the values obtained using the age strata method and the 
solid black columns represent values obtained using the logistic regression model. 
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FIGURE 4.4: Age at which physiological, radiological and health status 
parameters had deviated from normal values (defined in section 6.2) for non-
index subjects who had previously or who currently smoke. 
 
The columns represent the age at which the various physiological, radiological and 
health status parameters started to deviate from those expected in a normal healthy 
population for non-index subjects who had previously or who currently smoke. The 
columns filled with diagonal lines represent the values obtained using the age strata 
method and the solid black columns represent values obtained using the logistic 
regression model. 
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4.4 Discussion  
 
Using two different methods (one observational and one predictive), the current 
study demonstrated for the first time that KCO deviates from normal up to 30 years 
before spirometry in non-index subjects with AATD.  This was associated with a 
deterioration in health status and CT densitometric parameters especially in subjects 
who have never smoked, and may explain why a high proportion of a cohort of 
Swedish subjects with AATD and normal spirometry complain of breathlessness at 
the age of 3073. 
 Previous studies have suggested that spirometry becomes abnormal from age 
50-65 in subjects who have never smoked88,89 and from 25 years in those who 
have90.  This is consistent with the current observations from the age strata study and 
the predictions from logistic regression.  Although no similar age predictions have 
been quoted for non-index subjects per se, Seersholm et al.90 noted that they tended 
to have higher spirometry values than index subjects, and FEV1% predicted was 
<70% in only 3/27 (11%), again in general agreement with the current study.   
 There are little previous data available regarding the age at which gas transfer 
starts to deviate from normal in AATD.  However, it was measured in a small cohort 
of subjects (n=4 current smokers and n=52 subjects who had never smoked) from 
the Swedish cohort described earlier74 at the age of 30.  The mean KCO was 81% of 
predicted in smokers and 99% of predicted in those who had never smoked.  This is 
again consistent with the current work, which suggests KCO starts to deviate from 
that expected in a normal population well before the age of 30 in smokers, although 
after the age of 30 in those who have never smoked.  Furthermore, the mean FEV1 
was normal in the 30 year old Swedish cohort irrespective of smoking history, 
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whereas FEV1/FVC ratio was slightly reduced (91%) in PiZZ smokers but not in 
those who had never smoked.  This is also in keeping with the current predictive 
study.   
No previous data are available regarding the age at which health status and 
CT scans become abnormal in AATD.  However,  a high proportion of subjects from 
the Swedish cohort had symptoms of breathlessness, wheeze and sputum 
production from the age of 16, despite spirometry being normal at 30 years of age73, 
suggesting that pathological changes and hence clinical symptomatology occur 
before spirometry becomes abnormal.  This is again consistent with the observations 
presented here, showing deviation of health status, KCO and, in subjects who have 
never smoked, CT densitometry, several years before spirometry. 
 It is of interest that upper zone emphysema was one of the earliest tests to 
deviate from normal (around the age of 29) in non-index subjects, but one of the last 
tests to deviate from normal in smokers, in whom gas transfer and health status were 
observed or predicted to deviate first.  It is possible that AATD in the absence of 
other environmental factors is related initially to the development of mild upper zone 
emphysema.  However with the added environmental factor of smoking, lower zone 
emphysema develops and predominates by the time a delayed diagnosis254 is made, 
leading to the observation that the classical distribution of emphysema in AATD is 
basal.   
The current work also documented that the LZVI becomes abnormal at a 
similar time to spirometry.  This is consistent with our previous studies which 
demonstrated a close relationship between spirometry & lower zone 
emphysema108,230.   
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 There are, however, some limitations to the current study, most notably that 
the design is retrospective and based on deviation from a normal range rather than a 
prospective documentation of trends.  A cohort study such as for Swedish subjects 
described earlier72 is therefore ideal for these purposes.  Unfortunately the follow-up 
to date (30 years) has in the most part concentrated on spirometry and 
symptomatology alone.  Thus, it will be several decades before the Swedish study 
yields results which provide retrograde guidance for monitoring non-index subjects 
appropriately and cost effectively using FEV1 alone.  KCO has been assessed in a 
low number of subjects at only one point in time, at which point it had already started 
to deviate from normal in the smoking subgroup74.  Furthermore, health status and 
comprehensive CT data have not been assessed in the Swedish cohort, thus the 
opportunity to obtain valuable information indicating when these tests start to 
deteriorate has probably passed.  It would therefore seem critical to measure gas 
transfer at all subsequent visits, and to obtain CT scans for the majority of this cohort 
now, especially in the 40% who have dyspnoea.  However, the results of this current 
study for non-index subjects, and the limited Swedish study that examined gas 
transfer, suggest these data are likely to have deviated from normal already, and 
should be monitored from the teenage years onward. 
 A number of subjects did not have a CT scan in the current study.  This was 
usually omitted in asymptomatic subjects with normal lung function or where there 
were anxieties about the test such as claustrophobia and radiation exposure or 
previous scans obtained elsewhere that could not be analysed retrospectively by 
densitometry, and may possibly present some selection bias.   
106 
 
Furthermore it is difficult to make retrospective assumptions about index 
cases, as most had abnormal respiratory test parameters at the first visit to the UK 
AATD registry.  Thus any attempt to determine the age at which these became 
abnormal requires extrapolation of the model well beyond valid data points, rendering 
the results difficult to interpret.  However, clinically it is not relevant to determine 
when to test index subjects, as by definition, they have already presented with lung 
disease and automatically undergo investigation.  
There are few young subjects in the current cohort especially among index 
cases.  Our youngest index case was 26.4 years old at diagnosis.  The FEV1 was 
87.5% predicted whereas the KCO was 65% predicted, indicating that deterioration 
of lung function must have occurred below this age affecting KCO preferentially, 
again consistent with the concept of screening early using non-spirometric tests. 
The non-index cases in our cohort are predominantly family members of index 
subjects and an influence of shared genetic susceptibility factors cannot be ruled out.  
However, if these are present they are likely, if anything, to result in the development 
of lung disease at an earlier age than non-index subjects with no affiliated index case 
(such as those identified by population screening).  Since by definition all individuals 
identified by screening alone are non-index cases our observations and 
recommendations regarding the age at which screening should commence would 
also capture the onset of disease in those subjects. 
 Two different methods were used to determine the age at which test 
parameters become abnormal, and reasonable agreement was obtained between 
both.  The advantages of the logistic regression model include the fact that a linear 
relationship between age and each test parameter is not necessarily assumed, and 
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outlying data points have less impact on the predictions than in the 5 year age strata 
method.  Despite the high level of consistency of results obtained using both 
methods, the true validity of this type of mathematical modelling can only be 
absolutely confirmed by a future prospective study.  However the data do provide 
guidance to suggest potent evaluation should include more extensive physiological 
testing especially in early adulthood. 
 Both methods rely on using „normal‟ values for a healthy population for each 
test parameter. For physiology testing, these values are robust and used frequently75.  
However, little data are available regarding „normal‟ values for the SGRQ253 and no 
normal data for CT densitometry using the -910HU threshold is available.  Therefore 
data from a study reporting a similar but slightly less sensitive threshold of -912HU, 
although with the same model of GE Prospeed CT scanner106, has been used.  This 
provides the „best‟ estimate of normal values that can be applied to the current study.  
Nevertheless, these slight uncertainties should be borne in mind when interpreting 
the results.  However, the consistency with predicted deviation from normal of KCO 
suggest the data are likely to be a close estimate. 
 Importantly the current study has clearly demonstrated that KCO, health status 
and UZVI (in subjects who have never smoked) deviate from normal up to 30 years 
prior to spirometry in non-index subjects with AATD.  Gas transfer deviates from 
normal in the teens for smokers and the early 30s for never-smokers.  Based on 
these data, recommendations that screening for the presence and progression of 
lung disease should be undertaken in the 20s for all PiZ subjects who have never 
smoked, and the teens for subjects who have taken up smoking can be made.  Gas 
transfer is central to this assessment, and in addition to usual spirometry, 
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consideration should also be given to utilising health status and CT scan measures 
especially in those who have never smoked, although radiation exposure may restrict 
the frequency or use of the latter.  It seems logical that when gas transfer is 
deteriorating, subjects with AATD should undergo any possible lifestyle modification 
and possibly start effective therapies prior to the development of FEV1 impairment at 
which point a significant amount of lung disease will have occurred.     
 This study challenges the current understanding of COPD, its‟ severity and 
current treatment guidelines 248,255, as these are primarily based on spirometry, which 
is the last to become impaired in AATD.  Consideration needs to be given to similar 
studies of the natural history of usual COPD, and to modification of the monitoring of 
subjects at risk of developing COPD as this may well also identify such subjects at an 
earlier stage, facilitating the introduction of appropriate preventative therapy before 
airflow obstruction develops. 
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5. GAMMA-GLUTAMYL TRANSFERASE IN ALPHA-1 
ANTITRYPSIN DEFICIENCY 
 
 
5.1 Aims of the study  
 
 We hypothesised that serum GGT would be related to the severity of lung 
disease in subjects with AATD, and that this would be independent of an anticipated, 
primary association with liver disease. We therefore examined the relationship of 
serum GGT activity in adults with AATD in relation to clinical and physiological 
features of lung disease, clinical and biochemical liver disease, alcohol consumption 
and mortality in order to determine any independent predictors of the plasma GGT 
level.
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5.2 Method 
The ADAPT database was searched to identify the first 334 subjects with the 
PiZ phenotype who had serum GGT measured at the initial visit. 
GGT was measured by spectrophotometric assay using an Instrumentation 
Laboratory IL-900, (Instrumentation Laboratory Ltd, Warrington, U.K.).  The coefficient 
of variation for this assay is 2% and the reference range for GGT is <40 IU/L for 
females and <50 IU/L for males.   
Data from the initial visit were obtained for post bronchodilator FEV1, FVC and 
KCO expressed as a percentage of the value expected for healthy subjects of the 
same gender, age and height (% predicted)75. The stage of lung disease was 
determined according to the National Institute for Clinical Excellence (NICE) 
criteria248.  The PaO2 (KPa) was determined from arterialised blood from the earlobe. 
A history of chronic bronchitis, defined according to the MRC criteria68 was 
noted.  Information regarding the usual sputum appearance, (when present in the 
stable state) was obtained by matching to the BronkoTest sputum colour chart 
(BronkoTest, Middlesex, UK) to determine the degree of purulence234.  The number 
of exacerbations requiring a change in therapy was obtained for the previous year, 
along with smoking status and smoking history (pack years of cigarettes smoked). 
We recorded any previous diagnosis of liver disease and subjects who were 
suspected to have liver cirrhosis on clinical grounds had an ultrasound scan and (in 
some cases) liver biopsy to confirm the diagnosis.  These investigations were not 
routinely undertaken in the absence of clinical concerns.  However, we also 
documented the prevalence of abnormalities in aspartate transaminases (AST), 
bilirubin and alkaline phosphatase (ALP) in order to detect any biochemical evidence 
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of sub-clinical liver disease.  Subjects were divided into 3 categories for reported 
alcohol intake: 1. no alcohol; 2. within U.K. government guidelines (14 units per week 
for females and 21 units per week for males) and 3. in excess of government 
guidelines 256. 
We also reviewed the association of GGT with mortality.  There were 39 
deaths reported in subjects on the database at the time of this analysis and the GGT 
was compared between these 39 non-survivors and the remaining 305 survivors, 
before and after the exclusion of 3 subjects who had died specifically because of liver 
complications. 
Finally we noted the GGT measurements at baseline and at 3 years in the 128 
subjects who had both measurements, to determine its‟ stability over time.  
Data were presented using the mean (standard error [S.E.]) for parametric 
data and the median (interquartile range [I.Q.R.]) for non-parametric data.  Data were 
analysed using SPSS 12.0.1 for Windows (SPSS Inc, Chicago, IL, U.S.A.), to 
determine any univariate relationships between serum GGT and the physiological 
and clinical variables.  Single tail Spearman‟s correlations were used to determine 
any relationships between serum GGT and continuous variables.  The Jonckheere-
Terpstra test was used to determine differences between GGT for different 
categories of ordinal data. The Kruskal-Wallis test was used to determine differences 
in serum GGT for non-ordinal categorical variables with more than 2 groups and the 
Mann – Whitney test was used to assess the difference in serum GGT for variables 
with 2 groups.   
Although several factors were shown to relate to GGT levels, we were unable 
to perform conventional multiple logistic regression analysis as some of the 
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categorical variables had more than 2 groups. We therefore used the equivalent 
univariate analysis of variance test, to determine which variables remained 
independently associated with GGT after correction for all other associated factors 
that had been entered into the model.  GGT underwent log transformation in order to 
obtain a normal distribution for this analysis. 
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5.3 Results 
 
5.3.1 Relationship of GGT to demographic data 
 
Demographic data are shown in table 5.1.  The mean GGT for the 344 
subjects was 43.6 IU/L (S.E. ±2.0) and 26% of the subjects had an elevated level 
according to gender.  The group had a male predominance (61%) and males had a 
greater (p<0.001) mean serum GGT (51.9, S.E. ±2.7) than females (30.7, S.E. ±2.6).  
The mean age of all subjects was 50.0 (S.E. +/- 0.6), and no relationship was 
observed between age and GGT in this cohort (r = 0.088, p = 0.105).   
 
TABLE 5.1:  Demographic, smoking, alcohol consumption and pulmonary 
function data for the 344 subjects in whom GGT was studied. 
GGT (iU/L)   mean (S.E.) 43.6 (2.0) 
Age    mean (S.E.) 50.0  (0.6) 
Male gender   n = (%) 209  (61%) 
Smoking status   Never   n =
    Ex   n = 
    Current   n = 
70  (20%) 
237  (69%) 
37  (11%) 
Pack years smoked  mean (S.E.) 20.6  (0.8) 
Alcohol consumption  None   n =  
    Within guidelines n =  
    In excess of guidelines n =  
103  (30%) 
188  (55%) 
51  (15%) 
FEV1 (% predicted)  median (I.Q.R.) 46.0 (33.5-72.5) 
FEV1:FVC   median (I.Q.R.) 38.0  (29.4-55.7) 
KCO (% predicted)  mean (S.E.) 69.4 (1.3) 
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There was no change (p = 0.328) in GGT from baseline (39.9, S.E. ±2.9) to 3 
years (43.0, S.E. ±2.7) in the 127 patients where this was measured. 
 
 
5.3.2 Relationship of GGT to lung disease 
 
Subjects who had COPD according to the NICE guidelines248 had a greater (p 
= 0.001) serum GGT (median = 45.4, S.E. ±2.4) than those who did not (36.8, S.E. 
±3.8).  Serum GGT was negatively correlated with post-bronchodilator FEV1 % 
predicted (r = -0.148, p = 0.006), and with post-bronchodilator FEV1:FVC ratio (r = -
0.127, p = 0.018).  This relationship is demonstrated in figure 5.1, for subjects 
classified according to the individual NICE severity categories at the time that the 
analysis was performed248.  There was no relationship between serum GGT and 
transfer factor corrected for alveolar volume (KCO) expressed as % predicted (r = -
0.040, p = 0.5). 
Serum GGT was higher (p = 0.029) in subjects with a history of chronic 
bronchitis (46.6, S.E. ±3.1, n=137) compared to those without (42.2, S.E. ±2.7, 
n=207).  However, GGT was unrelated to the degree of sputum purulence in the 
stable state (p = 0.2) and the number of exacerbations documented over the previous 
12 months (p = 0.4). The mean GGT in 47 subjects with a PaO2 < 8.0 KPa was 58.7 
(S.E. ±8.6), but this was not significantly different (p = 0.15) to the 288 subjects with a 
PaO2 > 8.0 KPa (41.0, S.E. ±1.9). 
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FIGURE 5.1: Relationship of GGT to COPD severity according to NICE248. 
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The mean GGT (+/- S.E.) is shown related to increasing severity in each stage of 
COPD.  The significance of the relationship (p) is shown using the Jonckheere-
Terpstra test.  
 
5.3.3 Relationship of GGT to smoking 
 
GGT was elevated in ex smokers (43.9, S.E. ±2.4; p = 0.009; n=237) and 
current smokers (48.8, S.E. ±5.3; p = 0.003; n=37) compared with subjects who had 
never smoked (39.6, S.E. ±5.1; n=70) and the number of pack years smoked was 
positively correlated with serum GGT (r = 0.162, p = 0.007). 
 
 
 
P < 0.001 
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5.3.4 Relationship of GGT to liver disease 
 
Subjects with a history of jaundice as an infant, in childhood or after a 
miscarriage had GGT levels within the reference range (39.9, S.E. ±5.4) and were 
not different (p = 0.196) to those in subjects with no such history (44.1, S.E. ±2.2).  
Those with a previous diagnosis of hepatitis, either related to AATD, as a drug 
reaction or infective in nature (n = 12),  tended to have serum GGT levels that were 
elevated (62.5, S.E. ±18.1) by approximately 1.5 times the levels of those described 
above, with no such history, although this was not significantly different (p = 0.434).  
However, subjects with a proven diagnosis of cirrhosis (n = 5) had a significantly 
elevated GGT approximately 3 times the upper limit of the reference range (116.0, 
S.E. ±30.8; p = 0.004).  Bilirubin, AST and ALP were abnormal in 4.4%, 6.2% and 
0.3% respectively of subjects who did not have a history of cirrhosis, suggesting that 
the prevalence of „undiagnosed‟ biochemically important liver disease was relatively 
low. 
Table 5.2 depicts the demographic data, smoking history, alcohol consumption 
and lung function data for subjects who had no previous history or clinical evidence 
of liver disease and those who had a history of jaundice, hepatitis and liver cirrhosis.  
There were no significant differences between groups for any of these parameters. 
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TABLE 5.2:  Demographic, smoking, alcohol and pulmonary function data for 
subjects with no previous liver disease and those with a history of jaundice, 
hepatitis and cirrhosis for the 344 subjects in whom GGT was studied.   
 
 NO HISTORY 
OF LIVER 
DISEASE 
JAUNDICE HEPATITIS CIRRHOSIS 
N = 289 38 12 5 
Age mean (S.E.) 50.3  (0.6) 46.8  (1.4) 51.2  (2.6) 52.7  (3.4) 
Male gender n = 176  (61%) 20  (53%) 8  (67%) 5        (100%) 
Smoking status  
 Never n = 
 Ex n =  
 Current n = 
 
57  (20%) 
200  (69%) 
32  (11%) 
 
8  (21%) 
26  (68%) 
4  (11%) 
 
3  (25%) 
8  (67%) 
1  (8%) 
 
2  (40%) 
3  (60%) 
0 
Pack years smoked
 mean (S.E.) 
 
20.7  (0.9) 
 
17.1  (1.9) 
 
29.3  (5.2) 
 
17.3  (9.0) 
Alcohol consumption 
None   n =  
Within guidelines    n =  
In excess of guidelines n =  
 
82  (29%) 
160  (56%) 
45  (16%) 
 
14  (37%) 
22  (58%) 
2  (5%) 
 
3  (25%) 
5  (42%) 
4  (33%) 
 
4  (80%) 
1  (20%) 
0 
FEV1 (% predicted) 
 median (I.Q.R.) 
 
44.9   
(32.9-72.2) 
 
64.6   
(37.8-91.7) 
 
45.1   
(29.8-64.9) 
 
68.7   
(22.6-94.3) 
FEV1:FVC  
 median (I.Q.R.) 
37.6   
(28.1-54.7) 
42.3   
(32.6-62.7) 
33.9  
(31.0-41.1) 
47.8   
(33.5-68.7) 
Airflow obstruction present
  n = 
 
231  (80%) 
 
28  (74%) 
 
10  (83%) 
 
3 (80%) 
There were no significant differences in any of these parameters between the 4 
groups. The % figures in parentheses relate to the proportion of each group. 
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5.3.5 Relationship of GGT to reported alcohol 
consumption 
 
Alcohol consumption was positively correlated with GGT (r = 0.249, p < 0.001) 
but subjects who consumed alcohol within government guidelines (40.0, S.E. ±2.0, 
n=188), had a similar (p = 0.108) serum GGT to subjects who did not consume 
alcohol (44.2, S.E. ±5.1, n=103).  However, GGT was above the gender related 
reference range in 43% of subjects who exceeded the daily recommended alcohol 
intake.  The average value in this group (55.8, S.E. ±4.9, n=51) was greater than that 
for both non-drinkers (p < 0.001) or those who drank within recommended guidelines 
(p < 0.001), as shown in figure 5.2. 
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FIGURE 5.2: Relationship of GGT (iU/L) to alcohol consumption. 
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The mean GGT (+/- S.E.) is shown related to alcohol consumption (none; 
within; or greater than recommended U.K. government guidelines).  The 
significance (p) of differences between groups is shown.  
 
 
5.3.6 Relationship of GGT to mortality 
 
The cause of death in the 39 subjects from the final mortality study was COPD 
in 21, complications post lung transplant in 3, cancer in 4, pulmonary embolus in 2, 
cardiovascular disease in 2, liver disease in 3 and cerebral vasculitis, endocarditis, 
intracranial bleed and pancreatitis in 1 case each.  The baseline GGT in the non-
survivors was greater (65.0, S.E. ±10.2; p = 0.001) than in survivors (40.8, S.E. ±1.8), 
and this difference was unaltered by removal of the 3 subjects who died of liver 
related illness from the analysis, as shown in figure 5.3.  Survivors had a higher 
P < 0.001 
P < 0.001 
      None              Within           In exce s f 
                          guidelines         guidelines 
 
       ALCOHOL CONSUMPTION GROUP 
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(p<0.001) FEV1 % predicted (50.1, I.Q.R. 35.0 – 76.6) than non-survivors (33.5, 
I.Q.R. 25.4 – 43.6).   
 
FIGURE 5.3: Serum GGT in survivors and non-survivors. 
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The mean GGT (+/- S.E.) is shown for subjects who had died compared to those who 
had survived.  The significance of the difference (p) is shown. 
 
 
5.3.7 Independent relationships to GGT 
 
In order to predict which factors were independently related to GGT in subjects 
with AATD who remained alive, all factors where a relationship existed were entered 
into the analysis of variance model, except for mortality. The independent predictors 
of GGT in this model were post bronchodilator FEV1 % predicted (p = 0.042), 
P = 0.001 
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FEV1:FVC ratio (p = 0.042), male gender (p<0.001) and a history of liver cirrhosis (p 
= 0.006). 
However, if mortality is also entered into the model, the factors independently 
associated with GGT were survival (p = 0.038) along with gender (p < 0.001) and 
history of liver cirrhosis (p = 0.004), suggesting that GGT was related to mortality 
irrespective of pulmonary function. 
 
5.3.8 Summary of the results 
 
This study demonstrates that a high proportion of subjects with AATD have an 
abnormally elevated serum GGT activity (26%) compared with a healthy population 
(11%)166.  GGT was, as expected, related to liver cirrhosis in these subjects, but was 
also independently related to the severity of lung disease determined by FEV1, and 
mortality, the cause of which was mainly respiratory in nature. 
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5.4 Discussion 
 
Neutrophilic inflammation and oxidative stress are central to the 
pathophysiology of COPD.  Neutrophils release proteases such as neutrophil 
elastase, which are relatively unopposed in AATD.  Neutrophil elastase has been 
shown to cause many of the clinical features associated with COPD, such as loss of 
ciliated epithelia, reduced ciliary beat frequency and reduced mucociliary clearance, 
mucous gland hyperplasia, increased mucus secretion and squamous cell 
metaplasia42.  Neutrophils release inflammatory mediators that act as a 
chemoattractant for other neutrophils, and as such, inflammation is potentiated45.  
Neutrophils also release reactive oxygen species (ROS)46, and in addition, ROS are 
inhaled in cigarette smoke47 and in pollutants such as nitrogen dioxide and 
particulates48.  ROS can lead to DNA damage, disruption of function and apoptosis in 
respiratory cells as well as amplifying the inflammatory process.  Increased oxidative 
stress leads to the rapid conversion of intracellular GSH (reduced glutathione) to 
intracellular GSSG (oxidised glutathione), and thereby reduces the ratio of GSH to 
GSSG.  The reduction in this ratio causes an increase in transcription of chemokine 
and cytokine genes, the up-regulation of adhesion molecules and the release of 
inflammatory mediators, which subsequently potentiate inflammation and 
consequently oxidative stress further257.  
The number of airway neutrophils is associated with disease severity 
determined by FEV1 in COPD258.  It follows that an increased number of neutrophils 
in the airways would release more ROS, which would, in turn, lead to the reduction of 
GSH:GSSG ratio.  At this point, the production of GGT is increased, in order to 
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replenish intracellular levels of reduced GSH.  It is therefore not surprising that lung 
disease severity related to increased GGT activity in the current study. 
 However, an alternative explanation for the relationship between GGT activity 
and lung disease is that GGT may be implicated in causing the release of ROS, 
which subsequently leads to the development of COPD.  In the presence of iron, 
GGT can catalyse a series of reduction reactions, leading to the production of free 
radicals259.  It is known that the intracellular iron content of alveolar macrophages is 
increased in COPD subjects with chronic bronchitis, as well as in smokers260.  It is 
therefore possible that GGT contributes (at least indirectly) to the development of 
lung inflammation rather than antagonises it.   
The present study also demonstrated a relationship between serum GGT 
activity and chronic bronchitis.  Neutrophil elastase, released by neutrophils causes 
increased sputum production, and as neutrophils also release ROS which in turn may 
lead to an increase in GGT activity locally.  This relationship may explain why 
subjects with chronic bronchitis have greater GGT activity in sputum compared with 
healthy controls, (confirmed by the studies of Barton et al179).   
However the current work explored the relationships of serum GGT activity, 
and did not examine GGT activity at the local level in the lung.  Many of the previous 
mechanistic studies on GGT describe changes in membrane bound GGT, and little 
data are available about systemic GGT and its relationship to GGT activity in specific 
organs.  However, it is known that in subjects with alcoholic or drug-induced 
hepatitis, serum GGT activity is increased disproportionately (six fold that of healthy 
controls) compared with liver GGT activity (threefold that of healthy controls)149.  
COPD is associated with systemic inflammation, in addition to local inflammation in 
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the lungs.  For instance, subjects with COPD have higher circulating levels of CRP, 
fibrinogen, TNFα, white blood cells and IL8, and increased evidence of systemic 
oxidative stress compared with healthy subjects261,262, and this systemic inflammatory 
state is known to be associated with co-morbidities such as cardiovascular disease, 
diabetes, osteoporosis and muscle wasting71.  A relationship between systemic 
inflammation and severity of lung disease has been confirmed261, so the present 
study may reflect a relationship between the systemic inflammation associated with 
COPD and GGT activity, and not inflammation related to the lung alone.  
A further explanation for the current results is that AATD subjects with the 
most severe lung disease may also have the greatest degree of liver cirrhosis, and 
GGT may therefore be related to the individuals‟ liver disease as opposed to their 
lung disease.  However, this is unlikely, as serum GGT activity was shown to be 
related to FEV1 independent of liver cirrhosis and other serum markers of liver 
disease using the analysis of variance test.  In addition, there was no difference in 
lung function parameters when subjects who had no previous evidence of liver 
disease were compared with subjects with a history of jaundice, hepatitis or cirrhosis.  
Furthermore, FEV1 and FEV1:FVC ratio did not correlate with other measures of liver 
function (AST, ALP or bilirubin), despite their relationship to serum GGT activity. 
The retention of polymeric Z protein in the hepatocellular endoplasmic 
reticulum is also likely to be of primary pathogenic importance and is understood to 
be pro-inflammatory7.  Whether serum GGT levels reflect oxidant stress associated 
with hepatic inflammation or a direct cytopathological effect of Z polymers is 
speculative.  It is possible that inflammation related to the presence of Z polymers is 
sub-clinical and does not affect other serum measurements liver disease.  
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Although the present study demonstrated a relationship between serum GGT 
activity and spirometry, no such relationship was evident between serum GGT 
activity and KCO.  KCO is a measure of alveolar destruction in COPD whereas 
spirometry reflects potentially both alveolar destruction and airway abnormalities.  
The current data suggest, therefore that serum GGT reflects the severity of airway 
disease, but not necessarily emphysema.  Although airway tissue neutrophils are 
inversely related to FEV1, parenchymal neutrophils (and the associated local release 
of ROS) are not related to alveolar wall destruction263.  Furthermore, the inflammatory 
mediators CRP and IL8 have been shown to be related to bronchial wall thickening 
but not to measures of emphysema determined using CT scans264.  These facts may 
help to explain why no relationship between GGT and KCO was found.  However, 
alveolar macrophages are related to alveolar destruction, and are also capable of 
releasing ROS, which may in turn deplete intracellular glutathione and stimulate GGT 
production, but the present data suggest that GGT does not play an important role in 
the antioxidant defences in the process of emphysema development, despite its‟ 
relationship to airway disease.   
Serum GGT activity has previously been associated with current smoking 
habits, as described in section 1.2.2.3.3.3.  Cigarette smoke contains ROS, and is 
therefore likely to result in the activation of anti-oxidant defences, including the 
induction of GGT in the airways in current smokers.  However, smokers are also 
known to have evidence of increased systemic inflammation compared with a non-
smoking healthy population265, and the current study results would support this.  
However, the present study has also demonstrated for the first time, that serum GGT 
activity is increased in ex-smokers compared with those who have never smoked in 
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this cohort of subjects with AATD.  Having a history of smoking is associated with a 
greater risk of developing COPD in AATD, although in univariate analysis of 
variance, smoking status was not found to be independently related to serum GGT 
activity whereas the severity of COPD was.  Therefore, the increased GGT activity in 
this group is likely to be a reflection of lung disease as opposed to smoking status 
per se. 
No associations between serum GGT activity and the sputum colour in the 
stable state and the average annual number of exacerbations were demonstrated in 
this study.  Some exacerbations of COPD have been shown to be associated with an 
increase in airway markers of neutrophilic inflammation such as IL8, LTB4, neutrophil 
elastase and myeloperoxidase, and an increase in systemic inflammation and 
oxidative stress204,266.   As such, one might expect serum GGT activity to be 
increased with exacerbations.  However, all subjects studied currently were assessed 
having been free from exacerbations for at least the preceding four weeks.  
Therefore, it is possible that any changes that may have occurred in serum GGT 
activity due to an exacerbation had resolved by the time of assessment.  
Alternatively, GGT may not play an important role in oxidative stress associated with 
exacerbations. 
Similarly, sputum colour reflects sputum neutrophil load as it is a marker of 
myeloperoxidase which is present in and released by these cells234.  As neutrophils 
also release ROS, it may therefore have also been expected that local GGT activity 
would increase.  However, systemic GGT activity was measured, and as there is no 
current evidence that sputum colour is related to systemic oxidative stress, this may 
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explain the lack of relationship between serum GGT activity and sputum colour in the 
stable state. 
In common with many previous studies, the present work found that serum 
GGT activity was greater in subjects with liver cirrhosis, in subjects who consumed 
large quantities of alcohol, and in males.  
Serum GGT has been described in subjects with AATD up to the age of 26, 
where only 7% had abnormal levels126.  In our cohort, 26% had abnormally elevated 
serum GGT activity.  However, the present cohort is older (mean 50.0 years) than the 
Swedish cohort and most were identified as having AATD because they presented 
with lung disease, unlike the Swedish cohort who were identified by neonatal 
screening.  In addition, a greater proportion of the current cohort had smoked (82%) 
compared with the Swedish subjects (22%)73, and 5 subjects in the present group 
had liver cirrhosis, whereas it is not reported in the Swedish cohort.  All of these 
factors may explain the difference in the proportions with an abnormal serum GGT 
activity between the current and the Swedish cohort.  
An obvious limitation to using GGT as a biomarker of lung disease is that there 
are many potential confounding factors, and this is especially true in subjects with 
AATD who are known to be at risk of developing liver disease, as GGT is known to 
be a sensitive marker of liver disease.  However, it is useful to note that GGT remains 
independently related to lung disease, as a relatively high proportion of subjects had 
abnormal serum GGT measurements, with no evidence of clinically relevant liver 
disease.  It is therefore helpful to identify the factors such as lung disease that affect 
this measurement in order to interpret the results in context with the subject.   
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Despite the presence of several confounding factors in subjects with AATD, 
we have demonstrated that serum GGT activity is also a prognostic marker 
irrespective of its source, which is independently related to mortality.  
There is mounting evidence that serum GGT activity may be related to 
systemic inflammation and oxidative stress, which are becoming increasingly 
important in COPD due to the relation of COPD to co-morbidities and in hence 
overall prognosis.  It is possible therefore that although it is difficult to interpret the 
meaning of differences in serum GGT activity in terms of airway disease, it may 
provide a measure of systemic inflammation and oxidative stress.  Measuring 
systemic inflammation in addition to  FEV1 may prove more informative than using 
either measure alone, as demonstrated by measuring BMI (which is closely related to 
systemic inflammation) and airflow obstruction as part of the BODE index82. 
A potential limitation of the present study is that the presence of co-morbidities 
such as cardiovascular disease and diabetes was not specifically taken in account, 
as these data have only been collected more recently, and was therefore not 
available for all subjects.  However, for subjects for whom complete data had been 
collected, only 1.6% of subjects had a history of myocardial disease, and 0.8% had 
diabetes.  Hence, it is unlikely that not taking these factors into account will have 
impacted on the results. 
Further study is clearly required to determine the role of serum GGT activity 
measurements as a biomarker of lung disease or systemic inflammation in subjects 
with lung disease.  In particular, a cohort of subjects with usual COPD would provide 
more informative results, as the confounder of liver involvement is likely to be absent.  
In addition, studies to examine serum GGT activity in relation to local GGT levels, 
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other inflammatory mediators and markers of oxidative stress in both serum and 
airway secretions are indicated in order to obtain a clearer role of GGT in usual 
COPD and that associated with AATD. 
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6. CHARACTERISTICS OF PiSZ SUBJECTS 
 
 
6.1 Aims of the study 
 
The purpose of this section is to describe for the first time in a significant 
number of PiSZ subjects, the CT scan appearance, densitometry analysis and quality 
of life.  Symptoms, pulmonary physiology and liver disease were characterised in 
these subjects in order to add to the current understanding of the phenotype.  
Furthermore, we matched subjects in pairs for age, gender, smoking status and pack 
years with PiZ subjects to enable us to compare the variables described above taking 
these factors into account.  In order to reduce any selection bias associated with 
registry data further, we subsequently analysed data for index and non-index cases 
separately.  Finally we compared PiSZ and PiZ subjects matched for FEV1 to explore 
the impact of airflow obstruction on health status and clinical parameters in these 
groups. 
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6.2 Method 
 
  
The first sixty three subjects with the PiSZ phenotype were identified from the 
ADAPT database.  Information from the baseline visit regarding demographic details, 
the AAT level, the initial reason for testing for AATD, smoking status and pack years 
of cigarettes smoked, previous respiratory or liver disease and respiratory symptoms, 
including the MRC dyspnoea score233, the presence of chronic bronchitis, according 
to the MRC definition68 and the sputum colour in the stable state using the Bronko 
Test chart (BronkoTest, Middlesex, U.K.) were obtained. 
 In addition, the forced expiratory volume in 1 second (FEV1), forced vital 
capacity (FVC), residual volume (RV), total lung capacity (TLC) and carbon monoxide 
transfer factor corrected for alveolar volume (KCO) all expressed as % predicted, 
were recorded.  The FEV1:FVC ratio was determined along with the bronchodilator 
response. 
 A thoracic radiologist provided a descriptive report of the CT scan independent 
of this study.  If emphysema was present, two experienced investigators scrutinised 
all available CT scans and reached agreement regarding the morphological type of 
emphysema that was present, and the predominant type of emphysema in each 
case. 
 Density mask analysis was performed for all PiSZ subjects who had a CT scan 
at the University Hospital Birmingham NHS Foundation Trust, and their respective 
PiZ matches.  Pulmo CMS software (MEDIS Medical Imaging Systems BV, Leiden, 
Netherlands) was used to calculate the percentage of voxels that were less dense 
than -950 Hounsfield units in a slice at the level of the aortic arch (upper zone) and a 
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slice at the level of the inferior pulmonary veins (lower zone).  Upper zone 
emphysema predominance was defined as the upper zone voxel index being greater 
than the lower zone voxel index, and was determined for each subject. 
 SGRQ and SF-36 scores, were collated and serum measurements of GGT, 
AST, ALP and bilirubin were measured using an Instrumentation Laboratory IL-900 
(Instrumentation Laboratory (UK) Ltd, Warrington, U.K.), as an indicator of the liver 
function. 
These parameters were described for the 63 PiSZ subjects.  These subjects 
were paired with subjects who had the PiZ phenotype from the ADAPT cohort of 
around 800, to provide the best match for age, gender, smoking status (never 
smoked, ex-smoker or current smoker) and pack years smoked, and the two groups 
of data were compared. 
For PiSZ subjects, data were compared for those subjects who had never 
smoked and those who had, and for subjects with an AAT level of less or greater 
than 11μm as this is the threshold for worsened susceptibility to proteolytic 
damage43. 
The PiSZ lung index cases were then also matched as pairs with a different 
cohort of PiZ lung index cases for age, gender, smoking status and pack years.  Non-
index PiSZ subjects were matched to non-index PiZ subjects using the same criteria, 
and the groups were again compared.  Finally 62 PiSZ subjects who had valid 
spirometry measurements were matched with 62 PiZ subjects for FEV1 alone and all 
other variables were compared. 
 Data were analysed using SPSS 12.0.1 for Windows (SPSS Inc, Chicago, IL, 
U.S.A.), to determine any differences between the groups.  Categorical data were 
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analysed using the χ2 test if all categories had an expected value of more than 5, or 
the Fisher‟s exact test if any expected values were less than 5.  Continuous variables 
were compared using the t-test for parametric data and the Mann-Whitney test for 
non-parametric data.  A p-value of less than 0.05 was considered significant. 
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6.3 Results 
 
 
6.3.1. Characteristics of the PiSZ subjects compared to 
PiZ subjects matched for age, gender and smoking 
history 
 
6.3.1.1 Demographic data 
 
 Data regarding demographics, smoking, the reason for testing for AATD and 
the AAT levels for the 63 PiSZ subjects are shown in table 6.1.   
Subjects with the PiSZ phenotype had higher (p<0.001) AAT levels (13.2±3.0) 
than PiZ subjects (4.4±1.7), and thirteen PiSZ subjects (21%) had an AAT level of 
less than 11μm, compared to all PiZ subjects.  A greater proportion (p=0.011) of PiSZ 
subjects (31%) were diagnosed by family screening compared with PiZ subjects 
(13%).  1 PiSZ and 1 PiZ subject were diagnosed due to abnormal serum 
electrophoresis discovered as part of a medical screen, 1 PiZ subject was diagnosed 
after investigation for episodes of sweating and 2 PiSZ subjects were diagnosed 
during investigation for hypertension and arthritis. The reason for diagnosis is 
unknown for 1 PiSZ and 2 PiZ subjects. Matching for pack years smoked was 
difficult, as PiSZ subjects had generally smoked heavily, but the difference in 
smoking history compared with PiZ subjects was not significant.  
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TABLE 6.1: Characteristics of subjects with the Pi SZ phenotype compared 
with Pi Z subjects matched for gender, age, smoking status and pack years.  
 Pi SZ     (n = 63) Pi Z       (n = 63) p = 
Male gender   n = 36 (57%) 36 (57%) 1.0 
Age    mean (S.D.) 50.6 (14.4) 51.2 (12.9) 0.808 
Reason tested for AATD: Family screen n = 
    Lung index n = 
    Liver index n = 
    Other  n = 
    Unknown n = 
19 (31%) 
36 (58%) 
4 (7%) 
3 (5%) 
1 
8 (13%) 
49 (80%) 
2 (3%)  
2 (3%) 
2 
0.011 
0.147 
0.416 
0.663 
Smoking status   Never  n = 
    Ex  n = 
    Current  n = 
17 (27%) 
32 (51%) 
14 (22%) 
17 (27%) 
39 (62%) 
7 (11%) 
 
0.221 
Pack years smoked  mean (S.D.) 26.77 (31.03) 20.57 (18.98) 0.672 
AAT level in μM   mean (S.D.) 
AAT level missing  n = 
13.2 (3.0) 
2 
4.4 (1.7) 
4 
<0.001 
AAT level < 11μm      n = 13 (21%) 59 (100%) <0.001 
The significance in difference (p) between the 2 groups is shown. 
 
 
 
6.3.1.2 CT Scan data 
 
 Fifty four PiSZ subjects and 58 PiZ subjects had a CT scan at their baseline 
visit to ADAPT.  Details about the CT scan appearance and density mask analysis 
data are shown in table 6.2. 
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TABLE 6.2: CT scan appearance and densitometry for subjects with the Pi SZ 
phenotype compared with Pi Z subjects matched for gender, age, smoking 
status and pack years.   
 Pi SZ (n = 54)      Pi Z (n = 58) p = 
Normal CT scan   n =  
Emphysema on CT scan  n =  
Bronchiectasis on CT scan  n = 
Bullous disease on CT scan  n =  
23 (43%) 
19 (35%) 
7 (13%) 
2 (4%) 
5 (9%) 
51 (88%) 
12 (21%) 
4 (7%) 
<0.001 
<0.001 
0.276 
0.680 
 
Centrilobular emphysema present n = 
Panacinar emphysema present  n = 
Paraseptal emphysema present  n = 
N = 17 
6/17 (35%) 
11/17 (65%) 
1/17 (6%) 
N = 50 
21/50 (42%) 
37/50 (74%) 
0/50 (0%) 
 
0.626 
0.538 
0.254 
Centrilobular emphysema predominant n= 
Panacinar emphysema predominant n= 
Paraseptal emphysema predominant n=  
6/17 (35%) 
10/17 (59%) 
1/17 (6%) 
14/50 (28%) 
36/50 (72%) 
0/50 (0%) 
 
0.229 
 
CT Densitometry 
 Upper zone VI  mean (S.D.) 
 Lower zone VI  mean (S.D.) 
N = 41 
15.0 (19.1) 
14.6 (17.0) 
N = 41 
17.9 (17.2) 
29.2 (20.3) 
 
0.171 
<0.001 
Upper zone predominance  n = 16 (39%) 5 (12%) 0.005 
The significance in difference (p) between the 2 groups is shown. 
 
 
 Nineteen (35%) PiSZ subjects had evidence of emphysema, 7 (13%) had 
bronchiectasis and 2 (4%) had bullous disease on CT scanning.  A greater proportion 
(p<0.001) of PiZ subjects had emphysema visible on the CT scan (88%) compared 
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with PiSZ subjects.  There were no differences in the proportion with bronchiectasis 
or bullous disease between PiSZ and PiZ subjects. 
CT scans were available to assess the morphological type of emphysema in 
17 PiSZ and 50 PiZ subjects who had emphysema reported.  Approximately two 
thirds of PiSZ subjects had panacinar emphysema and one third had centrilobular 
emphysema, with only one subject having paraseptal emphysema.  These 
proportions were not significantly different to those observed in PiZ subjects.  Some 
subjects had more than one type of emphysema, and therefore the predominant type 
of emphysema only was also assessed.  However, the latter approach yielded similar 
results to the former.   
If only the 49 matched pairs where both subjects had a CT scan performed 
were considered, 37% of PiSZ and 90% of PiZ subjects (p<0.001) had visible 
emphysema and there were no differences between the two groups in terms of the 
type of emphysema present.   
CT scans were available for densitometric analysis in 41 PiSZ subjects and 
their PiZ matches.  There was no difference in upper zone density between PiSZ and 
PiZ subjects.  However, PiZ subjects had reduced density in the lower zones 
compared with PiSZ subjects.  A greater proportion (P=0.005) of PiSZ (16/41 [39%]) 
compared with PiZ (5/41 [12%]) subjects had lower lung density in the upper zone 
compared with the lower zone.    
If only the subjects who had emphysema present on the CT scan were 
considered (12 PiSZ and 37 PiZ subjects), no differences existed between the two 
groups in terms of absolute upper and lower zone densitometry.  However, a greater 
proportion (p=0.004) of PiSZ subjects (7/12 [58%]) continued to have upper zone 
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predominance compared with PiZ subjects (5/37 [14%]).  Similar results are also 
obtained if the 12PiSZ subjects with visible emphysema reported on the scan are 
compared to their 12 PiZ matches (who also all had emphysema).  
Of the subjects with centrilobular emphysema, 7 PiSZ subjects were 
compared with 27 PiZ subjects.  No differences were found between the two 
phenotypes in terms of upper or lower zone density.  However, a greater proportion 
(p=0.02) of PiSZ subjects had upper zone predominant emphysema (57%), 
compared with PiZ subjects (11%). 
Of the subjects with panacinar emphysema, 14 PiSZ subjects were compared 
with 48 PiZ subjects.  Once again, no differences were found between the two 
phenotypes in terms of upper or lower zone density, and a greater proportion 
(p<0.001) of PiSZ subjects (57%) had upper zone predominant emphysema 
compared with PiZ subjects (7%).   
 
 
6.3.1.3 Health status 
  
 SGRQ scores were recorded for 59 PiSZ subjects and all PiZ subjects.  SF-36 
scores were available for 58 PiSZ and all PiZ subjects. All health status data are 
given in table 6.3 below. 
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TABLE 6.3: Health status data for subjects with the Pi SZ phenotype compared 
with Pi Z subjects matched for gender, age, smoking status and pack years, 
using the SGRQ and SF-36.   
The significance in difference (p) between the 2 groups is shown. 
 
 
PiSZ subjects had greater scores in the symptoms (46.2±28.6), activity 
(45.8±35.7) and impacts (25.1±20.2) domains of the SGRQ, and a greater total score 
(34.9±32.4), indicating a poorer quality of life, compared to scores from a general 
population of a similar age (approximately 8, 13, 4.5, 8 respectively)253. 
 Compared with average scores of 49.6 from a general U.S. population of a 
similar age237, subjects with the PiSZ phenotype had a lower physical health 
summary score on the SF-36 (42.5±13.6), indicating a worse physical quality of life.  
The physical summary score in PiSZ subjects was similar to a U.S. population of 
subjects with self-reported chronic lung disease (42.3)237, despite around half having 
a normal CT scan and normal spirometry.  The mental health summary score of the 
SF-36 for PiSZ subjects (49.6±13.5) was similar to the general population (50.5), and 
 Pi SZ  Pi Z   p = 
 
SGRQ Symptoms  mean (S.D.) 
 Activity   mean (S.D.) 
 Impacts   mean (S.D.) 
 Total   mean (S.D.) 
n = 59 
46.2 (28.6) 
45.8 (35.7) 
25.1 (20.2) 
34.9 (32.4) 
n = 63 
63.2 (23.0) 
63.6 (27.1) 
36.8 (19.5) 
49.3 (10.6) 
 
<0.001 
0.009 
0.003 
0.001 
 
SF-36 Physical domain mean (S.D.) 
 Mental domain  mean (S.D.) 
n = 58 
42.5 (13.5) 
50.5 (13.1) 
n = 63 
36.7 (12.0) 
51.1 (10.6) 
 
0.014 
0.765 
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slightly better than that of the U.S. population of subjects with self-reported chronic 
lung disease (44.5). 
 PiSZ subjects had better health status than the PiZ subjects for the symptoms 
(p<0.001), activity (p=0.009) and impacts (p=0.003) domains and the total score 
(p=0.001) of the SGRQ, and the physical domain of the SF-36 (p = 0.014) 
questionnaire (table 6.3).   
 
6.3.1.4 Pulmonary physiology 
 
Pulmonary physiology data for PiSZ and PiZ subjects matched for age, gender 
and smoking is shown below in table 6.4. 
For PiSZ subjects, the mean FEV1:FVC ratio was lower than expected in a 
healthy population, but FEV1 and gas transfer factors were in the lower part of the 
reference range, with lung volumes being in the higher part of the reference range.  
Sixty percent of PiSZ subjects had no evidence of airflow obstruction compared to 
only 18% of PiZ subjects (p<0.001).  PiSZ subjects had a greater mean FEV1 % 
predicted, FVC % predicted, FEV1:FVC, & KCO % predicted  and a smaller RV % 
predicted compared with PiZ subjects.   
  There was no difference in the absolute change in FEV1 or the increase in % 
of predicted FEV1 between PiSZ and PiZ subjects following bronchodilation.  A 
similar proportion (p=0.307) of PiSZ (38%) and PiZ (28%) subjects had evidence of 
significant bronchodilator reversibility according to ATS guidelines239.   
 PaO2 while breathing room air was less than 10 KPa in 21 of the 48 PiSZ 
subjects in whom it was recorded but was significantly greater than in PiZ subjects 
(p=0.006). 
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TABLE 6.4: Pulmonary physiology for subjects with the Pi SZ phenotype 
compared with Pi Z subjects matched for gender, age, smoking status and 
pack years.   
 Pi SZ      Pi Z p = 
 
FEV1 % predicted median (I.Q.R.) 
FVC % predicted mean (S.D.) 
FEV1:FVC  median (I.Q.R.) 
n = 62 
91.65    (56.99-112.76) 
109.10  (17.61) 
67.79    (40.91-81.72) 
n = 63 
41.40   (32.54-70.00) 
98.10 (19.42) 
37.67 (28.75-52.27) 
 
<0.001 
0.001 
<0.001 
 
Bronchodilator response  
 
  (ml) mean (S.D.) 
Bronchodilator response  
  (%) mean (S.D.) 
Significant bronchodilator response 
  n = 
n = 60 
 
 
320       (240) 
 
10.13    (8.12) 
 
19 (38%) 
n = 60 
 
270       (180) 
 
8.48      (7.25) 
 
14 (28%) 
 
 
0.482 
 
0.341 
 
0.307 
 
RV % predicted  mean (S.D.) 
TLC % predicted median (I.Q.R.) 
KCO % predicted mean (S.D.) 
n = 62 
107.62  (37.85) 
107.74  (99.36-119.69) 
90.45    (23.62) 
n = 62 
136.42 (46.36) 
110.98(100.60-121.83) 
69.98 (25.04) 
 
0.002 
0.337 
0.002 
 
PaO2 (KPa)  mean (S.D.) 
PaCO2 (KPa)  median (I.Q.R.) 
n = 59 
10.22 (1.41) 
5.10      (4.90-5.60) 
n = 62 
9.36 (1.57) 
4.80 (4.57-5.20) 
 
0.002 
0.001 
The significance in difference (p) between the 2 groups is shown. 
 
 
The absolute change in FEV1, the change expressed as a percentage of 
predicted FEV1 and the numbers of subjects with significant bronchodilator 
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reversibility are shown for each NICE category of airflow obstruction severity (correct 
at the time of analysis248) in table 6.5 below. 
 
TABLE 6.5: Change in FEV1 expressed as an absolute value and as a percent 
of predicted and the proportion of subjects with significant bronchodilator 
reversibility according to the American Thoracic Society (ATS) guidelines239. 
 PiSZ PiZ P = 
Change in FEV1 after bronchodilator    ml 
 
No airflow obstruction 
Mild 
Moderate 
Severe 
 
 
280 (300) 
470 (190) 
320 (120) 
160 (100) 
 
 
320 (220) 
290 (250) 
290 (160) 
190 (90) 
 
 
0.706 
0.047 
0.650 
0.570 
Change in FEV1 after bronchodilator   % 
predicted 
 
No airflow obstruction 
Mild 
Moderate 
Severe 
 
 
 
 
8.60 (7.52) 
16.34 (6.80) 
9.85 (2.74) 
5.56 (3.22) 
 
 
 
 
9.56 (7.35) 
8.98 (6.19) 
9.22 (5.02) 
5.77 (2.31) 
 
 
 
 
0.724 
0.009 
0.725 
0.889 
 
Proportion with significant reversibility    
n = 
 
No airflow obstruction 
Mild 
Moderate 
Severe 
 
 
 
 
8/35 (23%) 
9/12 (75%) 
2/9 (22%) 
0/4  
 
 
 
 
3/7 (43%) 
4/13 (31%) 
7/24 (29%) 
0/13  
 
 
 
 
0.687 
0.027 
1.0 
 
Data are shown for subjects who have undertaken appropriate testing, in each NICE 
stage of COPD severity (correct at the time of analysis)248. The significance in 
difference (p) between the 2 groups is shown. 
 
 
Bronchodilator reversibility varied with the NICE stage of airflow obstruction 
severity to a greater extent in PiSZ compared to PiZ subjects.  For subjects with mild 
airflow obstruction, PiSZ subjects had a greater increase in FEV1 following 
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bronchodilation, in both absolute terms and in the percentage of the predicted value 
compared with PiZ subjects.  In addition, a greater proportion of PiSZ subjects with 
mild airflow obstruction had significant bronchodilator reversibility according to the 
ATS/ERS Standards239, compared with subjects with PiZ subjects who also had mild 
airflow obstruction.   
  
 
6.3.1.5 Previous respiratory and cardiovascular diagnoses 
 
The number of subjects who had been given a diagnosis of various types of 
respiratory disease prior to their initial visit to ADAPT is shown in table 6.6. 
 
TABLE 6.6: Number of PiSZ and PiZ subjects matched for age, gender and 
smoking with respiratory and cardiovascular diagnoses prior to the baseline 
ADAPT visit. 
 PiSZ PiZ P = 
Emphysema   n = 22 (35%) 50 (79%) <0.001 
Bronchiectasis   n =  1 (2%) 8 (13%) 0.033 
Asthma    n = 25 (40%) 30 (48%) 0.369 
Hayfever   n = 13 (21%) 17 (27%) 0.403 
Sinus disease   n =  24 (38%) 22 (35%) 0.711 
Thoracic surgery  n = 0 2 (3%) 0.496 
Heart disease   n = 2 (3%) 4 (6%) 0.680 
Hypertension   n = 12 (19%) 10 (16%) 0.639 
The significance in difference (p) between the 2 groups is shown. 
 
  
Twenty two PiSZ subjects had been given a clinical diagnosis of emphysema 
prior to the baseline ADAPT visit, and of these, emphysema was confirmed on the 
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CT scan in 15 (68%), but was absent in 7 (32%).  Of the 41 PiSZ subjects who did 
not have a pre-existing diagnosis of emphysema, 32 had a CT scan, and 
emphysema was seen in 4 cases (13%). 
 50 PiZ subjects had a pre-existing diagnosis of emphysema.  Of these, 
emphysema was confirmed by CT scanning in all 48 who underwent CT scanning.  
No CT scan data were available for the remaining 2 subjects.  Of the 13 PiZ subjects 
who had not been given a diagnosis of emphysema prior to their first visit to ADAPT, 
10 had a CT scan performed.  Of these, 3 (30%) had evidence of emphysema, and 7 
(70%) did not.    
 One PiSZ subject had been given a diagnosis of bronchiectasis prior to the 
baseline visit.  Bronchiectasis was not seen on CT scanning in this subject, but was 
found in 7 others.  Seven of the 8 PiZ subjects with a diagnosis of bronchiectasis 
prior to attending ADAPT had a CT scan. Of these, bronchiectasis was confirmed on 
the CT scan in 3 (43%), but was not seen in the remaining 4 (57%) subjects.  
Bronchiectasis was, however, present in 9 out of the 51 subjects (18%) who had no 
such previous diagnosis and had CT scan data available. 
 Twenty five (40%) of the PiSZ subjects had previously been diagnosed with 
asthma, although only 10 (40%) of them had significant bronchodilator reversibility, 
whereas 9 out of 35 (26%) of subjects with no previous physician diagnosis of 
asthma who also underwent reversibility testing had significant reversibility.  Of the 
30 PiZ subjects who had been given a diagnosis of asthma prior to attending ADAPT, 
28 had bronchodilator reversibility testing.  Of this 28, 10 (36%) had significant 
reversibility.  Thirty two of the 33 PiZ subjects who had not been given a previous 
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diagnosis of asthma had bronchodilator reversibility testing, and of these, 4 (13%) 
had significant reversibility. 
 There was no difference between the proportions of PiSZ and PiZ subjects 
reporting a diagnosis of hayfever, sinus disease, heart disease or hypertension prior 
to their initial assessment at ADAPT.   
 One PiZ subject had a surgical pleurodesis procedure following recurrent 
pneumothoraces. No PiSZ subject reported previous thoracic surgery. 
 
 
 
6.3.1.6 Respiratory symptoms 
 
 Symptoms described by the subjects while in the stable state are shown in 
table 6.7.  
 PiZ subjects had a greater mean MRC dyspnoea score, indicating a greater 
degree of breathlessness, than PiSZ subjects.  The most frequently recorded MRC 
dyspnoea score was 1 (only breathless on strenuous exercise) for PiSZ subjects, and 
4 (has to stop after 100 yards or a few minutes on the flat due to breathlessness) for 
PiZ subjects.    
A larger proportion of PiZ subjects reported wheezing most days or nights 
(43%) compared with PiSZ subjects (24%).  There was a trend for the proportion of 
PiZ subjects who described coughing regularly and the frequency of exacerbation in 
this group to be greater than in PiSZ subjects, but these observations were not 
statistically significant. 
 There was no difference in the proportion of subjects with chronic bronchitis68 
between PiZ and PiSZ subjects. 
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TABLE 6.7: Stable state symptoms in subjects with the Pi SZ phenotype 
compared with Pi Z subjects matched for gender, age, smoking status and 
pack years.   
The significance in difference (p) between the 2 groups is shown. 
  
 
6.3.1.7 Liver disease and liver function tests 
 
 The number of subjects who reported previous or current liver disease, 
the mean results for serum liver biochemistry tests and the number of subjects with 
abnormal results are shown below in table 6.8. 
 Pi SZ      
(n = 52) 
Pi Z        
(n = 52) 
p = 
MRC Dyspnoea score   median (I.Q.R.) 
1 –Breathless on strenuous exercise  n = 
2 – Breathless hurrying on level / slight hill n =  
3 – Walks slower or stops at own pace  n = 
4 – Stops after 100 yards or few minutes n = 
5 – Too breathless to dress or leave house n =  
3.0   (1.0-4.0) 
21    (33%) 
9      (14%) 
13    (21%) 
8      (13%) 
12      (19%) 
4.0   (3.0-4.0) 
4      (6%) 
11    (18%) 
16    (25%) 
19    (30%) 
13    (21%) 
0.006 
 
Chi 
square
= 
0.002 
Usually has cough   n = 23    (37%) 33    (52%) 0.073 
Wheeze most days or nights  n =  15    (24%) 27    (43%) 0.023 
Chronic bronchitis   n = 18    (29%) 24    (38%) 0.257 
Number of exacerbations per year median (I.Q.R.) 0.2   (0-1.2) 1.0   (0-2) 0.067 
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TABLE 6.8: Liver disease and liver biochemistry test results in PiSZ compared 
with PiZ subjects matched for age, gender, smoking status and pack years.  
P indicates the significance of the difference between the two groups. 
 PiSZ PiZ P =  
Neonatal jaundice   n =  15 (24%) 16 (25%) 1.0 
Childhood jaundice   n =  1 (2%) 1 (2%) 1.0 
Hepatitis    n =  2 (3%) 2 (3%) 1.0 
Cirrhosis    n =  2 (3%) 1 (2%) 1.0 
GGT (iU/l)   
   mean +/- S.D.  
   Number abnormal 
n = 62 
44.3 (51.6) 
17 (23%) 
n = 59 
50.6 (46.9) 
14 (29%) 
 
0.111 
0.432 
ALP (U/L)   
   mean +/- S.D. 
   Number abnormal 
n = 62 
177.4 (56.0) 
3 (5%) 
n = 62 
172.9 (56.0) 
1 (2%) 
 
0.654 
0.619 
AST    (U/L)   
   mean +/- S.D. 
   Number abnormal 
n = 62 
26.3 (13.1) 
5 (8%) 
n = 62 
26.8 (11.1) 
5 (8%) 
 
0.344 
1.0 
Bilirubin (μmol/L)  
   mean +/- S.D. 
   Number abnormal 
n = 62 
9.5 (5.5) 
2 (3%) 
n = 62 
9.6 (4.0) 
1 (2%) 
 
0.867 
1.0 
 
 
  
There was no difference in the number of subjects reporting past or current 
liver disease, the mean values for liver biochemistry or the number of subjects with 
abnormal liver biochemistry between PiSZ and PiZ subjects.  
 15 (24%) PiSZ and 16 (25%) PiZ subjects reported a history of neonatal  
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jaundice, and a further PiZ subject reported jaundice in childhood that resolved 
spontaneously.   
 Of the 15 PiSZ subjects who had neonatal jaundice, 1 continued to have 
jaundice into childhood, and a further subject developed hepatitis as an adult.  Of the 
PiSZ subjects with no history of neonatal jaundice, 2 developed liver cirrhosis and 1 
developed hepatitis as an adult.   
 Of the 16 PiZ subjects with a history of neonatal jaundice, 1 developed 
hepatitis and 1 developed liver cirrhosis as an adult.  A further PiZ subject with 
neonatal jaundice developed a transient hepatitis, which was thought to be due to a 
drug reaction in adult life.  The remaining 13 PiZ subjects with a history of neonatal 
jaundice had no current clinical evidence of liver disease currently.  Of the PiZ 
subjects who did not develop neonatal or childhood jaundice, none developed 
hepatitis or clinical evidence of liver cirrhosis.   
 Serum liver biochemistry was recorded at the baseline assessment in 62 PiSZ 
subjects.  Of these, 17 (23%) had an abnormal GGT, 3 (5%) had an abnormal ALP, 5 
(8%) had an abnormal AST and 2 (3%) had an abnormal bilirubin.  GGT 
measurements were available for 59 of the PiZ subjects, and 14 (29%) had an 
abnormal result.  The other serum liver biochemistry tests were available for 62 PiZ 
subjects, of whom, 1 (2%) had an abnormal ALP, 5 (8%) had an abnormal AST and 1 
(3%) had a normal bilirubin. 
 GGT was not measured in the PiZ subject with a history of liver cirrhosis, but 
the other liver function tests were within the normal range.  Of the PiSZ subjects with 
a history of liver cirrhosis, 1 had an abnormal GGT and AST, and the second subject 
had an abnormal bilirubin and ALP. 
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6.3.1.8 Relationship of CT scan to physiology 
 
 The proportions of subjects who had visible emphysema on the CT scan in 
each NICE stage of airflow obstruction severity (correct at the time of analysis248) are 
shown below in table 6.9. 
 
TABLE 6.9: Proportion of subjects in each NICE stage of airflow obstruction 
severity (correct at the time of analysis248) with emphysema visible on CT scan.   
 
Severity of airflow 
obstruction 
(NICE Stage) 
Proportion of subjects in each NICE 
stage with emphysema on CT scan 
 
P = 
 PiSZ PiZ  
No airflow obstruction 4/30  (13%) 3/8    (38%)  0.146 
Mild 5/10    (50%) 12/13    (92%) 0.052 
Moderate 35/9   (56%) 23/24    (96%) 0.013 
Severe 4/4   (100%) 13/13    (100%) 1.0 
P = <0.001 0.001  
P indicates the significance of the difference between the two groups. 
 
 
As the NICE stage of airflow obstruction severity increases, a greater 
proportion of both PiSZ and PiZ subjects have visible emphysema on the CT scan.  
However, for subjects with mild to moderate airflow obstruction, a smaller proportion 
of PiSZ subjects had emphysema compared to PiZ subjects with the same degree of 
airflow obstruction. 
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6.3.1.9 Relationship of health status to physiology 
 
 The SGRQ total score related to the FEV1% predicted, FEV1:FVC % 
predicted and KCO% predicted in both PiSZ  (r= -0.563, p<0.001; r= -0.691, p<0.001; 
r= -0.445, p<0.001 respectively) and the PiZ subjects (r= -0.507, p<0.001; r= -0.480, 
p<0.001; r= -0.312, p=0.004) as shown in figure 6.1 below.  
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FIGURE 6.1: The relationship of (a.) FEV1 % predicted (b.) FEV1:FVC % 
predicted and (c.) KCO % predicted to the total SGRQ score for PiSZ and PiZ 
subjects matched for age, gender, smoking status and pack years.   
The blue circles and fit line represent PiZ subjects and the green circles and fit line 
represent PiSZ subjects.  Each circle represents one case. 
(a.) 
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FIGURE 6.1 (continued) 
(b.) 
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FIGURE 6.1 (continued) 
(c.) 
 
 
 
 
 From the scatter plots, subjects with the PiSZ phenotypes appear to have a 
greater or similar degree of health status impairment compared to PiZ subjects when 
physiology measurements are most severely impaired, but a smaller degree of health 
status impairment when physiology measurements are normal.   
 For example, for subjects with an FEV1:FVC above the median, the mean 
total SGRQ score was lower (p=0.038), indicating a better health status for PiSZ 
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subjects (24.30 ± 22.71)  compared to PiZ subjects (36.72 ± 20.47).  For subjects 
with an FEV1:FVC below the median, the mean total SGRQ score was similar 
(p=0.590) for PiSZ subjects (58.88 ± 16.25)  compared to PiZ subjects (56.44 ± 
15.12).   
 
 
6.3.1.10 Relationship of CT scans to health status 
 
The mean values for the SGRQ domains, the total score and the physical and 
mental summary scores of the SF-36 are shown in table 6.10 below. 
 
PiSZ and PiZ subjects with visible emphysema on the CT scan had worse 
scores for all aspects of the SGRQ and for the SF-36 physical summary score 
compared with subjects with no emphysema. 
All subjects had higher SGRQ scores, indicating a worse health status 
compared to a general population of a similar age253, even if they did not have 
emphysema visible on the CT scan.  Average comparator scores for a general 
population age 39-49 (i.e. similar to the PiZ subjects with no emphysema visible on 
CT) published previously by Ferrer et al.253 were 7.97 (symptoms), 9.33 (activity), 
2.69 (impacts) and 5.78 (total).  Average comparator scores for a general population 
age 49-59 (i.e. similar to the PiZ subjects with emphysema visible on CT and both 
PiSZ groups) published previously253 were 8.74 (symptoms), 13.48 (activity), 4.55 
(impacts) and 8.19 (total) for PiZ subjects with emphysema, PiSZ subjects with no 
emphysema, and PiSZ subjects with emphysema. 
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TABLE 6.10: Mean (S.D.) SGRQ and SF-36 scores for PiSZ and PiZ subjects 
matched for age, gender, smoking status and pack years, with and without 
visible emphysema on the CT scan.    
 
 
PiSZ PiZ P = 
EMPHYSEMA VISIBLE ON CT SCAN 
 
 SGRQ – Symptoms domain 
 
 SGRQ – Activity domain 
 
 SGRQ – Impacts domain 
 
 SGRQ – Total score 
 
 SF-36 – Physical summary score 
 
 SF-36 – Mental summary score 
 
 
 
63.76 (14.91) 
 
72.53 (24.91) 
 
40.49 (21.14) 
 
53.8 (20.08) 
 
34.19 (33.25) 
 
55.32 (10.73) 
 
 
68.74 (16.84) 
 
71.04 (19.62) 
 
41.24 (17.56) 
 
54.84 (15.37) 
 
33.76 (10.38) 
 
51.49 (11.03) 
 
 
0.258 
 
0.520 
 
0.899 
 
0.853 
 
0.883 
 
0.091 
NO EMPHYSEMA VISIBLE ON CT SCAN 
 
 SGRQ – Symptoms domain 
 
 SGRQ – Activity domain 
 
 SGRQ – Impacts domain 
 
 SGRQ – Total score 
 
 SF-36 – Physical summary score 
 
 SF-36 – Mental summary score 
 
 
 
41.12 (29.60) 
 
36.17 (34.08) 
 
20.60 (21.89) 
 
29.26 (25.28) 
 
45.73 (13.18) 
 
47.71 (14.43) 
 
 
29.87 (26.42) 
 
20.54 (26.14) 
 
11.18 (13.16) 
 
17.12 (15.34) 
 
53.30 (4.84) 
 
52.87 (4.27) 
 
 
0.340 
 
0.335 
 
0.153 
 
0.231 
 
0.146 
 
0.945 
P = (EMPHYSEMA VS. NO EMPHYSEMA) 
 
 SGRQ – Symptoms domain 
 
 SGRQ – Activity domain 
 
 SGRQ – Impacts domain 
 
 SGRQ – Total score 
 
 SF-36 – Physical summary score 
 
 SF-36 – Mental summary score 
 
 
0.008 
 
0.001 
 
0.005 
 
0.001 
 
0.002 
 
0.045 
 
 
 
<0.001 
 
<0.001 
 
<0.001 
 
<0.001 
 
<0.001 
 
0.745 
 
 
The SGRQ and SF-36 scores are compared between PiSZ and PiZ subjects who 
have visible emphysema on the CT scan (row 1) and between PiSZ and PiZ subjects  
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TABLE 6.10 FOOTNOTE (continued):   
who have no visible emphysema on the CT scan (row 2).  P values are also given to 
denote the significance of any difference in SGRQ and SF-36 scores between PiSZ 
subjects with visible emphysema on the CT scan and PiSZ subjects with no visible 
emphysema(row 3, column 1).  Similarly, p values are shown to denote the 
significance of any difference in SGRQ and SF-36 scores between PiZ subjects with 
visible emphysema on the CT scan and PiZ subjects with no visible emphysema(row 
3, column 2). 
 
 
 
SF-36 physical summary scores were lower, indicating a worse general health 
status compared with the general population of a similar age in PiSZ and PiZ 
subjects with emphysema (comparator scores are 45.90 and 49.64 respectively237).  
However, for subjects with no evidence of emphysema on CT scanning, the SF-36 
physical summary scores were similar in both PiSZ and PiZ subjects compared to 
normal values generated in a general US population (49.64 and 52.15 
respectively237). 
There were no differences between PiSZ and PiZ subjects in any domain of 
the SGRQ or the SF-36 for subjects who had visible emphysema on the CT scan or 
for those who did not. 
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6.3.1.11 Relationship of physiology to pack years of cigarettes 
smoked 
 
 
Pack years of cigarettes smoked correlated negatively with FEV1 % predicted, 
FEV1:FVC and KCO % predicted, and correlated positively with RV % predicted and 
TLC % predicted in subjects with either the PiSZ or the PiZ phenotype.  However, the 
relationship to lung volumes and gas transfer was not as strong for PiZ compared to 
PiSZ subjects.  The change in FEV1 following bronchodilation also correlated 
positively with pack years smoked in PiSZ subjects but not in PiZ subjects.  These 
relationships are shown in figure 6.2 below. 
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FIGURE 6.2: Relationship between pack years smoked and (a.) FEV1 % 
predicted, (b.) FEV1:FVC % predicted, (c.) KCO % predicted, (d.) TLC % 
predicted (e.) RV % predicted and (f) change in FEV1 following bronchodilation 
for PiSZ subjects and PiZ subjects matched for age, gender, smoking status 
and pack years. 
 
(a.) PiSZ: r = -0.504, p<0.001; PiZ: r = -0.527, p<0.001. 
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FIGURE 6.2 (continued): 
(b.) PiSZ: r = -0.432, p=0.001; PiZ: r = -0.490, p<0.001. 
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FIGURE 6.2 (continued): 
(c.) PiSZ: r = -0.506, p<0.001; PiZ: r = -0.308, p = 0.015 
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FIGURE 6.2 (continued): 
(d.) PiSZ: r = 0.346, p = 0.006; PiZ: r = 0.250, p = 0.050 
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FIGURE 6.2 (continued): 
(e.) PiSZ : r = 0.522, p < 0.001 ; PiZ : r = 0.338, p = 0.007 
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FIGURE 6.2 (continued): 
(f.) PiSZ : r = 0.392, p = 0.002 ; PiZ : r = -0.107, p = 0.417 
 
 
 
 
 
6.3.2. PiSZ never smokers compared to PiSZ previous 
or current smokers 
 
 Seventeen PiSZ subjects had never smoked, 32 were ex-smokers and 14 
continued to smoke at the time of assessment.  The mean number of pack years in 
ex and current smokers was 36.67 (S.D.±30.92).  There were no differences between 
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never smokers and those who had smoked in terms of gender (47% male & 61% 
male respectively), age (46.96±17.82 & 51.90±12.81 respectively), AAT level 
(12.74±3.29 & 13.33±2.97 respectively) or the proportion of lung index (44% & 26% 
respectively) and non-index cases (44% & 63% respectively). 
 Forty one PiSZ ex or current smokers had a CT scan and 18 (44%) had 
evidence of emphysema, compared to only 1 out of the 13 PiSZ never smokers (8%) 
who had a CT scan (p = 0.021).  The subject who had emphysema visible on the CT 
scan despite never having smoked had been exposed to 19 years of passive 
smoking as a child and adolescent, and had worked as a farmer for 45 years.  The 
subject had also been exposed to fumes from coal and wood fires used to heat the 
home.  This subject had no evidence of airflow obstruction, but a mild isolated 
abnormality of KCO (78% predicted). 
  PiSZ subjects who had never smoked had worse SGRQ scores in the 
symptoms (27.22±26.32), activity (23.45 ±24.15) and impacts (8.36±12.57) domains 
and a worse total SGRQ score (16.07±16.87) than a general population of a similar 
age253 (7.97, 9.33, 2.69, 5.78 respectively).  However, never smokers had better 
scores than subjects who had smoked (53.49±26.13, 54.29±35.91, 31.84±22.99 & 
42.45±25.71 respectively).  Never smokers had a similar SF-36 physical summary 
score (51.11±10.07) to subjects from a general population of a similar age (49.64)237, 
but ex and current smokers had a worse mean score than both of these groups 
(38.98±13.27). 
 Current or ex smokers had worse FEV1 % predicted (75.21±32.07; p<0.001), 
FEV1:FVC (56.55±20.84;p<0.001), RV % predicted (113.70±38.58) and KCO % 
predicted (85.98±23.58; p=0.010) and a greater degree of bronchodilator reversibility 
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(370±270ml; p=0.005) than subjects who had never smoked (107.09±23.02, 
77.87±15.49, 91.52±31.47, 102.28±19.83, 160±140  respectively).  Two of 17 (12%) 
never smokers had evidence of airflow obstruction compared to 23/45 (51%) ex or 
current smokers who had their FEV1 measured. 
 A greater proportion (p<0.001) of ex or current smokers had been diagnosed 
with emphysema prior to attending ADAPT (48%) compared with those who had 
never smoked (0%).  Of those with a diagnosis of emphysema prior to attending 
ADAPT, emphysema was visualised on the baseline ADAPT CT scan in 15/22 (68%), 
but was not seen in 7 (32%) subjects, all of whom had evidence of airflow 
obstruction.  
 Mean MRC dyspnoea scores (1.71±0.85) were lower (p=0.001), indicating 
less severe breathlessness, and the frequency of cough (12%), chronic bronchitis 
(6%) and annual exacerbations (0.40±0.86) were less (p=0.013, p=0.025, p = 0.030 
respectively) in subjects who had never smoked compared with those who had 
previously smoked (3.07±1.55, 46%, 37%, 1.27±1.74 respectively).  There was no 
difference in the proportion of subjects who described wheeze or the sputum colour 
in the stable state between subjects who had previously smoked and those who had 
not.  
 Six (35%) of never smokers and 9 (20%) of ex or current smokers had a 
history of neonatal jaundice (p=0.204) and 1 subject from each group had a history of 
liver cirrhosis.  There were no differences in the mean GGT, ALP, AST or bilirubin 
measurements, or in the proportion of subjects who had abnormalities of these tests, 
when subjects who had never smoked were compared to subjects who had. 
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6.3.3. PiSZ with an AAT level of <11μm compared to 
PiSZ with an AAT level >11μm 
 
 Thirteen PiSZ subjects had an AAT level of <11µM (low level group), and 58 
had a level >11µM (intermediate level group).  Sixty nine percent of subjects with an 
AAT level of less than 11μM were male compared with 52% with a level greater than 
11Μm.  54% with a low AAT level were non-index subjects and 46% had never 
smoked compared with 23% and 21% respectively with an intermediate AAT level.  
However, none of these observations were significantly different between the two 
groups. 
 Forty four percent from the low level group had evidence of emphysema on 
their CT scans and 43% had airflow obstruction, compared with 28% and 39% 
respectively in the higher level group.  There was no significant difference in these 
observations between the two groups.  Despite this, the higher level group had a 
greater (p=0.046) mean MRC dyspnoea score (2.96±1.53), indicating more severe 
breathlessness, and a lower (p=0.009) SF-36 physical summary score (39.93±13.69) 
indicating a worse general health status than subjects with the lower level of AAT 
(2.0±1.22 and 50.02±9.98 respectively). 
 There were no differences in other respiratory symptoms, parameters of 
pulmonary function or SGRQ scores between the 2 groups. 
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6.3.4. Characteristics of PiSZ index subjects compared 
to PiZ index subjects matched for age, gender and 
smoking  
 
 Demographic data for the 36 PiSZ subjects who were diagnosed with AATD 
due to lung disease (lung index), and PiZ lung index subjects, matched in pairs for 
age, gender, smoking status and pack years are shown in table 6.11.   
 
 
TABLE 6.11: Demographic and smoking data for lung index Pi SZ subjects 
compared with lung index Pi Z subjects matched for gender, age, smoking 
status and pack years.    
 Pi SZ     (n = 36) Pi Z       (n = 36) p = 
Male gender   n = 20 (56%) 20 (56%) 1.0 
Age    mean (S.D.) 54.0 (10.8) 53.3 (10.4) 0.796 
Smoking status   
  Never  n = 
  Ex  n = 
  Current  n = 
 
7 (19%) 
20 (56%) 
9 (25%) 
 
7 (19%) 
25 (69%) 
4 (11%) 
 
0.290 
Pack years smoked  mean (S.D.) 27.78 (31.30) 25.48 (19.27) 0.709 
The significance in difference (p) between the 2 groups is shown. 
 
 
 Generally PiSZ and PiZ subjects were well matched.  Demographic data for 
PiSZ lung index cases were no different to those of other PiSZ subjects.  
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 Data regarding abnormalities reported on the CT scan, CT scan densitometry 
data and the proportion of subjects with upper or lower zone predominant 
emphysema (where available) are shown in table 6.12. 
 
TABLE 6.12: CT scan appearance and densitometry for lung index subjects 
with the Pi SZ phenotype compared with lung index Pi Z subjects matched for 
gender, age, smoking status and pack years.   
 Pi SZ (n = 33)      Pi Z (n = 33) p = 
Normal CT scan   n =  
Emphysema on CT scan  n =  
Bronchiectasis on CT scan  n = 
Bullous disease    n =  
9 (27%) 
15 (46%) 
4 (13%) 
1 (3%) 
3 (9%) 
30 (91%) 
6 (18%) 
3 (9%) 
0.056 
<0.001 
0.492 
0.613 
 
Centrilobular emphysema present    n = 
Panacinar emphysema present       n = 
Paraseptal emphysema present       n = 
N = 13 
3/13 (23%) 
9/13 (69%) 
1/13 (8%) 
N = 29 
8/29 (28%) 
25/29 (86%) 
1/29 (3%) 
 
1.0 
0.226 
0.528 
Centrilobular emphysema predominant  n= 
Panacinar emphysema predominant n= 
Paraseptal emphysema predominant n=  
3/13 (23%) 
9/13 (69%) 
1/13 (8%) 
8/29 (27%) 
20/29 (69%) 
1/29 (3%) 
 
1.0 
 
CT Densitometry 
 Upper zone VI            mean (S.D.) 
 Lower zone VI            mean (S.D.) 
N = 24 
16.7 (20.6) 
15.5 (18.9) 
N = 24 
17.9 (15.5) 
29.8 (16.6) 
 
0.826 
0.008 
Upper zone predominance  n = 10 (42%) 2 (8%) 0.008 
The significance in difference (p) between the 2 groups is shown. 
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 Twenty seven percent of PiSZ subjects had no abnormality reported on the CT 
scan despite all subjects being diagnosed with AATD due to lung disease.  Only 9% 
of PiZ lung index subjects were reported to have a normal CT scan, but this was not 
significantly different (p=0.056) to PiSZ lung index subjects. 
 Fewer (p = 0.002) PiSZ lung index subjects had a normal CT scan, and a 
greater proportion (p = 0.014) had emphysema visible on the CT scan compared with 
PiSZ subjects who were diagnosed with AATD for other reasons, but the proportions 
of bullous disease and bronchiectasis were not different between these 2 groups. 
 Visible emphysema was present in a greater proportion of PiZ compared with 
PiSZ lung index subjects.   There was no difference in the proportion of subjects with 
bronchiectasis or bullous disease on the CT scan between PiSZ and matched PiZ 
subjects. 
 Approximately one third of PiSZ subjects had panacinar emphysema and a 
quarter had centrilobular emphysema.  These proportions were no different to those 
observed for PiZ subjects.  
 As with the whole cohort, PiZ index subjects have a lower lung density in the 
lower zones but a similar density in the upper zones compared with PiSZ index 
subjects.  A greater proportion of PiSZ subjects had a reduced lung density in the 
upper zone relative to the lower zone compared with PiZ subjects. 
 When only subjects with visible emphysema on the CT scan were considered, 
more (P=0.003) PiSZ (5/8 [63%]) than PiZ (1/21[5%]) subjects had upper zone 
emphysema predominance, although the differences in the upper zone and the lower 
zone voxel indices between the two groups did not reach statistical significance.   
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 Health status data were available for all PiZ lung index subjects, 33 PiSZ 
subjects using the SGRQ and 32 subjects using the SF-36.  Scores are shown in 
table 6.13 below. 
 
TABLE 6.13: Health status data for lung index subjects with the Pi SZ 
phenotype compared with Pi Z subjects matched for gender, age, smoking 
status and pack years, using the SGRQ and SF-36.   
 Pi SZ      Pi Z   
      
p = 
 
SGRQ Symptoms  mean (S.D.) 
 Activity   mean (S.D.) 
 Impacts   mean (S.D.) 
 Total   mean (S.D.) 
n = 33 
60.73 (19.28) 
62.15 (33.15) 
35.52 (23.35) 
47.45 (24.06) 
n = 36 
61.39 (21.85) 
64.06 (23.49) 
36.10 (17.86) 
48.77 (17.82) 
 
0.894 
0.780 
0.908 
0.797 
 
SF-36 Physical domain mean (S.D.) 
 Mental domain  mean (S.D.) 
n = 32 
37.65 (13.07) 
50.29 (12.55) 
n = 36 
35.51 (9.07) 
52.84 (11.31) 
 
0.682 
0.384 
The significance in difference (p) between the 2 groups is shown. 
 
  
There was no difference in health status scores using the SGRQ or the SF-36 
between PiSZ and matched PiZ lung index cases, despite a greater proportion of PiZ 
subjects having emphysema visible on the CT scan, airflow obstruction and 
abnormalities of gas transfer.  PiSZ lung index subjects had greater scores, in all 
domains and the total SGRQ (p<0.001) and a lower SF-36 physical summary score 
(p = 0.030), indicating a worse physical health status compared with PiSZ subjects 
who were diagnosed for other reasons.  There was, however, no difference in the 
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mental health summary score of the SF-36 between PiSZ lung index subjects and 
other PiSZ subjects.  
 Pulmonary physiology is shown in table 6.14 below for PiSZ and matched PiZ 
lung index subjects. 
 
TABLE 6.14: Pulmonary physiology for lung index subjects with the Pi SZ 
phenotype compared with lung index Pi Z subjects matched for gender, age, 
smoking status and pack years.   
 Pi SZ      Pi Z        
 
p = 
 
FEV1 % predicted  median (I.Q.R.) 
FVC % predicted  mean (S.D.) 
FEV1:FVC   median (I.Q.R.) 
n = 36 
71.49   (36.91) 
102.69  (22.54) 
52.62    (22.90) 
n = 36 
50.44   (25.54) 
104.45 (21.61) 
39.45 (16.69) 
 
0.007 
0.737 
0.008 
 
Bronchodilator response (ml) mean (S.D.) 
Bronchodilator response (%) mean (S.D.) 
n = 35 
310       (230) 
10.64    (7.20) 
n = 34 
230       (140) 
7.93      (5.41) 
 
0.079 
0.076 
 
RV % predicted   mean (S.D.) 
TLC % predicted  median (I.Q.R.) 
KCO % predicted  mean (S.D.) 
n = 35 
123.40  (35.84) 
113.55  (14.15) 
86.26    (26.91) 
n = 35 
113.51 (55.22) 
111.96 (36.49) 
67.80 (20.27) 
 
0.373 
0.270 
0.002 
The significance in difference (p) between the 2 groups is shown. 
 
 
 Mean FEV1 % predicted, FEV1:FVC and KCO % predicted were greater (p = 
0.009, p = 0.012, p = 0.004 respectively) in PiSZ lung index subjects than in PiZ lung 
index subjects.  Lung volumes were not different for lung index cases between the 2 
172 
 
phenotypic groups.  Although PiSZ lung index subjects tended to have a greater 
increase in FEV1 following bronchodilation than matched PiZ subjects, this was not 
significantly different.  
 Twenty one of the 35 (60%) PiSZ lung index subjects had airflow obstruction 
compared with 33/36 (92%) of matched PiZ subjects (p=0.002), and 14/35 (40%) 
PiSZ subjects had an abnormal KCO %predicted compared with 28 (78%) of PiZ 
subjects (p=0.001).  A greater proportion (p<0.001) of lung index subjects had 
evidence of airflow obstruction compared with other PiSZ subjects (15%), but there 
was no difference (p = 0.083) in the proportion with an abnormal KCO %predicted 
between lung index and other PiSZ subjects (19%).  
 Despite PiZ lung index subjects having more emphysema visible on CT scans, 
worse CT densitometry, spirometry and gas transfer than matched PiSZ lung index 
subjects, there were no differences in the MRC dyspnoea score, the presence of 
cough, chronic bronchitis, daily wheeze, sputum colour in the stable state and the 
number of exacerbations over the previous year between the 2 groups.  
 Eight PiSZ and seven PiZ subjects had a history of neonatal jaundice, and this 
continued into childhood in 1 PiSZ subject.  One of the PiSZ subjects who had 
neonatal jaundice also developed hepatitis as an adult.  A further PiZ subject 
developed jaundice in childhood.  There were no differences in the mean serum ALP, 
AST and bilirubin measurements between the 2 groups. 
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6.3.5. Characteristics of PiSZ non-index subjects 
compared to non-index PiZ subjects matched for age, 
gender and smoking 
 
 Nineteen PiSZ subjects were initially diagnosed with AATD due to family 
screening (non-index).  Demographic, smoking, CT scan and physiology data for 
these subjects and 19 non-index PiZ subjects matched in pairs for age, gender, 
smoking status and pack years are shown in table 6.15.   
 
TABLE 6.15: Characteristics of non- index Pi SZ subjects compared with non-
index Pi Z subjects matched for gender, age, smoking status and pack years.    
 Pi SZ     (n = 19) Pi Z       (n = 19) p = 
 
Male gender   n = 13 (68%) 13 (68%) 1.0 
Age    mean (S.D.) 45.72 (16.14) 42.8 (13.65) 0.554 
Smoking status   
  Never  n = 
  Ex  n = 
  Current  n = 
 
7 (37%) 
7 (37%) 
5 (26%) 
 
5 (26%) 
12 (63%) 
2 (11%) 
 
0.220 
Pack years smoked  mean (S.D.) 23.6 (29.7) 16.8 (15.1) 0.405 
The significance in difference (p) between the 2 groups is shown. 
 
 
 The subjects were generally well matched with no difference in matching 
parameters between the two groups.  However, due to few PiZ non-index subjects 
having smoked heavily, unlike PiSZ non-index subjects, the mean number of pack 
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years smoked for ex and current smokers was 16.8 compared with 23.6 for PiSZ 
subjects. 
 Data regarding abnormalities reported on the CT scan, CT scan densitometry 
data and the proportion of subjects with upper or lower zone emphysema are shown 
in table 6.16. 
 
TABLE 6.16: CT scan appearance and densitometry for non-index subjects with 
the Pi SZ phenotype compared with non-index Pi Z subjects matched for 
gender, age, smoking status and pack years.   
 Pi SZ (n = 13)      Pi Z (n = 18) p = 
Normal CT scan   n =  
Emphysema on CT scan  n =  
Bronchiectasis on CT scan  n = 
Bullous disease    n =  
9 (70%) 
2 (15%) 
1 (8%) 
0 (0%) 
6 (33%) 
11 (61%) 
3 (17%) 
1 (6%) 
0.048 
0.011 
0.621 
1.0 
 
Centrilobular emphysema present n = 
Panacinar emphysema present  n = 
Paraseptal emphysema present  n = 
N = 2 
1/2 (50%) 
1/2 (50%) 
0/2 (0%) 
N = 9 
3/9 (33%) 
6/9 (67%) 
1/9 (11%) 
 
1.0 
1.0 
1.0 
Centrilobular emphysema predominant n= 
Panacinar emphysema predominant n= 
Paraseptal emphysema predominant n=  
1/2 (50%) 
1/2 (50%) 
0/2 (0%) 
3/9 (33%) 
5/9 (56%) 
1/9 (11%) 
 
1.0 
 
CT Densitometry 
 Upper zone VI  mean (S.D.) 
 Lower zone VI  mean (S.D.) 
N = 12 
12.2 (17.0) 
10.4 (6.2) 
N = 12 
9.8 (12.4) 
15.2 (11.4) 
 
0.692 
0.343 
Upper zone predominance  n = 6 (50%) 2 (17%) 0.193 
The significance in difference (p) between the 2 groups is shown. 
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A greater proportion (p = 0.031) of PiSZ non-index subjects had a normal CT 
scan compared with index PiSZ subjects (35%).  Fifteen percent of non-index PiSZ 
subjects had evidence of emphysema compared to 43% of index PiSZ subjects, but 
this was not statistically significant (p = 0.102), possibly due to the small numbers 
involved. 
Although subjects were identified by family screening, only 33% of PiZ 
subjects had a normal CT scan, compared with 70% of PiSZ subjects (p = 0.048).  
Sixty one percent of PiZ subjects had visible evidence of emphysema, compared with 
only 2 PiSZ subjects (p=0.011).  Despite this, there was no difference between the 
two groups in terms of densitometric measurements.    
A similar proportion of matched PiSZ and PiZ non-index subjects had 
bronchiectasis or bullous disease. 
 Health status data were available for 18 of the 19 non-index subjects from 
each group and scores are shown in table 6.17 below. 
Despite the difference in the proportions with CT scan abnormalities, there 
was no difference in SGRQ or SF-36 scores between PiSZ and matched PiZ non-
index subjects.  Both groups of subjects, however, had worse scores than the 
average for a general population of a similar age (SGRQ symptoms – 7.97; SGRQ 
activity – 9.33; SGRQ – impacts – 2.69; SGRQ – total 5.78; SF-36 physical summary 
score – 52.15). 
 All domains of the SGRQ and the total score were lower, indicating a better 
health status for PiSZ non-index subjects compared with other PiSZ subjects.  There 
were, however, no differences in SF-36 summary scores between PiSZ non-index 
subjects and index PiSZ subjects.  
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TABLE 6.17: Health status data for non-index subjects with the Pi SZ 
phenotype compared with non-index Pi Z subjects matched for gender, age, 
smoking status and pack years, using the SGRQ and SF-36.   
 Pi SZ  (n = 18)     Pi Z (n = 18)        p = 
 
SGRQ Symptoms  mean (S.D.) 
 Activity   mean (S.D.) 
 Impacts   mean (S.D.) 
 Total   mean (S.D.) 
 
30.88 (29.42) 
28.08 (28.76) 
13.36 (15.37) 
20.75 (20.82) 
 
36.89 (27.89) 
34.74 (35.10) 
22.45 (22.08) 
28.60 (26.03) 
 
0.534 
0.537 
0.162 
0.325 
 
SF-36 Physical domain mean (S.D.) 
 Mental domain  mean (S.D.) 
 
47.1 (14.3) 
47.9 (15.9) 
 
43.8 (13.0) 
50.8 (10.6) 
 
0.615 
0.552 
The significance in difference (p) between the 2 groups is shown. 
 
  
Pulmonary physiology is shown in table 6.18 below for PiSZ and matched PiZ 
non-index subjects.  Despite the differences in the proportion of subjects with visible 
emphysema on the CT scan, there were no differences between PiSZ and matched 
PiZ non-index subjects in terms of mean spirometry, lung volumes gas transfer and 
bronchodilator response. Four PiSZ subjects (21%) & 7 PiZ subjects (37%) had 
airflow obstruction, and four PiSZ subjects (21%) & eight (42%) matched PiZ subjects 
had an abnormal gas transfer, but these proportions were not significantly different 
between the 2 groups (p = 0.283 and p = 0.163 respectively). 
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 FEV1 % predicted, FEV1:FVC and RV % predicted were better in non-index 
PiSZ subjects compared with index PiSZ subjects, but there were no differences in 
gas transfer or bronchodilator reversibility between these two groups. 
 
TABLE 6.18: Pulmonary physiology for non- index subjects with the Pi SZ 
phenotype compared with non- index Pi Z subjects matched for gender, age, 
smoking status and pack years.   
 Pi SZ      Pi Z        p = 
 
FEV1 % predicted  mean (S.D.) 
FVC % predicted  mean (S.D.) 
FEV1:FVC   mean (S.D.) 
n = 19 
98.79   (19.21) 
114.12  (15.59) 
72.13    (14.43) 
n = 19 
89.63   (33.22) 
111.52 (16.37) 
65.38 (22.58) 
 
0.305 
0.618 
0.281 
 
Bronchodilator response (ml) mean (S.D.) 
Bronchodilator response (%) mean (S.D.) 
n = 17 
410       (310) 
11.85    (7.67) 
n = 17 
270       (140) 
7.84      (3.85) 
 
0.107 
0.066 
 
RV % predicted   mean (S.D.) 
TLC % predicted  mean (S.D.) 
KCO % predicted  mean (S.D.) 
n = 19 
93.42   (90.27) 
106.63  (15.16) 
97.53    (19.78) 
n = 19 
110.84 (35.45) 
112.83 (13.89) 
86.04 (19.48) 
 
0.122 
0.197 
0.080 
The significance in difference (p) between the 2 groups is shown. 
 
 
 Despite PiZ non-index subjects having more emphysema on visible on CT 
scans, there were no differences in the MRC dyspnoea score, the presence of 
cough, chronic bronchitis, daily wheeze, sputum colour in the stable state and the 
number of exacerbations over the previous year between the 2 groups.  
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 Five PiSZ and 1 PiZ subjects had a history of neonatal jaundice, there were no 
differences in ALP, AST and bilirubin between the 2 groups.  
 
 
6.3.6. Characteristics of PiSZ subjects compared to PiZ 
subjects matched for FEV1 % predicted 
 
53% of  PiSZ and 44% of PiZ subjects in this subset were lung index cases 
and PiSZ subjects had smoked more (median = 17.8 [IQR: 0 - 37.6] pack years) than 
the PiZ subjects (4.33 [0 - 16.6];p=0.001).    
45% of PiSZ and 28% of PiZ subjects had a normal CT scan, but this 
difference did not reach statistical significance (p = 0.052). 
Those with a PiSZ phenotype had a greater (p = 0.008) KCO % predicted 
(mean = 90.4 [S.D.23.8]) and a greater degree of bronchodilator reversibility (320ml 
[260]) than PiZ subjects (79.2 [22.2] & 220 [200] respectively). 
 There were, however, no differences in health status or respiratory symptoms 
between the groups, and the proportions with a previous history of jaundice, liver 
disease or abnormalities of liver function tests were similar. 
 
 
6.3.7. Summary of the results 
 
In summary, emphysema was visible on CT in only 46% of SZ index subjects 
and 15% of non-index subjects, and health status was impaired in PiSZ subjects 
compared with the general population.   
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Compared with PiZ subjects matched for age, gender and pack years smoked, 
PiSZ subjects had visible emphysema on the CT scan less frequently, but it was 
more frequently predominant in the upper zones, consistent with a similar voxel index 
in the upper zones, but a much better voxel index in the lower but not upper zones. 
The majority of PiSZ and PiZ subjects had the panacinar type of emphysema 
classically related to AATD.  The PiSZ subjects also had a better health status, better 
pulmonary physiology and were less symptomatic compared with matched PiZ 
subjects.  
When subjects were matched for ascertainment method, the magnitude of 
health status impairment was similar to PiZ subjects despite smaller proportions of 
PiSZ subjects having emphysema on the CT scan and generally better physiology.   
The parameters measured in PiSZ smokers were, not surprisingly, worse than 
those in PiSZ subjects who had never smoked.  PiSZ subjects with an AAT level of 
>11µM had worse MRC dyspnoea and SF-36 physical summary scores than those 
with a level <11µM, although conventional physiology was not different   
When matched for FEV1, PiSZ subjects had better gas transfer 
measurements but a greater degree of bronchodilator reversibility compared with PiZ 
subjects even though they had smoked more.  
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6.4 Discussion 
 
The low proportion of PiSZ subjects with visible emphysema relative to PiZ 
subjects might be predicted, as a circulating level of AAT <11μM is theoretically 
associated with a markedly reduced ability to inactivate neutrophil elastase, 
suggesting subjects above this level would be as protected from emphysema as 
someone with normal AAT267.  This is supported by the recognised increased risk of 
developing emphysema with the PiZ phenotype29,30,268,269 compared with the 
controversy that still exists regarding the PiSZ phenotype (section1.2.3.2.).  The 
current results regarding the proportion of PiSZ index subjects with CT evidence of 
emphysema and the proportions with upper zone predominance were similar to those 
described by Gishen et al.114 using routine chest X-rays. 
Relatively few PiSZ subjects (n=63) are known to the UK AATD registry 
compared with PiZ subjects (greater than 600), considering that the prevalence of the 
PiSZ phenotype is estimated to be 4 times that of the PiZ phenotype in the UK270.  It 
is possible therefore that the PiSZ index cases are those with usual COPD who 
happen to have had tests for AATD, and would have developed COPD irrespective of 
their phenotype.   
The present study attempted to examine this possibility by assessing the type 
of emphysema that subjects had and the distribution, as disease related to AATD is 
classically basal and panacinar, whereas disease seen in usual COPD is usually 
apical and centrilobular in nature.  The current work showed that around two thirds of 
PiSZ subjects had panacinar emphysema, which is similar to the proportion seen in 
PiZ subjects, suggesting that PiSZ subjects were not typical of those with usual 
COPD who happened to have a test for AATD, but were more typical AATD related 
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disease.  It is possible that the lower zone predominance in the PiSZ patients 
reported here may have, in itself, led to AAT testing because of the known 
association with PiZ.  However, a greater proportion of PiSZ subjects, especially 
among index cases, had more upper zone predominant emphysema compared with 
PiZ subjects, which is more typical of usual COPD. 
An alternative explanation for the development of panacinar emphysema in 
the upper zones in some subjects with the PiSZ phenotype is that it is a reflection of 
early AATD related disease.  Several groups of PiZ subjects with discordant lung 
function have previously been described from the ADAPT cohort230 (see chapter 3).  
It was demonstrated that subjects with an abnormal KCO but normal FEV1 had much 
less extensive emphysema as defined by CT densitometry than those with an 
isolated abnormality of FEV1 or subjects in whom both values were abnormal.  In 
addition, these subjects had predominantly upper zone emphysema, and it has 
previously been demonstrated that KCO is related more to upper zone disease than 
lower zone disease108.  We have also described that KCO and the upper zone voxel 
index tend to become abnormal early in the course of COPD in subjects with PiZ 
AATD271.  These studies add credence to the argument that upper zone predominant 
panacinar emphysema may be a feature of early AATD related disease in some PiSZ 
subjects.  Because 39% of PiSZ and 12% of PiZ subjects present with upper rather 
than classical lower zone emphysema108,  perhaps the World Health Organisation 
(WHO) recommendations of testing all subjects with COPD for AATD272 should be 
more widely accepted, and testing should not be confined to those subjects with 
lower zone predominant emphysema more typical of the classical PiZ disease. 
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It is also possible that PiSZ subjects develop a different type of lung disease to 
PiZ subjects and to those with usual COPD (perhaps a hybrid).  This may help to 
explain the presence of panacinar emphysema in a slightly different distribution to 
that seen in PiZ subjects.  This study also raises the possibility that PiSZ subjects 
develop a condition in which the airway disease is a more common feature relative to 
parenchymal disease.  This hypothesis is supported by the fact that a smaller 
proportion of PiSZ subjects compared with PiZ subjects had visible emphysema on 
the CT scan, even among index subjects. Of subjects with mild to moderate airflow 
obstruction, only around half of PiSZ subjects had visible emphysema on the CT 
scan compared to over 90% of PiZ subjects.  Furthermore, PiSZ subjects with mild 
airflow obstruction had a much greater degree of bronchodilator reversibility than 
matched PiZ subjects, suggesting a significant asthma component.  Indeed, when 
PiSZ and PiZ subjects were matched for FEV1, PiSZ subjects had a better KCO but 
a greater degree of bronchodilator reversibility compared with PiZ subjects 
suggesting, along with the comments above, that PiSZ subjects had more airway 
disease and less parenchymal disease for the same degree of airflow obstruction 
compared with PiZ subjects.  In addition, the prevalence of chronic bronchitis, which 
is typically associated with airway disease was similar between PiSZ and PiZ 
subjects despite the latter having a greater proportion with emphysema, worse CT 
densitometry and worse pulmonary physiology.   
Alternatively, it remains possible that  PiSZ subjects behave like subjects with 
usual COPD, in whom O‟Brien et al 116 found visible emphysema in <50% of subjects 
with airflow obstruction, as opposed to subjects with the PiZ phenotype where 
emphysema is usually present (86%).  It is important to clarify this issue using a 
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prospective study such as the Swedish cohort72, especially as many PiSZ subjects 
had been told that they had emphysema prior to attending ADAPT, even when CT 
scans had not been performed. 
When CT densitometry was studied, the lower zone voxel index was greater in 
PiZ subjects than PiSZ subjects, both in the cohort as a whole, and when index 
cases only were matched.  This may reflect the higher proportion of PiZ subjects with 
emphysema as opposed to the severity of emphysema per se, as no differences 
were observed between the two groups when only those who had visible 
emphysema on the CT scan were studied.  Thus, although PiSZ subjects are less 
likely to develop emphysema than PiZ subjects of the same gender, age and 
smoking history, when this does develop, its‟ severity is similar to that of PiZ subjects.   
Subjects with the PiSZ phenotype from the whole cohort had worse health 
status scores than the general population, but better scores than matched PiZ 
subjects.  This is likely to be influenced by the differences in the prevalence of 
emphysema on CT scanning, CT densitometry, physiological impairment and 
dyspnoea, which are all associated with a reduced health status83,230,273.  However, 
despite persistent radiological and physiological differences, health status and 
indeed, symptoms were the same for PiSZ and PiZ subjects when index and non-
index subjects were analysed separately.  This indicates that PiSZ subjects may feel 
generally worse than PiZ subjects with the same degree of emphysema assessed on 
CT scan or the same degree of physiological impairment, as demonstrated in figure 
6.1.  The former may be explained by PiSZ subjects having a relatively greater 
amount of airway to parenchymal disease - a possibility discussed above.  However, 
it does not explain the same degree of health status impairment and symptoms 
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between the 2 phenotypes in the presence of better physiology in the PiSZ group.  
Further investigation about the cause and nature of health status impairment in 
subjects with the PiSZ phenotype is warranted to try to dissect the implications of this 
observation. 
Indeed, even non-index subjects had worse quality of life scores than subjects 
from the general population, and their scores were similar in the SF-36 to those 
obtained from a cohort of subjects with chronic lung disease237.  It is possible that 
simply having knowledge of their phenotype may cause anxiety in some subjects, but 
against this, the SF-36 mental health summary scores were normal in every group 
examined.  Subjects with the PiSZ phenotype may alternatively have a heightened 
awareness of symptoms, especially those related to the respiratory system, and may 
have preconceived ideas about exercise in the presence of AATD.  It is possible that 
these attitudes may have influenced their answers during completion of the health 
status questionnaires.     
We uniquely studied pulmonary physiology, respiratory diagnoses made prior 
to assessment and symptoms in PiSZ subjects who were matched for age, gender 
and pack years.  In the cohort as a whole, mean respiratory physiology values 
expressed as a percent of the predicted value were within the normal range, except 
the FEV1:FVC ratio which was slightly lower than normal.   
Contrary to Turino et al.220, we did not find a difference in bronchodilator 
reversibility between PiSZ and PiZ subjects in the cohort as a whole, although this 
was a feature of subjects with mild to moderate airflow obstruction in the present 
study.  It is possible that these PiSZ subjects had a more asthmatic respiratory 
disease than COPD, and this is supported by the argument made above that PiSZ 
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subjects seemed to have a larger component of airway disease relative to 
parenchymal disease.  In addition, ex and current smokers had a greater degree of 
reversibility than those who had never smoked, and it is possible that environmental 
factors such as  smoking increases the likelihood of developing asthma in this cohort.  
Indeed, previous work has described that environmental factors can increase 
bronchial hyperresponsiveness in subjects with the S and Z alleles217.  Smoking 
could therefore potentially have a greater effect on this parameter in Pi SZ subjects.  
Turino et al.220 also described that the relationship between pack years 
smoked and spirometry measurements was stronger for PiSZ than PiZ subjects, and 
suggested that smoking was a more important risk factor for the development of lung 
disease for PiSZ than PiZ subjects.  We found that the two phenotypes had a similar 
relationship between pack years smoked and spirometric values, but this may be 
artefactual based on the fact that the current PiSZ subjects were matched in pairs 
with their PiZ comparators for age, gender and more importantly smoking, particularly 
as fewer PiSZ compared with PiZ subjects smoked in the Turino study.  However, the 
relationship between pack years smoked and KCO, RV and TLC was stronger for 
PiSZ compared with PiZ subjects, and therefore, the concept that smoking is a 
greater risk factor in PiSZ than PiZ subjects may still be correct. 
Index subjects and smokers had worse physiological measurements, which 
were generally in agreement with the Seersholm221 study, in which subjects were of a 
similar age (mean = 47), but there were less ex and current smokers (61%) who had 
smoked a similar amount (28.1 pack years) as in our study.  However, PiSZ subjects 
in our study had better pulmonary physiology than those described in the Turino 
study220 despite the latter cohort being younger and fewer having smoked.  However, 
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Turino et al. did not state the pack year history of the smokers, which may account 
for the variance compared to the data provided here.  However, we found that PiSZ 
subjects had better spirometry and gas transfer measurements than PiZ subjects, 
even when matched for age, gender and smoking, which is concordant with the 
report by Turino et al.220 and continues to support the concept that this is a different 
disease.   
No differences in pulmonary physiology were found between PiSZ non-index 
subjects and matched PiZ non-index subjects, despite a greater proportion of PiZ 
subjects having emphysema on the CT scan.  However, the majority of the non-index 
PiSZ or PiZ subjects with emphysema had no or only very mild abnormalities of 
physiology, supporting evidence that CT scan evidence of emphysema may occur in 
the presence of normal physiological tests. 
There were no differences in the rates of neonatal or childhood jaundice, 
hepatitis or cirrhosis between the PiSZ and PiZ subjects.  This may be explained 
because S & Z proteins can produce heteropolymers195 which may have the same 
overall hepatotoxic effect as Z polymers alone, thereby explaining the lack of 
difference in history of liver morbidity.  A large proportion of PiSZ subjects had 
abnormal serum GGT measurements.  This could be a reflection of sub-clinical liver 
involvement due to the retention of these heteropolymers in hepatocytes.   
The AAT level was <11μM (the threshold commonly thought to protect from 
the development of lung destruction) in only 21% of the PiSZ subjects from our 
cohort.  Of this group, 35% had evidence of emphysema, and 60% had airflow 
obstruction.  Importantly, there were no differences in CT measures or lung function 
in SZ subjects with AAT concentrations greater or less than 11μM, suggesting that 
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within the PiSZ phenotype, the absolute AAT level in PiSZ subjects is not a major 
factor in determining lung disease.  However, AAT is an acute phase protein.I  It is 
therefore possible that initially, subjects with alower AAT level develop lung disease, 
and subsequently, the associated inflammation leads to an acute phase rise in serum 
AAT.  This could then mask any original relationship to AAT level, although clearly 
this concept can only be answered by longitudinal studies.  Nevertheless, subjects 
with an AAT level of >11M in our cohort described more severe breathlessness and a 
worse health status compared with subjects with a level <11M, which could relate to 
more subtle differences in the severity of lung disease and hence be reflected in a 
systemic response. 
Limitations to the study include the fact that some data, for example CT scans, 
were not obtained.  It is possible that this introduced a selection bias.  A proportion of 
asymptomatic subjects with normal pulmonary physiology declined a CT scan due to 
anxieties about radiation exposure and claustrophobia within the scanner.  It is 
possible therefore that the proportions of emphysema may be slightly over-estimated 
in some groups, for example non-index PiSZ subjects, of whom, only 13/19 had a CT 
scan.  Similarly, not all subjects who had a CT scan had CT densitometry recorded 
(41 of 54), but this was due to scans being obtained elsewhere prior to referral rather 
than not being indicated. 
In conclusion, we have described that less than half of PiSZ subjects in our 
registry cohort have CT scan evidence of emphysema, even if they are index cases.  
Of those who do have emphysema, it is upper zone dominant in a greater proportion 
of PiSZ subjects compared with PiZ subjects although it is likely to be panacinar.  It is 
possible that PiSZ subjects have early AATD related disease.  Health status was 
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impaired to the same extent in PiSZ subjects compared with PiZ subjects, despite 
better physiology and fewer having evidence of emphysema.  The reasons for this 
remain unclear, and further investigation is necessary to clarify these issues. 
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